enalapril profile

Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5388962
CHEMBL ID	578
CHEBI ID	4784
SCHEMBL ID	18
MeSH ID	M0007330

Synonym
BIDD:GT0751
AB00053615-17
AB00053615-18
KBIO1_000408
DIVK1C_000408
n-{(1s)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-l-alanyl-l-proline
SPECTRUM_001307
IDI1_000408
cas-76095-16-4
NCGC00016932-01
BSPBIO_003035
SPECTRUM5_001107
BPBIO1_000340
PRESTWICK3_000314
C06977
75847-73-3
enalapril
NCGC00021569-04
(s)-1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline
(s)-1-{(s)-2-[1-((s)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(n-((s)-1-carboxy-3-phenylpropyl)-l-alanyl)-l-proline 1'-ethyl ester
DB00584
BSPBIO_000308
gadopril
bonuten
enalapril [inn:ban]
l-proline, n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl-
l-proline, 1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-, (s)-
enalaprila [inn-spanish]
enalaprilum [inn-latin]
enalapril richet
KBIO2_004355
KBIO3_002535
KBIOGR_000355
KBIO2_006923
KBIO2_001787
KBIOSS_001787
SPECTRUM4_000008
SPECTRUM2_001455
SPECTRUM3_001478
SPBIO_001349
NINDS_000408
NCGC00021569-05
NCGC00021569-06
HMS2090E08
enalaprila
CHEBI:4784 ,
analapril
n-[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-l-alanyl-l-proline
enalaprilum
olinapril
CHEMBL578 ,
c09aa02
D07892
enalapril (tn)
enalapril (inn)
(2s)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
1-[2-(1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid(enalapril)
(s)-1-[(r)-2-((r)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid
(sss)1-[2-(1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid
1-[2-(1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid
(s)-1-((s)-2-((r)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)pyrrolidine-2-carboxylic acid
1-[2-(1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid (enalapril)
bdbm50017129
2-[2-(1-carboxy-3-phenyl-propylamino)-propionyl]-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid(enalapril)
(s,s,s)-1-[2-(1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid
A838609
A838525
(2s)-1-[(2s)-2-[[(1r)-1-ethoxycarbonyl-3-phenyl-propyl]amino]propanoyl]pyrrolidine-2-carboxylic acid; maleic acid
(s)-1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline;enalapril maleate salt
l-proline, n-[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl-
69pn84io1a ,
unii-69pn84io1a
cas-75847-73-3
dtxcid202982
dtxsid5022982 ,
tox21_110872
enalapril [mart.]
enalapril [inn]
enalapril [who-dd]
enalapril [vandf]
enalapril [mi]
gtpl6322
(2s)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid
enaladex
AKOS025310615
HY-B0331
n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanyl-l-proline
n-[1-(s)-ethoxycarbonyl-3-phenylpropyl]-l-alanyl-l-proline
nalpha -[(s)-1-ethoxycarbonyl-3-phenylpropyl]-l-alanyl-l-proline
SCHEMBL18
tox21_110872_1
NCGC00021569-09
AB00053615_19
AB00053615_20
enalapril, aldrichcpr
SBI-0051691.P002
((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-l-alanyl-l-proline
Q422185
BRD-K57545991-050-16-5
H10947
(s)-1-((s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)pyrrolidine-2-carboxylic acid
n-[(2s)-1-ethoxy-1-oxo-4-phenyl-2-butanyl]-l-alanyl-l-proline
(s)-1-((s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)pyrrolidine-2-carboxylicacid
EN300-7481394
enalaprila (inn-spanish)
enalaprilum (latin)
enalaprilum (inn-latin)
n-((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl-
(s)-1-((s)-2-(1-((s)-ethoxycarbonyl)-3-phenyl-propylamino)-propionyl)-pyrrolidine-2-carboxylic acid
n-((2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-l-alanyl-l-proline
enalapril (mart.)

Excerpt	Reference	Relevance
"Enalapril (EN) is an antihypertensive drug that is sparingly soluble in water with limited oral bioavailability. "	( Enhanced bioavailability and pharmacokinetics parameters of Enalapril solid self nanoemulsifying oral dispersible tablet: formulation, in vitro and in vivo evaluation. Ammar, AA; Hassan, DH; Ramadan, AA; Younis, MK, )	1.82
"Enalapril maleate is an antihypertensive ethyl ester pro-drug with two crystalline forms. "	( Studies on charge transfer of enalapril maleate: from solid-state to molecular dynamics. Fajemiroye, JO; Lourenço, ACM; Napolitano, HB; Oliveira, SS; Santin, LG, 2023)	2.64
"Enalapril is a common drug for the treatment of hypertension in Ethiopia."	( A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial. Alemayehu, C; Aseffa, A; Clavarino, A; McGree, J; Mitchell, G; Nikles, J, 2017)	1.4
"Enalapril is an off-patent angiotensin-converting enzyme inhibitor for which no paediatric age-appropriate formulation is commercially available in Europe, and enalapril maleate (EM) orodispersible minitablets (ODMTs) have previously been formulated within the LENA (labelling enalapril from neonates to adolescents) project. "	( Flexible and precise dosing of enalapril maleate for all paediatric age groups utilizing orodispersible minitablets. Breitkreutz, J; Thabet, Y; Walsh, J, 2018)	2.21
"Enalapril maleate (EM) is a widely used anti-hypertensive drug which is unstable when mixed with excipients. "	( Effect of stearic acid on enalapril stability and dissolution from multiparticulate solid dosage forms. Cunha, TA; de Freitas, LA; de Oliveira, AP; Diniz, DG; Lima, EM; Marreto, RN; Nasser, LN; Serpa, RC; Taveira, SF, 2013)	2.13
"Enalapril is a pharmacologically inactive prodrug of enalaprilat."	( Role of multidrug resistance-associated protein 4 in the basolateral efflux of hepatically derived enalaprilat. Bridges, AS; Brouwer, KL; Ferslew, BC; Köck, K, 2014)	1.34
"Enalapril is an effective drug acting on the renin-angiotensin-aldosterone axis."	( Vascular effects of the lercanidipine/enalapril combination: clinical relevance. Parati, G, 2016)	1.43
"Enalapril is an angiotensin converting enzyme (ACE) inhibitor that is frequently used in human, feline and canine patients with cardiac disease. "	( Chronic oral therapy with enalapril in normal ponies. Ely, JJ; McDonnell, SM; Reef, VB; Sleeper, MM, 2008)	2.09
"Enalapril is an effective and well tolerated angiotensin converting enzyme inhibitor."	( Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. Barrios, V; Echarri, R; Escobar, C, 2008)	1.29
"Enalapril maleate is a low-dose drug substance with poor granulating and tableting behavior."	( Role of continuous moisture profile monitoring by inline NIR spectroscopy during fluid bed granulation of an Enalapril formulation. Hartung, A; Knoell, M; Langguth, P; Schmidt, U, 2011)	1.3
"Enalapril is a non-thiol angiotensin-converting enzyme inhibitor that is commonly used in the treatment of diabetes-associated hypertension."	( Protective effects of enalapril in streptozotocin-induced diabetic rat: studies of DNA damage, apoptosis and expression of CCN2 in the heart, kidney and liver. Jena, GB; Kushwaha, S; Vikram, A, 2012)	1.41
"Enalapril is an angiotensin-converting enzyme (ACE) inhibitor approved for the treatment of mild to severe hypertension and congestive heart failure. "	( Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Han, L; Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S, 2011)	2.02
"Enalapril is an angiotensin-converting enzyme inhibitor widely used in the treatment of hypertension and heart failure."	( Spectrophotometric determination of enalapril through ternary complex formation. Dorneanu, V; Simona, M; Spac, AF; Zavastin, D, )	1.85
"Enalapril appears to be an effective and generally well-tolerated antihypertensive agent in children ages 6 to 16 years."	( A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. Frame, V; Herrera, P; Shahinfar, S; Shaw, W; Soffer, B; Wells, T; Zhang, Z, 2002)	1.26
"Enalapril is a highly specific and competitive inhibitor of angiotensin-I converting enzyme (ACE) and thus belongs to the category of ACE inhibitors. "	( The effects of enalapril maleate and cold stress exposure on tyrosine hydroxylase activity in some rat tissues. Talas, ZS; Yurekli, M, )	1.93
"Enalapril maleate is a prodrug which when administered orally is hydrolysed to release the active converting enzyme inhibitor enalaprilat. "	( An overview of the clinical pharmacology of enalapril. Davies, RO; Gomez, HJ; Irvin, JD; Walker, JF, 1984)	1.97
"Enalapril is a long-acting, sulphydryl-free, ACE inhibitor whose humoral and hypotensive effects are maximal at 4-8 h and remain detectable at 24 h after a single dose. "	( Kinetic and metabolic aspects of enalapril action. Lant, AF; McNabb, RW; Noormohamed, FH, 1984)	1.99
"Enalapril is a new angiotensin converting enzyme (ACE) inhibitor and has been shown to be of benefit in the treatment of both renovascular and essential hypertension. "	( Systemic and renal effects of enalapril and its effects on cardiac mass. Dunn, FG; Frohlich, ED; Kobrin, I; Messerli, FH; Oigman, W; Ventura, HO, 1984)	2
"Enalapril (MK 421) is a long-acting angiotensin converting-enzyme inhibitor which specifically lacks the sulfhydryl group of captopril. "	( Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects. Davies, RO; Hollenberg, NK; Shoback, DM; Swartz, SL; Williams, GH, )	1.8
"Enalapril is a converting enzyme inhibitor with a prolonged duration of action. "	( Duration of action and short-term hormonal responses to enalapril (MK 421) in normal subjects. Given, BD; Hollenberg, NK; Taylor, T; Williams, GH, )	1.82
"Enalapril (MK-421) is a new angiotensin converting enzyme inhibitor which effectively lowers elevated blood pressure and might also be useful in heart failure. "	( Effects of a new angiotensin converting enzyme inhibitor, enalapril, in acute and chronic left ventricular failure in dogs. Franciosa, JA; Leddy, CL; Wilen, M, )	1.82
"Enalapril maleate is an investigational oral prodrug whose hydrolyzed diacid metabolite is a potent angiotensin-converting enzyme inhibitor. "	( Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination. Ferguson, RK; Irvin, JD; Koplin, JR; Lee, RB; Rotmensch, HH; Swanson, BN; Vlasses, PH, )	1.84
"Enalapril (MK-421) is a new oral angiotensin-converting enzyme inhibitor which was administered to eight patients with chronic congestive heart failure. "	( Enalapril (MK-421), a new angiotensin-converting enzyme inhibitor. Acute and chronic effects in heart failure. Dunkman, WB; Franciosa, JA; Wilen, M, 1983)	3.15
"Enalapril is an effective anti-hypertensive agent with a favourable effect on renal haemodynamics."	( Effects of enalapril on blood pressure and renal haemodynamics in essential hypertension. de Jong, PE; de Zeeuw, D; Donker, AJ; Navis, GJ, 1983)	1.38
"Enalapril is an angiotensin-converting enzyme inhibitor that promoted a cutaneous eruption in a patient with renal failure secondary to diabetes."	( Enalapril-associated erythema and vasculitis. Carrington, PR; Sanusi, ID; Winder, PR; Zahradka, S, 1993)	2.45
"Enalapril is a new converting enzyme blocker with a longer plasma half-life and less side effects than captopril."	( Use of enalapril in neonatal hypertension. Schilder, JL; Van den Anker, JN, 1995)	1.47
"Enalapril is an angiotensin converting enzyme (ACE) inhibitor with an established clinical profile. "	( Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension. Bryson, HM; Goa, KL; Wilde, MI, 1994)	3.17
"Enalapril is a widely used antihypertensive drug with a very powerful in vitro acantholytic effect. "	( In vivo enalapril-induced acantholysis. Aurilia, A; Cozzani, E; Guerrera, V; Lo Schiavo, A; Pinto, F; Ruocco, E, 1999)	2.18
"Enalapril is a dipeptidic angiotensin converting enzyme inhibitor. "	( Study of the cis-trans isomerization of enalapril by reversed-phase liquid chromatography. Bouabdallah, S; Bouzouita, K; Raouafi, F; Sabbah, S; Trabelsi, H, 2000)	2.02
"Enalapril is an antihypertensive drug of the class of angiotensin-converting enzyme inhibitors (ACEI) used in pregnancy for treatment of pre-existing or pregnancy-induced hypertension. "	( Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. A review. Kimmel, CA; Tabacova, SA, )	3.02
"Enalapril is an effective anti hypertensive drug in mild to moderate essential hypertension."	( Enalapril in hypertension. Misra, NP; Shah, JY; Verma, Y, 1992)	2.45
"Enalapril is an effective agent in the treatment of mild to severe hypertension. "	( Enalapril: benefit-to-risk ratio in hypertensive patients. Cirillo, VJ; Gomez, HJ; Smith, SG, 1990)	3.16
"Enalapril is an effective angiotensin-converting enzyme (ACE) inhibitor which produces salutary, beneficial haemodynamic effects in patients with congestive heart failure. "	( Systemic and coronary haemodynamics and pharmacodynamics of enalapril and enalaprilat in congestive heart failure. Chatterjee, K; De Marco, T, 1990)	1.96
"Enalapril (MK-421) is an esterified prodrug, which in man is converted by the liver to the bioactive potent ACE inhibitor enalaprilate (enalaprilic acid, MK-422)."	( Evaluation of angiotensin converting enzyme (ACE) in the pharmacokinetics and pharmacodynamics of ACE inhibitors. Arnolda, L; Cubela, R; Jackson, B; Johnston, CI; Larmour, I, 1986)	0.99
"Enalapril is a long acting ACE inhibitor, and its molecule does not have the sulphydryl group present in captopril."	( [Role of prostaglandins in the antihypertensive effect of the converting enzyme inhibitor, enalapril]. Espinoza, F; Gallego, A; Garza Flores, J; Herrera-Acosta, J; Morato, T; Pérez-Grovas, H; Ruiz, A, )	1.07
"Enalapril is shown to be an effective and well-tolerated antihypertensive medication in elderly patients."	( Rationale for ACE inhibition in the elderly: treatment of arterial hypertension with enalapril. Alexandre, JM; Billaud-Mesguish, E; Bouchacourt, P; Forette, F; Fouchard, M; Handfield-Jones, R; Henry, JF; Henry-Amar, M; Hervy, MP, 1987)	1.22
"Enalapril maleate is a new ACE inhibitor with actions similar to those of captopril but with fewer side-effects."	( Comparison of the antihypertensive effect of enalapril and propranolol in black South Africans. Coull, A; Goodman, C; Rosendorff, C, 1985)	1.25
"Enalapril is a recently developed angiotensin-converting enzyme inhibitor that improves cardiac function at rest in patients with congestive heart failure. "	( Acute and long-term effects of enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. Creager, MA; Faxon, DP; Friedman, SD; Kramer, BL; Massie, BM; Melidossian, CD; Ryan, TJ; Topic, N; Weiner, DA, 1985)	2
"Enalapril is a prodrug that is well absorbed from the gastrointestinal tract, with 60 to 70% of an oral dose being absorbed."	( Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. Cody, RJ; Kubo, SH, )	0.85
"Enalapril is a new, oral, long-acting nonsulfhydral angiotensin converting enzyme inhibitor. "	( Effects of enalapril alone, and in combination with hydrochlorothiazide, on renin-angiotensin-aldosterone, renal function, salt and water excretion, and body fluid composition. Bauer, JH; Gaddy, P, 1985)	2.1
"Enalapril is an inhibitor of the converting enzyme which transforms angiotensin I into angiotensin II, an octapeptide with pharmacological properties uniformly tending to increase blood pressure. "	( [Clinical pharmacology of enalapril]. Giudicelli, JF, 1985)	2.01
"Enalapril maleate is a new angiotensin converting enzyme inhibitor marketed in the U.S. "	( Enalapril: a new angiotensin converting enzyme inhibitor. Cleary, JD; Taylor, JW, 1986)	3.16
"Enalapril maleate is an orally active angiotensin-converting enzyme inhibitor. "	( Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Heel, RC; Todd, PA, 1986)	3.16
"Enalapril is an oral ACE inhibitor useful in the treatment of renovascular hypertension."	( Renovascular hypertension: treatment with the oral angiotensin-converting enzyme inhibitor enalapril. Jackson, B; Johnston, CI; Kincaid-Smith, P; Murphy, BF; Whitworth, JA, 1986)	1.21
"Enalapril is a new angiotensin converting enzyme inhibitor which, when absorbed by the digestive tract, is converted to enalaprilat. "	( Clinical pharmacology of the angiotensin converting enzyme inhibitor, enalapril. Brunner, HR; Nussberger, J; Waeber, B, 1986)	1.95
"Enalapril is a non-sulfhydryl pro-drug that requires enzymatic conversion to enalaprilic acid, a potent angiotensin converting enzyme inhibitor."	( Pharmacology of angiotensin converting enzyme inhibitors. A review. Nelson, EB; Pool, JL; Taylor, AA, 1986)	0.99
"Enalapril is shown to be an effective treatment in Bartter's syndrome as it improves serum potassium, TBK and complaints."	( Total body potassium in Bartter's syndrome before and during treatment with enalapril. Hené, RJ; Koomans, HA; van de Stolpe, A; van der Vijver, JC; Verhoef, GE, 1987)	1.22
"Enalapril maleate is a prodrug requiring in vivo hepatic esterolysis to yield the active diacid inhibitor enalaprilat."	( Pharmacokinetics of enalapril in congestive heart failure. Dickstein, K, 1986)	1.32
"Enalapril maleate is a prodrug requiring in vivo hepatic esterolysis to yield the active diacid inhibitor enalaprilat."	( The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. Aarsland, T; Abrahamsen, AM; Dickstein, K; Gomez, HJ; Gregg, H; Hichens, M; Kristianson, K; Till, AE; Tjelta, K, 1987)	1.3

Excerpt	Reference	Relevance
"Enalapril has a role in reducing cardiac toxicity after anthracycline administration."	( Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Agrawal, V; Bali Singh, T; Gupta, V; Kumar Singh, S, 2018)	1.92
"Enalapril has a good safety profile as measured by frequency of clinical and laboratory adverse experiences."	( The efficacy and safety of enalapril in moderate to severe essential hypertension. Kramsch, DM; Kulaga, SF; Walker, JF, 1984)	1.29
"Enalapril has an antiproteinuric effect independent of the effect on systemic blood pressure. "	( Renal protective effect of enalapril in diabetic nephropathy. Aurell, M; Björck, S; Johnsen, SA; Mulec, H; Nordén, G, 1992)	2.02
"Enalapril, therefore, has a potent and slightly superior antihypertensive effect to that of atenolol, and may be used as a 'first-step' drug in the treatment of hypertensive patients."	( Efficacy of enalapril in essential hypertension and its comparison with atenolol. Basha, A; Bolya, YK; el Mangoush, M; Gamati, A; Gupta, BS; Kumar, S; Singh, NK, 1990)	1.38
"Enalapril has a sustained beneficial action in patients with moderate heart failure."	( Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure. Espiner, EA; Fitzpatrick, MA; Hamilton, EJ; Ikram, H; Nicholls, MG; Webster, MW; Wells, JE, 1985)	1.38
"Enalapril has a much more gradual onset and longer duration of action."	( Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril. Cohn, JN; Levine, TB; Olivari, MT, 1986)	1.2
"Enalapril has a role in reducing cardiac toxicity after anthracycline administration."	( Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Agrawal, V; Bali Singh, T; Gupta, V; Kumar Singh, S, 2018)	1.92
"Enalapril has similar effects to losartan on systemic blood pressure, renal function and serum UA in patients with CKD, but carries a higher risk of dry cough. "	( Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis. Feng, L; He, YM; Huo, DM; Liao, YH; Yang, ZH, 2013)	3.28
"Enalapril has antiproliferative and HA suppressing actions in both GO and control fibroblasts. "	( Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts. Altea, MA; Botta, R; Casini, G; Latrofa, F; Leo, M; Lisi, S; Marcocci, C; Marinò, M; Menconi, F; Nardi, M; Pinchera, A; Rocchi, R; Sellari-Franceschini, S; Sisti, E; Vitti, P, 2013)	3.28
"Enalapril has been shown to reduce proteinuria in adult patients with SCA, but the potential benefits of hydroxyurea in this clinical setting have not been reported."	( Enalapril and hydroxyurea therapy for children with sickle nephropathy. Fitzhugh, CD; Ware, RE; Wigfall, DR, 2005)	2.49
"Enalapril has a good safety profile as measured by frequency of clinical and laboratory adverse experiences."	( The efficacy and safety of enalapril in moderate to severe essential hypertension. Kramsch, DM; Kulaga, SF; Walker, JF, 1984)	1.29
"Enalapril has no major influence on these reactivities."	( Platelet and leukocyte activation after myocardial infarction. Influence of enalapril. Bergström, K; Chen, J; Eneroth, P; Hagerman, I; Karlberg, KE; Saldeen, T; Sylvén, C; Wallin, R, 1995)	1.24
"Enalapril has been effective against the progression of tubulointerstitial lesions in various animal models."	( Enalapril prevents tubulointerstitial lesions by hyperoxaluria. Angerosa, M; de Cavanagh, E; Ferder, L; Inserra, F; Stella, I; Toblli, JE, 1999)	2.47
"Enalapril has an antiproteinuric effect independent of the effect on systemic blood pressure. "	( Renal protective effect of enalapril in diabetic nephropathy. Aurell, M; Björck, S; Johnsen, SA; Mulec, H; Nordén, G, 1992)	2.02
"Enalapril has been administered with digitalis and diuretic for 12 months 5 mg twice a day; in 60 control patients only digitalis and diuretic have been administered."	( [Efficacy of long-term treatment with enalapril in patients with congestive heart failure]. Buttafarro, A; Cannavà, G; Casella, F; Cordiani, A; Mangano, A; Pavia, L; Silipigni, C, 1990)	1.27
"Enalapril, therefore, has a potent and slightly superior antihypertensive effect to that of atenolol, and may be used as a 'first-step' drug in the treatment of hypertensive patients."	( Efficacy of enalapril in essential hypertension and its comparison with atenolol. Basha, A; Bolya, YK; el Mangoush, M; Gamati, A; Gupta, BS; Kumar, S; Singh, NK, 1990)	1.38
"Enalapril has recently joined captopril as an approved, orally active ACE inhibitor."	( Enalapril: a long-acting angiotensin-converting enzyme inhibitor. Borek, M; Charlap, S; Frishman, W, 1987)	2.44
"Enalapril has central effects on ANP binding sites, specific to the circumventricular organs."	( Effect of chronic administration of the converting enzyme inhibitor enalapril (MK 421) on brain atrial natriuretic peptide receptors in Wistar-Kyoto and spontaneously hypertensive rats. Correa, FM; Gutkind, JS; Nazarali, AJ; Saavedra, JM, 1988)	1.23
"Enalapril has been compared with thiazides and beta-blockers (propranolol, metoprolol and atenolol)."	( Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety. Davies, RO; Moncloa, F; Sromovsky, JA; Walker, JF, 1985)	2.43
"Enalapril has natriuretic and uricosuric properties."	( Enalapril: a review of human pharmacology. Cirillo, VJ; Gomez, HJ; Irvin, JD, 1985)	2.43
"Enalapril has a sustained beneficial action in patients with moderate heart failure."	( Effects of enalapril on clinical status, biochemistry, exercise performance and haemodynamics in heart failure. Espiner, EA; Fitzpatrick, MA; Hamilton, EJ; Ikram, H; Nicholls, MG; Webster, MW; Wells, JE, 1985)	1.38
"Enalapril has been proved to be a highly effective therapeutic agent which is well tolerated by patients with arterial hypertension or severe congestive heart failure."	( Clinical pharmacology of the angiotensin converting enzyme inhibitor, enalapril. Brunner, HR; Nussberger, J; Waeber, B, 1986)	1.23
"Enalapril has a much more gradual onset and longer duration of action."	( Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril. Cohn, JN; Levine, TB; Olivari, MT, 1986)	1.2
"Enalapril also has favourable effects on electrolytes and, although it increases renal blood flow, it reduces the glomerular filtration rate."	( Effects of enalapril on different aspects of the clinical state in congestive heart failure. Dargie, HJ, 1986)	1.38

Excerpt	Reference	Relevance
"Enalapril prevented the increase in plasma ANG II levels but did not protect against ventilator-induced diaphragmatic oxidative stress or diaphragm weakness."	( AT1 receptor blocker losartan protects against mechanical ventilation-induced diaphragmatic dysfunction. Hall, SE; Kwon, OS; Morton, AB; Powers, SK; Smuder, AJ; Sollanek, KJ; Talbert, EE; Toklu, HZ; Tumer, N; Wiggs, MP, 2015)	1.14
"Enalapril can suppress them significantly."	( [Interventions of enalapril on airway inflammation in rat models induced by acrolein]. Feng, YL; Qiu, T; Tang, YJ; Xiao, J; Xu, ZB, 2008)	1.4
"Enalapril can suppress the airway inflammation induced by acrolein."	( [Interventions of enalapril on airway inflammation in rat models induced by acrolein]. Feng, YL; Qiu, T; Tang, YJ; Xiao, J; Xu, ZB, 2008)	1.4
"Enalapril alone did not suppress secondary hyperparathyroidism or vascular calcification."	( Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. Finch, JL; Martin, DR; Mizobuchi, M; Nakamura, H; Slatopolsky, E; Tokumoto, M, 2009)	1.07
"Enalapril could inhibit the renal interstitial fibrosis by affecting TGF-beta1, p-Smad2/3 and Smad7 of TGF-beta/smads pathway in the renal tissues of UUO rats."	( [Effect of enalapril on the expression of TGF-beta1, p-Smad2/3 and Smad7 in renal interstitial fibrosis in rats]. Chen, J; Hu, J; Liu, C; Ning, W; Sun, J; Tao, L; Wang, W; Xiao, Y; Zheng, X, 2009)	2.19
"Enalaprilat eyedrops lower IOP in rabbits. "	( Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. Fridriksdóttir, H; Loftsson, T; Stefánsson, E; Thorisdóttir, S, 2010)	3.25
"Enalapril may cause an increase in plasma Hcy levels among the hypertensives with low baseline Hcy levels. "	( Effect of enalapril on plasma homocysteine levels in patients with essential hypertension. Fan, FF; Huo, Y; Li, JP; Wang, BY; Wang, X; Xu, X; Xu, XP, 2010)	2.21
"Enalapril caused an increase in plasma active renin concentration and plasma renin activity (PRA)."	( Pharmacokinetics, pharmacodynamics, and tolerability of ACT-077825, a new direct renin inhibitor after multiple-ascending doses in healthy subjects. Binkert, C; Dingemanse, J; Gutierrez, M; Nicolas, LB, 2013)	1.11
"enalapril alone to enhance vascular effects, increase LV contractility and prevent unfavorable remodeling and are consistent with vascular delivery of exogenous NO."	( A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. Condorelli, G; Del Soldato, P; Dieterle, T; Gu, Y; Iwanaga, Y; Ongini, E; Peterson, KL; Presotto, C; Ross, J, 2004)	1.31
"Enalapril prevented the increase in heart weight index (HWI), carotid cross-sectional area (CSA) and albuminuria induced by Ang II."	( Prevention and reversal by enalapril of target organ damage in angiotensin II hypertension. Cordaillat, M; Jover, B; Mimran, A; Rugale, C, 2005)	1.35
"Enalapril can inhibit its expression."	( [P21 expression in renal interstitial fibrosis and regulative effect of enalapril]. Damu, T; Hu, J; Jin, O; Liu, CY; Ning, WB; Shen, M; Sun, J; Tao, LJ; Xiao, Y; Zhou, JH, 2006)	1.29
"Enalaprilat did not inhibit erythropoiesis in cell culture."	( Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Barker, CV; Curtis, JJ; Diethelm, AG; Gaston, RS; Julian, BA; Krystal, G, 1994)	1.29
"Enalapril was given to lower plasma AII levels and observe whether JG cell hypertrophy and hyperplasia were increased or decreased."	( Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists. Eydelloth, RS; Hubert, MF; Keenan, KP; Molon-Noblot, S; Owen, RA; Siegl, PK, 1994)	1.01
"Enalapril could suppress cardiac sympathetic activity and nitrendipine had no effect on it. "	( Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. Kurata, C; Sakata, K; Shirotani, M; Yoshida, H, 1998)	2.05
"Enalapril caused an increase of the AP amplitude (APA) and the resting potential (RP) in a concentration-dependent manner without any significant change of AP duration, Vmax and overshoot of AP. "	( Electrophysiologic effect of enalapril on guinea pig papillary muscles in vitro. Gao, Y; Hu, DY; Liu, B; Liu, XL, 1997)	2.03
"Both enalapril and losartan increase MBF in SHR, suggesting that the medullary circulation of SHR is influenced by endogenous levels of angiotensin II. "	( Differing effects of enalapril and losartan on renal medullary blood flow and renal interstitial hydrostatic pressure in spontaneously hypertensive rats. Dukacz, SA; Kline, RL, 1999)	1.14
"Enalapril induced increase of urinary excretion of bicyclo-PGE2 (4.32 +/- 0.62 vs."	( [Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome]. Crkovská, J; Jirsa, M; Seráková, M; Stípek, S; Tesar, V; Vernerová, Z; Zima, T, 1999)	1.33
"Enalapril and the lower dose of valsartan attenuated the CsA-induced hypertension to the same extent, while the higher dose of valsartan totally abolished it."	( Comparison of enalapril and valsartan in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet. Ahonen, J; Finckenberg, P; Krogerus, L; Lassila, M; Nurminen, ML; Pere, AK; Vapaatalo, H, 2000)	1.39
"and enalapril 20 mg o.d. lower BP to approximately the same extent, except for a more pronounced effect of enalapril on daytime ambulatory BP."	( A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. Fagard, R; Lijnen, P; Pardaens, K; Thijs, L; Vinck, W, 2001)	1.02
"The enalapril-induced increase in urinary excretion of bicyclo-PGE(2) was possibly mediated by kinins."	( Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome. Crkovská, J; Jirsa, M; Seráková, M; Stípek, S; Tesar, V; Vernerová, Z; Zima, T, 2002)	1.1
"Enalapril limited the increase in left ventricular asynergy in the reperfused group."	( Beneficial effects of therapy on the progression of structural remodeling during healing after reperfused and nonreperfused myocardial infarction: different effects on different parameters. Jugdutt, BI; Menon, V, 2002)	1.04
"Enalaprillat did not produce any statistically significant changes in pulmonary pressures and resistances or cardiac output."	( Acute effect of intrapulmonary enalaprilat in ten patients with severe pulmonary hypertension due to toxic oil syndrome. Alonso Gutierrez, M; Fernandez Cruz, A; Gabriel Sanchez, R; Gomez Pajuelo, C; Gomez Sanchez, MA; Lombera Romero, F; Saenz de la Calzada, C, 1990)	1.29
"2. Enalapril did not increase the maximum rate of sodium excretion, but caused the rats to excrete more than the load in the first 24 h and then to have a slow fall in body sodium while on a sodium-free diet."	( Effect of enalapril on handling of a sodium chloride load by genetically hypertensive and normotensive rats. Ledingham, JM; Simpson, FO, 1989)	1.19
"Both enalapril and ramipril increase the sensitivity of the cough reflex appreciably in patients who complain of cough during treatment, but they do not change the se"	( Change in cough reflex after treatment with enalapril and ramipril. Choudry, N; Fuller, RW; McEwan, JR; Street, R, 1989)	1.05
"Enalapril was used to inhibit angiotensin converting enzyme."	( The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Crean, PA; Fox, KM; Gibbs, R; Mockus, L; Simon, J; Sutton, GC; Wright, C, 1989)	1
"Enalapril caused an increase in plasma renin activity (1.22 +/- 0.08 to 3.66 +/- 2.50 ng/ml/h), whereas aldosterone levels remained unchanged."	( Rationale for ACE inhibition in the elderly: treatment of arterial hypertension with enalapril. Alexandre, JM; Billaud-Mesguish, E; Bouchacourt, P; Forette, F; Fouchard, M; Handfield-Jones, R; Henry, JF; Henry-Amar, M; Hervy, MP, 1987)	1.22
"Enalapril does not produce hypokalaemia, hyperglycaemia, hyperuricaemia or hypercholesterolaemia."	( Enalapril: a review of human pharmacology. Cirillo, VJ; Gomez, HJ; Irvin, JD, 1985)	2.43

Excerpt	Reference	Relevance
"Enalapril (oral) treatment conserved the blood pressure (systolic and diastolic), restored the level of antioxidants, restored the lipid peroxidation marker, nitrite content, ionic content, ATPase function, protein content, and thus delayed the cataract formation. "	( Topical Administration of ACE Inhibitor Interrupts the Progression of Cataract in Two Kidney One Clip Induced Hypertensive Cataract Model. Bodakhe, SH; Choudhary, R; Pandey, DP; Shree, J; Singh, A, 2022)	2.16
"Enalapril treatment lowered the SBP (from 110 to 104 mmHg, p = 0.003) and levels of N-terminal pro-B-type natriuretic peptide (from 80 to 72 ng/L, p = 0.036)."	( 3-Month Enalapril Treatment in Pediatric Fontan Patients With Moderate to Good Systolic Ventricular Function. Blom, NA; Harteveld, LM; Hazekamp, MG; Kuipers, IM; Rammeloo, LAJ; Ten Harkel, ADJ; Terol Espinosa de Los Monteros, C; van Dijk, JG, 2022)	1.88
"Enalapril-treated rats had a lower expression of MasR in the colon."	( Enalapril Diminishes the Diabetes-Induced Changes in Intestinal Morphology, Intestinal RAS and Blood SCFA Concentration in Rats. Chabowski, D; Gawryś-Kopczyńska, M; Hutsch, T; Jaworska, K; Konop, M; Kopacz, W; Koper, M; Szudzik, M; Ufnal, M, 2022)	2.89
"Enalapril treatment alone from week 8 to 12 reduced SBP versus controls, decreased albuminuria, and resulted in numerically lower glomerulosclerosis."	( Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model. Al Tuhaifi, T; Badal, SS; Breckenridge, DG; Fogo, AB; Joly, K; Liles, JT; Lopez, D; Plato, CT; Yang, HC; Yu, YF, 2022)	1.44
"Enalapril treatment did not alter the response."	( Orthostatic stress response in pediatric Fontan patients and the effect of ACE inhibition. Blom, NA; de Geus, EJC; Harteveld, LM; Kerkhof, FI; Kuipers, IM; Rammeloo, LAJ; Reijntjes, RH; Ten Harkel, ADJ; van Dijk, JG; van Someren, PJ, 2022)	1.44
"Enalapril treatment showed significant alterations in cellular senescence in neonatal rat kidneys."	( Angiotensin inhibition and cellular senescence in the developing rat kidney. Bae, ES; Yim, HE; Yoo, KH, 2020)	1.28
"Enalapril treatment decreased kidney angiotensin II whereas diltiazem induced significant elevations in plasma and kidney levels."	( Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging. Beanlands, RS; Burns, KD; Croteau, E; DaSilva, JN; deKemp, RA; Hadizad, T; Ismail, B, 2017)	1.53
"Enalapril treatment significantly enhanced the total antioxidant status (TAS) (P < 0.001), reduced the oxidized glutathione ratio (GSH : GSSG) (P < 0.001), and reduced to thibarbituric acid reactive substances (TBARS) (P < 0.001) and protein carbonyl content (PCO) (P < 0.001), which thus reduced the oxidative stress in the heart."	( Effect of Antihypertensive Drug Treatment on Oxidative Stress Markers in Heart of Spontaneously Hypertensive Rat Models. Govindasamy, C; Mustapha, Z; Sharif, SET; Sirajudeen, KNS; Yusoff, NSN, 2017)	1.18
"Enalapril treatment in the chronic model, however, protected against cardiac dysfunction and cardiomyocyte atrophy and was associated with increased activation of the PI3K/AKT/mTOR pathway along with normal levels of CTGF."	( Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Basquin, D; Hullin, R; Maillard, M; Martin, D; Métrich, M; Regamey, J; Sarre, A, 2018)	1.52
"Enalapril-treated rats had higher tubular injury scores and lower glomerular maturity grades than those of untreated rats."	( Capillary rarefaction and altered renal development: the imbalance between pro- and anti-angiogenic factors in response to angiotensin II inhibition in the developing rat kidney. Bae, ES; Hong, YS; Yim, HE; Yoo, KH, 2018)	1.2
"Enalapril treatment resulted in a reduction in the proinflammatory cytokines interleukin (IL)-1α, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1a in older female mice, and an increase in the anti-inflammatory cytokine IL-10 in older male mice compared with control animals."	( Chronic Treatment With the ACE Inhibitor Enalapril Attenuates the Development of Frailty and Differentially Modifies Pro- and Anti-inflammatory Cytokines in Aging Male and Female C57BL/6 Mice. Grandy, SA; Heinze-Milne, S; Howlett, SE; Kane, A; Keller, K, 2019)	1.5
"Enalapril treatment also reduced the renal expression of FGF-1, FGF-2, and FGFR-1."	( Angiotensin inhibition in the developing kidney; tubulointerstitial effect. Bae, ES; Hong, YS; Yim, HE; Yoo, KH, 2019)	1.24
"Enalapril treatment during postnatal renal maturation can disrupt renal lymphangiogenesis along with tubulointerstitial changes, which may result in a pro-fibrotic environment in the developing rat kidney."	( Angiotensin inhibition in the developing kidney; tubulointerstitial effect. Bae, ES; Hong, YS; Yim, HE; Yoo, KH, 2019)	1.96
"The enalapril treatment, but not aliskiren or losartan, was effective in improving leptin, glucose intolerance, IR, hepatic steatosis, and triglycerides and in preventing increased hepatic protein levels of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6Pase), and glucose transporter-2 (GLUT-2)."	( Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice. Aguila, MB; Batista, Tde M; Frantz, ED; Mandarim-de-Lacerda, CA; Penna-de-Carvalho, A, 2014)	0.88
"Enalapril treatment significantly enhanced the renal TAS level (P < 0.001) and SOD activity (P < 0.001), reduced the TBARS levels (P < 0.001), and also prevented the renal dysfunction and histopathological changes."	( Effect of the antihypertensive drug enalapril on oxidative stress markers and antioxidant enzymes in kidney of spontaneously hypertensive rat. Chandran, G; Samarendra, MS; Sirajudeen, KN; Swamy, M; Yusoff, NS, 2014)	1.4
"Enalapril treatment resulted in contrasting molecular expression profiles involved in renal maturation and repair in the kidneys of the rats from the Lean and Obese groups."	( Differential modification of enalapril in the kidneys of lean and 'programmed' obese male young rats. Bae, IS; Hong, YS; Lee, JW; Yim, HE; Yoo, KH, )	1.14
"Enalapril treatment counteracted the reduction of leukocytes in the diabetic kidney towards levels noted in the non-diabetic kidney."	( Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy. Cucak, H; Højgaard Pedersen, M; Nielsen Fink, L; Rosendahl, A, 2015)	2.58
"Enalapril treatment partially protected the testicles from these alterations, restoring normal spermatozoid production."	( Testicular Morphology and Spermatozoid Parameters in Spontaneously Hypertensive Rats Treated with Enalapril. Bechara, GR; Costa, WS; de Souza, DB; Felix-Patrício, B; Medeiros, JL; Sampaio, FJ; Simoes, M, 2015)	1.36
"Enalapril treatment throughout the superovulation protocol decreased 17β-estradiol (E2) output and raised progesterone:estradiol (P4:E2) ratio without a direct influence on ovulation and quality of embryos."	( The effect of angiotensin-converting enzyme inhibition throughout a superovulation protocol in ewes. Costa, AR; de Souza Júnior, A; Feitosa, LC; Gonçalves, GK; Honorato-Sampaio, K; Machado, FB; Pereira, AM; Reis, AM; Santos, RA, 2015)	1.14
"Enalapril pre‑treatment did not improve cardiac function or the 6-h survival rate after CA and resuscitation; however, this intervention ameliorated myocardial ultrastructural damage, reduced the level of plasma cardiac troponin I and decreased myocardial apoptosis."	( Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation. Li, C; Wang, G; Wu, J; Yuan, W; Zhang, Q, 2016)	2.6
"Enalapril-treated subtotal nephrectomy rats receiving control endothelial basal medium-2 injections experienced only partial renoprotection when compared to vehicle-treated subtotal nephrectomy rats. "	( Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD. Connelly, KA; Gilbert, RE; Kepecs, DM; Thai, K; Yuen, DA; Zhang, Y, 2016)	1.88
"Enalapril treatment (25 mg/kg/day in drinking water) had no effect on nondiabetic rats (NE, n=8) as compared with untreated NC rats, but significantly improved RIHP response (DeltaRIHP) to VE in diabetic rats (DE, n=9; 2.8+/-0.5 mm Hg)."	( Enalapril treatment restores the decreased proximal tubule reabsorption in response to acute volume expansion in diabetic rats. Khraibi, AA; Yu, T, 2008)	2.51
"Enalapril treatment restored the volume expansion-induced decrease in RSNA in SHRE (-41 +/- 8%) compared with WKY rats (-44 +/- 3%)."	( Role of cardiac hypertrophy in reducing the sensitivity of cardiopulmonary reflex control of renal sympathetic nerve activity in spontaneously hypertensive rats. Abreu, GR; Bissoli, NS; de Andrade, TU; de Melo Cabral, A; Moysés, MR, 2008)	1.07
"Enalapril treatment exerted a similar, but weaker protective effect against postinfarction myocardial remodeling and heart failure."	( Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure. Bartha, E; Habon, T; Halmosi, R; Hideg, K; Kálai, T; Kalman, E; Kiss, GN; Kulcsár, G; Sumegi, B; Toth, K, 2008)	1.31
"Enalapril treatment of SHRs reduced blood pressure and restored sensitivity to 14,15-EEZE, but not to gap junction blockers, and failed to reverse the morphological changes."	( Enalapril treatment alters the contribution of epoxyeicosatrienoic acids but not gap junctions to endothelium-derived hyperpolarizing factor activity in mesenteric arteries of spontaneously hypertensive rats. Brackenbury, TD; Chaston, DJ; Ellis, A; Falck, JR; Goto, K; Hill, CE; Meaney, KR; Wojcikiewicz, RJ, 2009)	2.52
"Enalapril treatment began 4 days before and continued throughout the experiment."	( Sexual dimorphism in the blood pressure response to angiotensin II in mice after angiotensin-converting enzyme blockade. Glover, PH; Reckelhoff, JF; Ryan, MJ; Sartori-Valinotti, JC; Venegas-Pont, M, 2010)	1.08
"The enalapril-treated group showed no increase in mRNA expression of angiogenic factors."	( Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Hur, DY; Kim, HW; Kim, JL; Kim, SD; Lee, HK; Yun, IH, 2009)	2.28
"Enalapril treatment prevented increased angiogenic factor levels in the retinas of experimentally induced diabetic rats."	( Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Hur, DY; Kim, HW; Kim, JL; Kim, SD; Lee, HK; Yun, IH, 2009)	3.24
"Enalapril treatment caused a notable decrease in corneal neovascularization of 44% (1 mm(2)), 28% (2.1 mm(2)), and 31% (2.2 mm(2)) on the three tested time points, respectively."	( Localization of angiotensin converting enzyme in rabbit cornea and its role in controlling corneal angiogenesis in vivo. Bettis, DI; Cowden, JW; Mohan, RR; Sharma, A, 2010)	1.08
"Enalapril treatment applied to the recovery of chronic bronchopneumonia in rats, after enalapril administration, two-dimensional electrophoresis and mass spectrometry were performed to analyze the difference of the peptide finger print map and amino acid sequence of rat lung tissues in acrolein inhalation group and enalapril treatment group."	( [Changes of proteomics in the lung of rats subjected to acrolein inhalation after enalapril administration]. Huang, YC; Wang, SL; Wang, ZJ; Yuan, B; Zhang, L; Zhang, YH; Zhao, S, 2010)	2.03
"The enalapril-treated group exhibited a peak of plasma insulin higher than controls."	( Angiotensin-converting enzyme inhibition changes the metabolic response to neuroglucopenic stress. Bastos Fóscolo, R; Campos Machado, LJ; Carvalho Miranda, PA; Celso Coimbra, C; de Oliveira Longo, JR; Dos Santos, RA; Magalhães Madureira, M; Ribeiro-Oliveira, A; Simões E Silva, AC; Vilas Boas, WW, 2011)	0.85
"Enalapril-pretreated dTG rats are suitable for long-term MAP monitoring and sequential evaluation of human renin inhibitors."	( Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors. Auger, A; Binkert, C; Cromlish, W; Fischli, W; Harris, J; Hess, P; Liu, S; Percival, MD; Riendeau, D; St-Jacques, R; Steiner, B; Toulmond, S, 2011)	1.81
"Enalapril treatment significantly restored the malondialdehyde and glutathione content as well as the DNA damage in the heart, kidney and liver of diabetic rat."	( Protective effects of enalapril in streptozotocin-induced diabetic rat: studies of DNA damage, apoptosis and expression of CCN2 in the heart, kidney and liver. Jena, GB; Kushwaha, S; Vikram, A, 2012)	1.41
"Enalapril treatment decreased blood pressure of SHR only and resulted in significantly more elastase-2 mRNA expression in carotid artery of both enalapril-treated WNR and SHR."	( Angiotensin-converting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme. Becari, C; Oliveira, EB; Salgado, MC; Teixeira, FR, 2011)	1.09
"Enalapril treatment significantly prevented hypertrophy, apoptosis, and CaMKII activity."	( Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensin system activity involves CaMKII. Mattiazzi, A; Palomeque, J; Velez Rueda, JO, 2012)	1.1
"Enalapril treatment diminished the urinary concentration capacity without affecting Na(+) and K(+) urinary excretion. "	( Effect of chronic inhibition of converting enzyme on renal handling of salt and water: a study on a pediatric population. Amorena, C; Cánepa, CA; Dieguez, SM, 2012)	1.82
"Enalapril treatment reduced the signal intensity to a level comparable to the normal hamster."	( Upregulation of vasopressin V2 and aquaporin 2 in the inner medullary collecting duct of cardiomyopathic hamsters is attenuated by enalapril treatment. Tsui, JK; Wong, NL, 2002)	1.24
"Enalapril treatment resulted in a 24% mortality, reduced body weight, and decreased heart weight (p < 0.05)."	( Angiotensin converting enzyme inhibition decreases cell turnover in the neonatal rat heart. Cheon, HW; Choi, JH; Hong, YS; Kim, CH; Kim, KB; Kim, SK; Lee, JW; Yoo, KH, 2002)	1.04
"Enalapril treatment, but not placebo, reduced plasma von Willebrand factor (p = 0.03) and ADMA levels (p = 0.01) and increased NOx levels (p = 0.01) and the ratio of L-arginine to ADMA (p <0.01)."	( Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Chang, MS; Chen, JW; Hsu, NW; Lin, SJ; Wu, TC, 2002)	1.04
"Enalapril treatment alone inhibited the expansion of interstitial volume due to UUO by 52%."	( ACE inhibition increases expression of the ETB receptor in kidneys of mice with unilateral obstruction. Fitzgerald, M; Guo, G; Klahr, S; McCracken, R; Moridaira, K; Morrissey, J; Tolley, T, 2003)	1.04
"Enalapril treatment resulted in 24% fewer events. "	( The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited. Naylor, CD; Parker, AB; Yusuf, S, 2002)	1.76
"Enalapril treatment significantly improved water maze performance (P<0.05), hippocampal long term potentiation (P<0.05) and hippocampal blood flow (P<0.05)."	( Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Biessels, GJ; Cameron, NE; Cotter, MA; Gispen, WH; Kamal, A; Kappelle, LJ; Manschot, SM, 2003)	1.04
"Enalapril treatment resulted in an increased mortality (30.4%) by day 7, and reduced body weight and kidney weight ( P<0.05 versus vehicle)."	( ACE inhibition modulates transforming growth factor-beta receptors in the young rat. Bae, IS; Choi, BM; Choi, JH; Hong, YS; Kang, NS; Kim, SK; Lee, JW; Yim, HE; Yoo, KH, 2003)	1.04
"Enalapril-treated animals showed an increased mtNOS functional activity in heart mitochondria that inhibited state 3 O(2) uptake (from 22% in control rats to 43%) and increased state 4 hydrogen peroxide (H(2)O(2)) production (from 30% in control rats to 52%)."	( Enalapril increases mitochondrial nitric oxide synthase activity in heart and liver. Boveris, A; Costa, LE; D'Amico, G; Lores-Arnaiz, S, 2003)	2.48
"Enalapril treatment decreased the left ventricular (LV) mass index in SHRs, even in animals with NO synthesis blocked."	( Enalapril attenuates cardiorenal damage in nitric-oxide-deficient spontaneously hypertensive rats. Bezerra, DG; Machado, DL; Mandarim-de-Lacerda, CA; Pereira, LM, 2004)	2.49
"Enalapril intervention treatment had no effect on nerve conduction velocity and on visual evoked potential latencies, but improved brain stem auditory evoked potential latencies (p < 0.05) after 10 weeks of treatment."	( Nerve conduction velocity and evoked potential latencies in streptozotocin-diabetic rats: effects of treatment with an angiotensin converting enzyme inhibitor. Biessels, GJ; Gispen, WH; Kappelle, LJ; Manschot, SM, )	0.85
"Enalapril treatment did not influence exercise performance, but did reduce LVESWS in the first year; this reduction was maintained over the study period. "	( Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. Barber, G; Chin, AJ; Clark, BJ; Cnaan, A; Cohen, MI; Delaat, C; Hogarty, AN; Kimball, TR; Paridon, SM; Rutkowski, M; Rychik, J; Silber, JH; Steinherz, LJ; Zhao, H, 2004)	3.21
"Enalapril treatment reduced heart sympathetic activity in obese subjects but did not change angiotensinogen levels."	( Sympathetic activity and response to ACE inhibitor (enalapril) in normotensive obese and non-obese subjects. Amador, N; Guizar, JM; Malacara, JM; Paniagua, R; Pérez-Luque, E, )	1.1
"Enalapril co-treatment (25 mg/(kg day), in drinking water) prevented the development of atherosclerosis without affecting blood pressure or circulating cholesterol."	( Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. da Cunha, V; Deng, G; Ho, JJ; Martin-McNulty, B; Rutledge, JC; Sullivan, ME; Tham, DM; Vergona, R; Wang, YX; Wilson, DW, 2005)	2.49
"Enalapril treatment for 3.0 +/- 1.3 years normalized serum albumin (3.9 +/- 0.3 g/dl) without significant changes in serum potassium, serum creatinine, or systolic blood pressure."	( Enalapril and hydroxyurea therapy for children with sickle nephropathy. Fitzhugh, CD; Ware, RE; Wigfall, DR, 2005)	2.49
"Enalapril treatment decreased Ht levels in PTE but not in control patients."	( Iron deficiency--an underrecognized problem in nonanemic and erythrocytic kidney transplant recipients: risks and effects of ACEI and of iron treatment. Campos, M; Jimeno, L; Lanuza, M; Rodado, R, 2005)	1.05
"Enalapril treatment significantly decreased Ht levels."	( Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis. Barrios, Y; Campos, M; Jimeno, L; Llorente, S; Minguela, A; Nicolas, F; Rodado, R, 2005)	1.26
"3. Enalapril-treated rats showed significant reductions in glomerular filtration rate (GFR; -44 +/- 6%; P < 0.05), effective renal plasma flow (ERPF; -33 +/- 6%; P < 0.05) and filtration fraction (-16 +/- 3%; P < 0.05) compared with saline-treated controls."	( Renal haemodynamics and function in weanling rats treated with enalapril from birth. Guron, G, 2005)	1.08
"Enalapril treatment was associated with a redistribution of fat mass from abdominal to subcutaneous depots."	( Treatment of obese female and male SHHF/Mcc-fa(cp) rats with antihypertensive drugs, nifedipine and enalapril: effects on body weight, fat distribution, insulin resistance and systolic pressure. Chu, YY; Hoepf, TM; McCune, SA; Radin, MJ, 1993)	1.22
"Enalapril treatment reduced all of these changes."	( Enalapril reduces the expression of nuclear factor-kappaB and c-Jun N-terminal kinase in the renal cortices of five-sixths-nephrectomized rats. Coimbra, TM; Costa, JC; Costa, RS; Silva, CG, 2006)	2.5
"Enalapril pretreatment (5 microg/0.2 mL) did not modify the effects induced by CES on heart rate or blood pressure, and the verapamil pretreatment (1 microg/0.2 mL) reduced both cardiovascular changes by 85% (p < 0.01)."	( Cardiovascular excitatory effect on rats of a fraction isolated from the eyestalk of shrimp: Peneaus vanameii. Antequera, R; Cedeño, J; Estrada, O; León, L; Romero-Vecchione, E; Rosa, F; Vásquez, J, 2006)	1.06
"Both enalapril and EGCG treatment of SHR improved insulin sensitivity and raised plasma adiponectin levels."	( EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Colantuono, G; Federici, A; Kim, JA; Marasciulo, FL; Montagnani, M; Potenza, MA; Quon, MJ; Tarquinio, M; Tiravanti, E, 2007)	0.79
"Enalapril treatment could partially reverse the myocardial destruction in the diabetic rats."	( [Effect of enalapril on diabetic rat myocardial ultrastructure]. Li, ZL; Wu, HC; Xu, CS; Xue, SR; Yan, QN, 2007)	1.45
"Enalapril treatment increased the B2 kinin receptor expression."	( Enalapril treatment corrects the reduced response to bradykinin in diabetes increasing the B2 protein expression. de Carvalho, MH; de Cássia Tostes Passaglia, R; dos Santos, R; Fortes, ZB; Nigro, D; Oliveira, MA; Rastelli, VM, 2008)	2.51
"Enalapril treatment decreased serum angiotensin-converting enzyme (ACE) activity and both drugs reduced serum cholesterol levels. "	( Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Coppey, LJ; Davidson, EP; Kleinschmidt, TL; Lund, DD; Oltman, CL; Yorek, MA, 2008)	2.02
"Enalapril treatment induced an approximately 50% increase in J(HCO(3)(-))."	( Effect of chronic inhibition of converting enzyme on proximal tubule acidification. Amorena, CE; Diaz-Sylvester, PL; Dieguez, SM; Fiori, MC; Lopardo, ML; Müller, AC, 2008)	1.07
"Enalapril treatment did not change urinary immunoreactive prostaglandin E2 (PGE2) excretion and indomethacin did not modify plasma renin activity of enalapril-treated rats."	( Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats. Genest, J; Gutkowska, J; Schiffrin, EL; Thibault, G, 1984)	1.39
"Enalapril treatment over three days induced a positive cumulative balance of sodium and potassium, and a small increase in plasma potassium."	( Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG, 1983)	1.24
"Enalapril treatment was associated with a significant reduction in weight."	( Enalapril in essential hypertension: a comparative study with propranolol. Enalapril in Hypertension Study Group (UK). , 1984)	2.43
"Enalapril treatment was continued for 24 weeks."	( Effects of enalapril treatment on gene expression of smooth muscle myosin heavy chain isoforms in glomeruli of diabetic rats. Ebihara, I; Fukui, M; Kimura, K; Koide, H; Makita, Y; Nagai, R; Nakamura, T; Tomino, Y; Yazaki, Y, )	1.24
"Enalapril pretreatment resulted in lower MAP and marked renal vasodilation at baseline but no significant alteration in the response to UNX."	( Influence of dopamine and angiotensin II blockade on the acute response to unilateral nephrectomy in rats. Mimran, A; Ribstein, J; Valentin, JP, 1994)	1.01
"Enalapril treatment was continued for 24 wk."	( Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. Ebihara, I; Fukui, M; Koide, H; Nakamura, T; Osada, S; Takahashi, T; Tomino, Y, 1995)	2.46
"Enalapril treatment reduced blood pressure from 94 +/- 2 to 87 +/- 3 mm Hg (P < .05) and prevented the hypertensive response to endothelin."	( Effectiveness of enalapril versus nifedipine to antagonize blood pressure and the renal response to endothelin in humans. Kaasjager, KA; Koomans, HA; Rabelink, TJ, 1995)	1.35
"Enalapril pretreatment alone, compared with placebo, produced slight nonsignificant increments in absolute and fractional sodium excretions and a marked increase in effective renal plasma flow but no change in glomerular filtration rate."	( Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men. Cramb, G; Lang, CC; Motwani, JG; Struthers, AD, 1995)	1.25
"Enalapril treatment did not alter the number of myocytes in either the LVFW or RVFW as compared to hearts from untreated piglets."	( Mechanisms of rapid growth in the neonatal pig heart. Beinlich, CJ; Morgan, HE; Rissinger, CJ, 1995)	1.01
"In enalapril-treated failing hearts, phosphoryl transfer via the CK reaction increased with contractile performance."	( Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Friedrich, J; Ingwall, JS; Liao, R; Nascimben, L; Pauletto, P; Pessina, AC, 1995)	2.25
"Enalapril treatment results in increased phosphoryl transfer through the CK reaction in failing myocardium, and this increase is coupled to improved cardiac performance."	( Enalapril treatment increases cardiac performance and energy reserve via the creatine kinase reaction in myocardium of Syrian myopathic hamsters with advanced heart failure. Friedrich, J; Ingwall, JS; Liao, R; Nascimben, L; Pauletto, P; Pessina, AC, 1995)	2.46
"Enalapril treatment resulted in a 42% decrease (P < 0.01) in COL IV mRNA in the cortex and a remarkable decrease in the renal tubules of the obstructed kidney at five days."	( Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kaneto, H; Klahr, S; McCracken, R; Morrissey, J; Reyes, A, 1994)	2.45
"Enalapril pretreatment significantly attenuated this fall in sodium excretion (P < 0.05) and effective renal plasma flow (P < 0.05), and had a similar attenuating effect on the noradrenaline-induced decrease in the fractional excretion of lithium."	( Enalapril blunts the antinatriuretic effect of circulating noradrenaline in man. Balfour, DJ; Lang, CC; Rahman, AR; Struthers, AD, 1993)	2.45
"Enalapril treatment significantly reduced proteinuria (731 +/- 23 vs."	( Effects of antihypertensive drugs on the progress of renal failure in hyperlipidemic Imai rats. Baba, N; Sakemi, T, 1993)	1.01
"With enalapril treatment, total vascular resistance in the responder group tended to decrease (891 +/- 576 dyne.sec.cm-5), but slightly increased in the nonresponder group (679 +/- 276 dyne.sec.cm-5)."	( Assessment of hemodynamic effects of angiotensin-converting enzyme inhibitor therapy in chronic aortic regurgitation by using velocity-encoded cine magnetic resonance imaging. Blake, L; Bourne, M; Cheitlin, M; Duerinckx, A; Fujita, N; Globits, S; Higgins, CB; Szolar, D, 1996)	0.75
"enalapril-treated group at > or = 15 mm Hg, p < 0.001)."	( Comparative effects of type 1 angiotensin II-receptor blockade with angiotensin-converting-enzyme inhibitor on left ventricular distensibility and collagen metabolism in spontaneously hypertensive rats. Fujii, A; Katayama, K; Matsuzaki, M; Umemoto, S; Yonezawa, T, 1996)	1.02
"Two enalapril-treated patients were dropped from the study due to protocol deviations."	( Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Becker, GJ; Cnaan, A; Ihle, BU; Kincaid-Smith, PS; Shahinfar, S; Whitworth, JA, 1996)	0.77
"Enalapril treatment decreased systolic blood pressure of 11.3 mmHg during daytime and of 9.4 mmHg at night, diastolic blood pressure of 6.1 mmHg during daytime and 5.8 mmHg at night, all differences were significant in comparison to placebo (p < 0.01)."	( [24-hour ambulatory monitoring of blood pressure in patients with essential hypertension: the effectiveness of enalapril therapy]. Dusek, J; Fiser, B; Siegelová, J, 1996)	1.23
"Enalapril treatment for an average period of 5.1 months following MI resulted in no clinically significant beneficial effects on NYHA and dyspnea class. "	( Effect of enalapril initiated early after acute myocardial infarction on heart failure parameters, with reference to clinical class and echocardiographic determinants. CONSENSUS II Multi-Echo Study Group. Berning, J; Bonarjee, VV; Caidahl, K; Carstensen, S; Edner, M; Nilsen, DW, 1996)	2.14
"Enalapril treatment significantly blunted the increase in all parameters during UUO."	( Nitric oxide generation ameliorates the tubulointerstitial fibrosis of obstructive nephropathy. Ishidoya, S; Klahr, S; McCracken, R; Morrissey, JJ, 1996)	1.02
"Both enalapril and losartan treatment reduced the acute albuminuria, measured 1 day after injection of a monoclonal antibody against aminopeptidase A, by 91% and 83%, respectively."	( Inhibition of aminopeptidase A activity causes an acute albuminuria in mice: an angiotensin II-mediated effect? Assmann, KJ; de Jong, AS; Dijkman, HB; Koene, RA; Mentzel, S; van Son, JP; Wetzels, JF, 1996)	0.75
"In enalapril-pretreated Agtr1A -/- mice, angiotensin II caused significant and dose-proportional increases in mean arterial pressure."	( Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. Arendshorst, WJ; Best, CF; Coffman, TM; Kim, HS; Oliverio, MI; Smithies, O, 1997)	0.81
"Enalapril treatment caused regression of cardiac hypertrophy that normalized heart weight in aortic-banded rats."	( Regression of cardiac hypertrophy normalizes glucose metabolism and left ventricular function during reperfusion. Allard, MF; Bondy, GP; English, DR; Henning, SL; Wambolt, RB, 1997)	1.02
"Enalapril treatment for 5 weeks resulted in a significant reduction of the mean systolic blood pressure, which was accompanied by attenuation of vascular hypertrophy and attenuation of changes in the vascular extracellular matrix proteins."	( Cerebrovascular changes in chronic hypertension. Protective effects of enalapril in rats. Kilty, DW; Nag, S, 1997)	1.25
"Enalapril treatment had a protective effect and attenuated vascular hypertrophy and the increase in vascular extracellular matrix proteins observed in chronic hypertension. "	( Cerebrovascular changes in chronic hypertension. Protective effects of enalapril in rats. Kilty, DW; Nag, S, 1997)	1.97
"Enalapril treatment resulted in 40% mortality by d 14, reduced body and kidney weight, decreased glomerular area, and caused tubular dilatation (p < 0.05 versus vehicle group)."	( Angiotensin-converting enzyme inhibition decreases growth factor expression in the neonatal rat kidney. Chevalier, RL; Wolstenholme, JT; Yoo, KH, 1997)	1.02
"Enalapril treatment of BN/Kat rats (lacking circulating kininogens) caused a similar increase in ACE as in other rats."	( Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia. Alhenc-Gelas, F; Allegrini, J; Clozel, JP; Costerousse, O; Ménard, J, 1998)	1.02
"Enalapril or SC-51316 treatment had no significant effect on ICAM-1 mRNA levels."	( Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Klahr, S; Morrissey, JJ, 1998)	1.02
"Enalapril treatment lowered blood pressure and attenuated the atrial natriuretic factor-induced increase in urinary excretion of sodium. "	( Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. Hertenberg, F; Smits, P; Vervoort, G; Wetzels, JF, 1998)	1.74
"Enalapril treatment significantly reduced systolic blood pressure in SHR and completely regressed cardiac hypertrophy."	( Enalapril induces regression of cardiac hypertrophy and normalization of pHi regulatory mechanisms. Alvarez, BV; Camilión de Hurtado, MC; Cingolani, HE; Ennis, IL, 1998)	2.46
"Enalapril treatment, which decreases macrophage infiltration of the obstructed kidney, had no effect on the increase in osteopontin mRNA but significantly attenuated the increase in protein in tubular cells."	( Osteopontin expression in the kidney during unilateral ureteral obstruction. Kaneto, H; Klahr, S; McCracken, R; Morrissey, J; Reyes, A, 1998)	1.02
"enalapril); combined treatment also reduced nonmyocyte cellular proliferation but did not reach statistical significance (p = 0.08 vs."	( Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. Aronovitz, MJ; Konstam, MA; Patten, RD; Salomon, RN; Smith, JJ; Taylor, K; Wight, J, 1998)	1.02
"Enalapril treatment resulted in an absolute risk reduction of 12.5% (95% CI, 2% to 23%; P = 0.042) for development of microalbuminuria."	( Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Bar-Dayan, Y; Brosh, D; Levi, Z; Rachmani, R; Ravid, D; Ravid, M, 1998)	1.48
"With enalapril treatment, ventricular diastolic dimension decreased from 59.3 +/- 8.1 to 58 +/- 9.3 mm and the area of mitral insufficiency decreased from 8.1 +/- 3.5 to 6.6 +/- 3.1 cm2."	( [Comparison of the effects of digoxin or enalapril in the treatment of heart failure due to mitral insufficiency]. Díaz, M; Eggers, G; Gamboa, C; Garcés, E; Lanas, F; Montecinos, A; Stockins, B, 1998)	1.02
"Enalapril treatment lowered daytime percent time elevation index (PTI) from 56 +/- 30% to 27 +/- 23% (p < 0.05), nighttime PTI from 64 +/- 34% to 37 +/- 35% (p < 0.05), and hyperbaric impact values from 183 +/- 152 mmHg x hour to 97 +/- 128 mmHg x hour (p < 0.01)."	( [Evaluation of captopril-enalapril replacement therapy in hypertensive patients under ambulatory blood pressure monitoring]. Dudás, M; Hidas, I; Iványi, J; Molnár, S; Ruszty, L, 1996)	1.32
"With enalapril treatment, (1) left ventricular ejection fraction (LVEF) increased significantly from 38.3 +/- 6.9% to 47.5 +/- 14.7%; (2) sub-maximal exercise time increased significantly from 205 +/- 112 to 272 +/- 120 seconds; (3) the heart to mediastinum (H/M) ratio of 123I-MIBG increased significantly (early image: 1.99 +/- 0.38 versus 2.20 +/- 0.50; delayed image: 1.86 +/- 0.44 versus 2.09 +/- 0.51); and (4) the washout rate of 123I-MIBG decreased slightly from 29.1 +/- 9.1% to 25.4 +/- 7.0%."	( Long-term effects of the angiotensin-converting enzyme inhibitor enalapril on chronic heart failure. Examination by 123I-MIBG imaging. Bandou, K; Fukuda, N; Shinohara, H; Soeki, T; Sui, O; Takeichi, N; Tamura, Y; Tanaka, H; Yui, Y, 1998)	0.99
"Enalapril treatment within 3 to 13 d after birth induced abnormalities in renal function and morphology long-term, whereas treatment initiated at 14 d of age did not."	( Postnatal time frame for renal vulnerability to enalapril in rats. Friberg, P; Guron, G; Marcussen, N; Nilsson, A; Sundelin, B, 1999)	1.28
"The enalapril treatment did not affect maximum binding of angiotensin II to renal tubules and glomeruli in SHR."	( Intrarenal angiotensin converting enzyme inhibition in spontaneously hypertensive rats. Aihara, H; Hisa, H; Kasuya, A; Ogawa, H; Satoh, S; Suzuki-Kusaba, M; Yoshida, M, 1999)	0.78
"Enalapril treatment prevented CsA-induced hypertension and deterioration of kidney function as well as CsA-induced vascular injuries in the kidneys and myocardium."	( Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet. Karppanen, H; Krogerus, L; Lähteenmäki, T; Lassila, M; Mervaala, E; Vapaatalo, H; Vaskonen, T, 1999)	1.02
"Enalapril treatment (20 mg every 12 hours) of 24 patients with essential hypertension and left ventricular (LV) hypertrophy established normal blood pressures after 8 weeks, and after 5 years, it had reduced LV mass index by 39% (from 148+/-34 to 90+/-16 g/m(2)) and had normalized LV structure and function and QT dispersion. "	( Step-down of enalapril treatment for arterial hypertension. Cabezas-Cerrato, J; García-Acuña, JM; González-Juanatey, C; González-Juanatey, JR; Reino, AP; Valdes, L, 1999)	2.12
"Enalapril treatment was associated with significant and persistent diminution of proteinuria from 1.32 +/- 0.23 to 0.53 +/- 0.11 and 0.44 +/- 0.07 g/day on the 4th and 8th week of treatment, respectively."	( Enalapril treatment of proteinuria in normotensive children. Boor, A; Jurkovic, I; Kovacs, L; Mitro, A; Podracka, L; Sasinka, MA, 1999)	2.47
"Enalapril treatment for 3 weeks, started after the onset of diabetes, reduced the glomerular expression of p16INK4 and p27Kip1 but not of p21Cip1."	( Angiotensin converting-enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 expression in diabetic BBdp rats. Stahl, RA; Wenzel, U; Wolf, G; Ziyadeh, FN, 1999)	1.02
"Enalapril treatment abolishes the deleterious effects of eNOS deficiency on BP, atherosclerosis, and kidney dysfunction in nnee mice."	( Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. Jennette, JC; Knowles, JW; Maeda, N; Reddick, RL; Shesely, EG; Smithies, O, 2000)	1.25
"Enalapril-treated animals developed less proteinuria and other signs of chronic rejection."	( Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Antus, B; Hamar, P; Heemann, U; Lutz, J; Philipp, T; Schleimer, K; Szabo, A, 2000)	1.03
"With enalapril treatment, the LV/BW ratio was reduced to 19% in SHRE."	( The cardiopulmonary reflexes of spontaneously hypertensive rats are normalized after regression of left ventricular hypertrophy and hypertension. Abreu, GR; Bissoli, NS; Cabral, AM; Sampaio, KN; Uggere, TA, 2000)	0.76
"Enalapril treatment (20 mg/kg per day, p.o.) was started after surgery to induce hypertension or nephrectomy and continued for 5 weeks."	( Enalapril prevents aortic hyperreactivity and remodelling in one-kidney, one-clip hypertensive rats without reducing arterial pressure. Cunha, V; Salgado, HC; Salgado, MC, 2000)	2.47
"Enalapril treatment progressively regressed cardiac and vascular structure during the 1 and 2-week treatment periods with a mean tissue yield point plus or minus standard deviation of -5.91% +/- 5.1% (p <0.05) and -12.1% +/- 6.0% (p <0.05), and a mean left ventricle mass of -11.8% +/- 2.2% (p <0.05) and -13.6% +/- 3.2% (p <0.05), respectively. "	( Antihypertensive drugs induce structural remodeling of the penile vasculature. Adams, MA; Hale, TM; Heaton, JP; Okabe, H, 2001)	1.75
"More enalapril-treated than nifedipine-treated patients required supplemental treatment with hydrochlorothiazide (59% versus 34%, P<0.001) but not atenolol (27% versus 22%, NS)."	( Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluat Bella, JN; Dahlöf, B; De Quattro, V; de Simone, G; Devereux, RB; Hahn, RT; Palmieri, V; Sharpe, N; Walker, JF, 2001)	0.95
"Enalapril treatment significantly attenuated the reduction of total glutathione."	( Enalapril attenuates oxidative stress in diabetic rats. de Cavanagh, EM; Ferder, L; Fraga, CG; Inserra, F; Stella, I; Toblli, J, 2001)	2.47
"Enalapril treatment up to one year depressed mass concentrations of PAI-1 and transiently tPA and tPA/PAI-1 complex indicating an improvement of the fibrinolytic balance in both genders with uncomplicated myocardial infarction."	( Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction. Boman, KO; Jansson, JH; Nilsson, TK; Nyhlén, KA, 2002)	2
"Enalapril treatment inhibited NF-kappaB and AP-1 activation, the enhanced TNF and collagen mRNA expression, and the deposition of collagen in bleomycin-exposed C57BL/6 mice."	( Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappaB and AP-1. Beasley, MB; Champion, HC; Friedman, M; Gambelli, F; Gozal, E; Hoyle, GW; Hyman, AL; Kadowitz, PJ; Lasky, JA; Ortiz, LA, 2002)	2.48
"Enalapril treatment significantly reduced myocardial infarction, unstable angina, and cardiac mortality in patients with low ejection fractions."	( Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Benedict, C; Bourassa, M; Garces, C; Kostis, J; Pepine, CJ; Pitt, B; Pouleur, H; Rousseau, M; Salem, D; Yusuf, S, 1992)	1.41
"Enalapril treatment increased the number of renin secreting cells by approximately 10-fold (P < 0.05)."	( Effects of angiotensin converting enzyme inhibition, sodium depletion, calcium, isoproterenol, and angiotensin II on renin secretion by individual renocortical cells. Carey, RM; Geary, KM; Gomez, RA; Hunt, MK; Peach, MJ, 1992)	1
"Enalapril treatment in HF rats increased renin mRNA level (2.5-fold, P < 0.005), KRC (5.6-fold, P = 0.005), and PRC (15.5-fold, P < 0.005)."	( Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. Dzau, VJ; Hirsch, AT; Ingelfinger, JR; Litwin, SE; Schunkert, H; Talsness, CE; Tang, SS, 1992)	1
"Enalapril treatment (7 days; n = 5) increased the number of plaque-forming cells to 22 +/- 2 for ANG I (P less than 0.0005) and to 39 +/- 7 for renin (P less than 0.001)."	( Colocalization and release of angiotensin and renin in renal cortical cells. Carey, RM; Geary, KM; Gomez, RA; Hunt, MK; Norling, LL; Peach, MJ; Ramos, SP, 1992)	1
"Enalapril-treated OZR had less albuminuria and lower blood pressure, but Pgc was not reduced."	( Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril. Kasiske, BL; Katz, SA; Keane, WF; O'Donnell, MP; Schmitz, PG, 1992)	1.23
"Enalapril treatment (50 or 200 mg/l drinking water) significantly lowered blood pressure in Dahl S rats, but did not significantly affect albuminuria or glomerulosclerosis."	( Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Kasiske, BL; Katz, SA; Keane, WF; O'Donnell, MP; Schmitz, PG, 1992)	1.33
"2. Enalapril treatment led to a greater fall in body Na in the first 24 h after the Na load (as expected from the known effect of ACE inhibition on aldosterone production) and thus to a slightly faster excretion of an amount equivalent to the load."	( Effect of enalapril on body sodium and handling of a sodium chloride load in hypertensive and normotensive rats. Ledingham, JM; Simpson, FO, 1992)	1.2
"Enalapril treatment had no significant effect on body weight and small, generally non-significant effects on systolic and diastolic blood pressures."	( Enalapril suppresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Elmoselhi, A; Keeley, FW; Leenen, FH, 1992)	2.45
"Enalapril treatment also significantly limited (P less than 0.01) the development of glomerular structural lesions (mean percentage of sclerotic glomeruli was 4.2 +/- 3.5% [treated] vs."	( Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. Battaglia, C; Bertani, T; Puntorieri, S; Remuzzi, A; Remuzzi, G, 1990)	1
"Enalapril treatment had no definite effect on the concentrations of plasma atrial natriuretic peptide or other neurohormone."	( Effect of enalapril on plasma atrial natriuretic peptide in late recovery phase of acute myocardial infarction. Hirvonen, T; Mustonen, J; Pyörälä, K; Remes, J; Tenhunen, M; Tikkanen, I, 1991)	1.41
"Enalapril pretreatment resulted in maintenance of small bowel blood flow after thermal injury and was associated with a significantly reduced incidence of BT (20% vs."	( Splanchnic vasoconstriction and bacterial translocation after thermal injury. Barber, AE; Fahey, TJ; Jones, WG; Minei, JP; Shires, GT, 1991)	1
"With enalapril treatment heart rate, pulmonary capillary wedge pressure, mean arterial pressure, and systemic vascular resistance decreased significantly both at rest and during submaximal exercise. "	( Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: a double blind study. Herrlin, B; Nyquist, O; Sylvén, C, 1991)	1.04
"Enalapril pretreatment did not alter the glomerular vasodilation and hyperfiltration following protein meal."	( Preservation of renal reserve in chronic renal disease. Kapoor, SC; Krishna, GG, 1991)	1
"Enalapril treatment resulted in a significant and similar shift to the left of the pressure-natriuresis relation in both strains of rats so that a lower renal artery pressure was required to excrete a similar amount of sodium when compared with their respective untreated controls.(ABSTRACT TRUNCATED AT 250 WORDS)"	( Effect of enalapril treatment on the pressure-natriuresis curve in spontaneously hypertensive rats. Kline, RL; McLennan, GP; Mercer, PF, 1991)	1.41
"Enalapril treatment normalized not only glomerular synthesis and content but also various fractions of heparan sulfate in diabetic rats."	( Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Dhuper, S; Lasker, N; Miller, M; Ramamurthi, R; Reddi, AS, 1991)	2.45
"Enalapril treatment was associated to a significant (p < 0.05) decrease in creatinine clearance which remained within normal limits."	( [Microalbuminuria in insulin-dependent diabetics: the prevention of diabetic nephropathy]. Durruty, G; Durruty, P; García de los Ríos, M; Krause, P; López, G; Pérez, F, 1990)	1
"Enalapril-treated animals were relatively hypotensive with lower GFR than CS controls."	( Effects of chronic volume expansion and enalapril on chronic cyclosporine nephropathy. Gillum, DM; Truong, L, 1990)	1.27
"Enalapril-treated spontaneously hypertensive rats eventually exhibited albuminuria as severe as that found in hypertensive rats."	( Enalapril and renal injury in spontaneously hypertensive rats. Cachero, S; Feld, LG; Noble, B; Van Liew, JB; Zamlauski-Tucker, M, 1990)	2.44
"In enalapril-treated patients (n = 27) Hb fell gradually from a median value of 7.6 to 6.7 mmol/l at 90 days of treatment."	( Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Kamper, AL; Nielsen, OJ, 1990)	1.2
"Enalapril treatment increased renal renin mRNA specific activity (renin mRNA/total RNA)."	( Angiotensin II regulates renin gene expression. Carey, RM; Gomez, RA; Inagami, T; Johns, DW; Peach, MJ, 1990)	1
"Enalapril treatment was stopped for 2 weeks in five rats."	( Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat. Franze, L; Jackson, B; Johnston, CI; Sumithran, E, 1990)	1
"Enalapril treatment (5 mg/kg/day, n = 11) or felodipine (30 mg/kg/day, n = 11) reduced systolic blood pressure to a comparable degree."	( Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. Cubela, R; Debrevi, L; Jackson, B; Johnston, CI; Whitty, M, 1987)	0.99
"Enalapril pretreatment blunted these responses."	( Renal effects of atrial natriuretic peptide in conscious rabbits with renal wrap hypertension. Anderson, WP; Denton, KM; Takata, M; Woods, RL, 1989)	1
"Enalapril treatment decreased blood pressure in only SHR, inhibited plasma angiotensin-converting enzyme activity by 85%, and increased plasma ANG I concentration and renin activity in both WKY and SHR."	( Enalapril decreases angiotensin II receptors in subfornical organ of SHR. Correa, FM; Gutkind, JS; Nazarali, AJ; Saavedra, JM, 1989)	2.44
"With enalapril treatment urinary K excretion was unchanged following K loading but moderately reduced following NH4Cl loading."	( Potassium homeostasis during angiotensin-converting enzyme inhibition with enalapril. Izzo, JL; McKenna, BA; Ornt, DB; Pabico, RC; Radke, KJ; Scandling, JD, 1989)	0.96
"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs."	( Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy. Meyer, TW; Miller, PL; Rennke, HG; Scholey, JW, 1989)	1
"Enalapril treatment caused a further reduction in urinary albumin excretion and an increase in serum albumin concentration in nephrotic rats fed 8.5% protein."	( Effect of dietary protein intake and angiotensin converting enzyme inhibition in Heymann nephritis. Davies, RW; Hutchison, FN; Kaysen, GA, 1989)	1
"Four enalapril-treated and six metoprolol-treated patients discontinued treatment because of side effects.(ABSTRACT TRUNCATED AT 250 WORDS)"	( A comparison of enalapril and metoprolol as initial therapy for mild to moderate hypertension. Miola, SR; Nugent, LW; Walker, JF, 1987)	1.07
"Enalapril pretreatment had no significant effect on protein-induced glomerular hyperfiltration."	( Protein-induced glomerular hyperfiltration: role of hormonal factors. Heeger, P; Hoeldtke, R; Kapoor, S; Krishna, GG; Miller, E; Newell, G; Polansky, M; Smith, R, 1988)	1
"Enalapril treatment (5 mg/day for 5 days and 10 mg thereafter) was added to the diuretic therapy and after 2 months a further decrease in blood pressure was observed (to 158 +/- 5.6 mmHg systolic, P less than 0.001; 87.2 +/- 5.0 mmHg diastolic, P less than 0.001)."	( Effects of the angiotensin converting enzyme inhibitor enalapril compared with diuretic therapy in elderly hypertensive patients. Arpino, G; Cacciapuoti, F; D'Avino, M; D'Errico, S; Sepe, J; Spiezia, R; Varricchio, M; Verza, M, 1988)	1.24
"Enalapril treatment was withdrawn for 2 weeks in five rats, but the clipped kidney remained small and non-functional."	( Chronic angiotensin converting enzyme inhibition in the two-kidney, one clip hypertensive rat. Franze, L; Jackson, B; Johnston, C; Sumithran, E, 1988)	1
"Enalapril treatment for 7 days reduced BP without a significant change in heart rate and pNE."	( Effect of chronic inhibition of angiotensin converting enzyme on baroreceptor reflex in essential hypertension. Eto, T; Fukiyama, K; Kimura, Y; Matsumura, K; Muratani, H; Noda, Y, 1988)	1
"3. Enalapril-treated rats (n = 12) had no significant reduction in systolic blood pressure, and a similar reduction in creatinine clearance to that in untreated rats."	( Effect of enalapril treatment on progression of the nephrotoxic serum nephritis model of renal failure in the rat. Debrevi, L; Jackson, B, 1988)	1.19
"3. Enalapril treatment normalized blood pressure to that of age-matched Wistar-Kyoto rats in both groups."	( Vascular smooth muscle polyploidy in the development and regression of hypertension. Adams, MA; Black, MJ; Bobik, A; Campbell, GR; Campbell, JH, 1988)	0.79
"Enalapril treatment significantly improved functional class, symptom score for breathlessness, and exercise tolerance."	( Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Ball, SG; Cleland, JG; Dargie, HJ; East, BW; Ford, I; Gillen, G; Hodsman, GP; Morton, JJ; Robertson, I; Robertson, JI, 1985)	1.38
"Enalapril treatment also prevented the increases in urine volume, and excretion of osmotically active solutes, Na, Cl and K with age."	( Chronic effects of enalapril on blood pressure, stroke, plasma renin, urinary electrolytes and PGE2 excretion in stroke-prone spontaneously hypertensive rats. Kawashima, K; Sokabe, H; Watanabe, TX, 1985)	1.32
"Enalapril treatment did not alter the aldosterone response to metoclopramide."	( Stimulation of aldosterone secretion by metoclopramide is not affected by chronic converting enzyme inhibition. Dupont, AG; Six, RO; Smitz, JJ; Vanderniepen, P, 1985)	0.99
"The enalapril treatment group had a decrease in the mean arterial blood pressure of 22.2 mmHg compared to the propranolol group of 17.9 mmHg at the end of the study."	( Long-term enalapril--a new converting enzyme inhibitor--in the treatment of mild to moderate essential hypertension, results of a worldwide multiclinic study. Comparing two ways of analyzing data. Espie, J; Lessem, JN; Rucinska, E; Sromovsky, JA; Vickers, FF, 1985)	1.15
"Enalapril treatment resulted in an 83% rise in RBF of the obstructed kidney, from 2.58 +/- 0.26 to 4.73 +/- 0.48 ml/min (P less than 0.001), which was associated with a 26% increase in number of perfused glomeruli (P less than 0.01)."	( Hemodynamic effects of enalapril on neonatal chronic partial ureteral obstruction. Chevalier, RL; Peach, MJ, 1985)	1.3
"Non-enalapril-treated diabetic rats exhibited significant elevations in mean glomerular capillary hydraulic pressure and transcapillary hydraulic pressure gradient, compared with the other groups studied, and only this group eventually developed marked and progressive albuminuria."	( Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. Anderson, S; Brenner, BM; Dunn, BR; Meyer, TW; Rennke, HG; Zatz, R, 1986)	0.75
"Enalapril treated rats had lower urinary protein excretion than controls (15 +/- 3 mg/24 hr vs 85 +/- 22 mg/24 hr, p less than 0.0001) at 6 weeks."	( Preservation of renal structure and function in the rat remnant kidney model of chronic renal failure by enalapril treatment. Cubela, R; Debrevi, L; Jackson, B; Whitty, M, 1987)	1.21
"Enalapril treatment was then started and both placebo and hypoglycaemic tests were repeated 15 days thereafter."	( Angiotensin converting enzyme inhibition reduces ACTH release due to hypoglycaemia. Alagna, S; Bandiera, F; Dessì-Fulgheri, P; Glorioso, N; Madeddu, P; Masala, A; Rappelli, A; Rovasio, PP; Rubattu, S; Soro, A, 1987)	0.99
"The treatment with enalapril and paricalcitol in combination was the most potent in decreasing the elevated serum glucose levels."	( Effects of enalapril and paricalcitol treatment on diabetic nephropathy and renal expressions of TNF-α, p53, caspase-3 and Bcl-2 in STZ-induced diabetic rats. Abdel Gaid, MA; Ahmed, OM; Ali, TM; Elberry, AA, 2019)	1.22
"Rats treated with enalapril showed a significantly lower plasma TMAO level and a trend towards higher 24 h urine excretion of TMA and TMAO. "	( Enalapril decreases rat plasma concentration of TMAO, a gut bacteria-derived cardiovascular marker. Grochowska, M; Konop, M; Perlejewski, K; Radkowski, M; Samborowska, E; Ufnal, M, )	1.91
"Treatment with enalapril significantly decreased Ang II levels in the renal cortex and medulla of male and female WKY rats as compared with those in vehicle-treated controls (P < 0.05); enalapril did not change the plasma levels of Ang II."	( Sex differences in angiotensin-converting enzyme modulation of Ang (1-7) levels in normotensive WKY rats. Bhatia, K; Sullivan, JC; Zimmerman, MA, 2013)	0.73
"Treatment with enalapril or losartan reduced the lipid peroxidation in lung and brain tissues, while preserving the tissue glutathione content and plasma antioxidant capacity."	( The effects of enalapril and losartan on mechanical ventilation-induced sympathoadrenal activation and oxidative stress in rats. Kirichenko, N; Kwon, OS; Llinas, K; Powers, SK; Sakarya, Y; Scarpace, PJ; Smuder, AJ; Sollanek, KJ; Talbert, EE; Toklu, HZ; Tümer, N; Wiggs, MP, 2014)	1.1
"Treatment with enalapril and ASS led to significant downregulation of known target genes Vegf and Rela at RNA level."	( Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors. Baier, A; Bartsch, DK; Fendrich, V; Holler, JP; Lopez, CL; Manoharan, J; Maschuw, K; Ramaswamy, A; Waldmann, J; Wichmann, S, 2014)	2.18
"Pre-treatment of enalapril or valsartan for 14 days reduced (p < 0.001) serum AST and plasma MDA levels and increased the concentration of erythrocyte GSH in enalapril pre-treated group (p < 0.01) and in valsartan pre-treated group (p < 0.05)."	( Modulation of oxidative stress by enalapril and valsartan in adrenaline treated rats: a comparative study. Akhter, N; Huda, S, 2014)	1.01
"Treatment with enalapril, paricalcitol or the combination of the two protected uremic rats from cardiac oxidative stress by inhibiting enzyme activity."	( Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Ferder, L; Finch, J; Husain, K; Mizobuchi, M; Slatopolsky, E, 2009)	0.96
"Treatment with enalapril for 2 years (0.1-1 mg/kg per day) did not bring about any change in urinary protein excretion."	( Nail-patella syndrome, infantile nephrotic syndrome: complete remission with antiproteinuric treatment. Devriendt, K; Proesmans, W; Van Dyck, M, 2009)	0.69
"Treatment with enalapril and a low-NaCl diet for 7 days led to a 35-fold increase in PRC among wild-type mice but no significant change in PRC among Gsalpha-deficient mice."	( Stimulation of renin secretion by angiotensin II blockade is Gsalpha-dependent. Briggs, JP; Chen, L; Chen, M; Eisner, C; Gomez, RA; Huang, Y; Kim, SM; Li, L; Mizel, D; Oppermann, M; Schnermann, J; Sequeira Lopez, ML; Weinstein, LS, 2010)	0.7
"The treatment of enalapril resulted in a significant decrease of airway secretion, as well as the downregulation of NF-kappaB in both protein and gene level."	( [Effects of enalapril on NF-kappaB expression in mucus hypersecretion rats induced by acrolein exposure]. Dan, QQ; Huang, YC; Meng, BL; Tan, Y; Wang, SL; Zhang, YH, 2010)	1.07
"Treatment with enalapril decreased blood pressure in hypertensive patients. "	( Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. Biagi, C; Fontana, V; Palei, ACT; Sertório, JTC; Silva, PS; Tanus-Santos, JE, 2011)	1
"Cotreatment with enalapril and paricalcitol had an additive effect in increasing CuZn-SOD expression."	( Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Cardema, MC; Ferder, L; Finch, JL; Gardner, DG; Glenn, DJ; Husain, K; Liapis, H; Slatopolsky, E; Suarez, EB, 2012)	0.71
"Co-treatment with enalapril inhibited these changes."	( Role of the renin-angiotensin system in the nandrolone-decanoate-induced attenuation of the Bezold-Jarisch reflex. Abreu, GR; Alcure, SM; Andrade, TU; Bissoli, NS; Lenz, D; Loiola, LZ; Medeiros, AR; Moysés, MR; Santos, MC; Uggere de Andrade, T, 2011)	0.69
"Treatment with enalapril, but not metformin or losartan, reversed the suppression of hepatic CYP epoxygenase metabolic activity and induction of renal CYP ω-hydroxylase metabolic activity, thereby restoring the functional balance between the pathways."	( Enalapril reverses high-fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. Deng, Y; Kannon, MA; Lee, CR; Miller, TM; Oni-Orisan, A; Poloyac, SM; Schuck, RN; Theken, KN, 2012)	2.16
"Treatment with enalapril resulted in longer survival compared with placebo."	( Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. Chiba, S; Kitabatake, A; Kumamoto, H; Matsui, Y; Mikami, T; Okamoto, H; Onozuka, H; Shimizu, T; Sugawara, T, 2002)	0.65
"Cotreatment with enalapril and the ET(B) receptor antagonist BQ-788 inhibited the expression of interstitial volume by only 19%."	( ACE inhibition increases expression of the ETB receptor in kidneys of mice with unilateral obstruction. Fitzgerald, M; Guo, G; Klahr, S; McCracken, R; Moridaira, K; Morrissey, J; Tolley, T, 2003)	0.65
"Pretreatment with enalapril (10 mg/kg iv) before ET-1 infusion inhibited the increase in MAP (121 +/- 4 vs."	( Enalapril attenuates endothelin-1-induced hypertension via increased kinin survival. Elmarakby, AA; Morsing, P; Pollock, DM, 2003)	2.09
"Treatment with enalapril or losartan reduced this increase."	( Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats. Coimbra, TM; Costa, RS; da Silva, CG; Volpini, RA, )	0.87
"Treatment with enalapril for 3-4 years led to a sustained improvement in survival beyond the original trial period in patients with left ventricular systolic dysfunction, with an important increase in life expectancy."	( Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Ahn, SA; Bangdiwala, SI; Jong, P; Rousseau, MF; Yusuf, S, 2003)	1.07
"The treatment with enalapril of hypertensive rats during pregnancy alters the collagen content and structure of the myocardium of newborns."	( Enalapril alters the formation of the collagen matrix in spontaneously hypertensive rats. Bomfim, Ade S; Mandarim-de-Lacerda, CA, 2003)	2.09
"1. Treatment with enalapril induces smooth muscle cell apoptosis and regression of aortic hypertrophy in spontaneously hypertensive rats (SHRs), whereas combined blockade of angiotensin II AT(1) and AT(2) receptors does not. "	( Kinin B2 receptor is not involved in enalapril-induced apoptosis and regression of hypertrophy in spontaneously hypertensive rat aorta: possible role of B1 receptor. Couture, R; deBlois, D; Der Sarkissian, S; Duguay, D; Kouz, R; Ongali, B, 2004)	0.93
"Treatment with enalapril, losartan and their combination attenuated the observed memory deficits indicating a possible role of renin angiotensin system in cognitive function."	( Effect of losartan and enalapril on cognitive deficit caused by Goldblatt induced hypertension. Ahamed, KF; Jayadev, S; Kumaran, D; Ramanathan, M; Srinivasan, J; Suresh, B, 2005)	0.98
"Treatment with enalapril or losartan for 8 weeks not only reduced blood pressure but also decreased serum ADMA (P <0.01 )."	( [Changes of serum asymmetric dimethylarginine in essential hypertension before and after the treatment]. Chen, BM; Tao, LJ; Xiong, Y; Zhang, WR, 2005)	0.67
"Treatment with enalapril or L-158809 was also effective in improving impaired acetylcholine-mediated vasodilation, but the efficacy was diminished from groups 1 to 4."	( ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Coppey, LJ; Davidson, EP; Gellett, JS; Lund, DD; Oltman, CL; Rinehart, TW; Yorek, MA, 2006)	0.67
"Treatment with enalapril (25 mg/kg perorally) in the early period of postnatal ontogeny produced delayed hypotensive and nephroprotective effects."	( Delayed effects of enalapril on structural characteristics of the glomerular apparatus in the kidneys of NISAG rats. Buzueva, II; Filyushina, EE; Kudryashova, DR; Lazarev, VA; Markel, AL; Shmerling, MD; Yakobson, GS, 2006)	1
"Treatment with enalapril was not associated with any increase in serum amylase concentrations in either animal subgroup."	( Enalapril increases the local extravasation of macromolecules and nitric oxide synthase in pancreas of the fructose-fed insulin-resistant rat model. Bouffard, L; Maheux, P; Papirakis, ME, 2006)	2.12
"Treatment with enalapril or losartan also decreased renal plasminogen activator inhibitor-1 in TSLPtg mice, assessed by immunohistochemistry and quantitative real-time reverse transcriptase-PCR."	( Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. Alexandrescu, S; Alpers, CE; Banas, M; Guo, S; Hudkins, KL; Iyoda, M; Kowalewska, J; Spencer, M; Wang, L; Wietecha, TA; Yi, K, 2008)	0.69
"Oral treatment with enalapril (15-100 mg X kg-1 X day-1) and HTZ (60-400 mg X kg-1 X day-1) caused a significant reduction of SBP in the DS rats with the high salt diet (P less than 0.001); however, this was not observed until after 4 weeks of treatment when the dosage was 30 and 150 mg X kg-1 X day-1, respectively."	( Systolic blood pressure responses to enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide in conscious Dahl salt-sensitive and salt-resistant rats. Fernandez, PG; Kim, BK; Sharma, JN; Triggle, CR, 1984)	0.86
"Treatment with enalapril attenuated the reflex tachycardia observed after nifedipine."	( Hemodynamic and humoral responses to enalapril and nifedipine in the rat. Ferguson, RK; Shepley, K; Swanson, BN; Vincent, ME, 1984)	0.88
"Treatment by enalapril prior to and during a 6 day period following abrupt suppression of dietary Na+ was associated with a sodium wasting state (urinary Na+ always exceeded intake during the observation period) and blunting by 90% of the aldosterone response to Na+ restriction In rats on chronic low Na+ intake, enalapril produced a slight, transient natriuresis together with a marked increase in drinking volume."	( Effect of converting enzyme inhibition by enalapril on sodium homeostasis in the rat. Jover, B; Mimran, A, 1984)	0.88
"Treatment with enalapril attenuated myocyte hypertrophy and the accumulation of interstitial collagen in comparison to untreated dogs."	( Ventricular remodeling: insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors. Cook, JM; Goldstein, S; Sabbah, HN; Sharov, VG, )	0.47
"Treatment with enalapril produces regression of left ventricular hypertrophy, normalization of thallium-201 uptake, and an increase in exercise capacity in patients with microvascular angina."	( Microvascular angina in systemic hypertension: diagnosis and treatment with enalapril. Caso, R; Iriarte, MM; López de Argumedo, M; Murga, N; Sagastagoitia, D, 1995)	0.86
"Treatment with enalapril or ramipril, initiated 3 weeks after aortic banding and continued for 3 more weeks, failed to prevent the progression or cause regression of cardiac hypertrophy."	( Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal. Mohabir, R; Strosberg, AM; Young, SD, 1994)	0.63
"Treatment with enalapril did not eliminate these correlations."	( Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Lishner, M; Neumann, L; Ravid, M, 1995)	0.63
"Treatment with enalapril significantly reduced plasma angiotensin II levels and supine blood pressure compared to placebo."	( Angiotensin converting enzyme inhibition does not affect response to exogenous angiotensin II in the forearm of mild-moderate hypertensive patients. Benjamin, N; Lyons, D; Webster, J, 1994)	0.63
"Treatment with enalapril significantly reduced plasma angiotensin II levels and supine blood pressure compared with placebo."	( Angiotensin converting enzyme inhibition does not affect the response to exogenous angiotensin II in the human forearm. Benjamin, N; Lyons, D; Stewart, D; Webster, J, 1994)	0.63
"Treatment with enalapril for 48 months may have a beneficial effect on the decline of microalbumin excretion in NIDDM patients."	( Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Hara, T; Hotta, N; Kawamura, T; Matsumae, H; Matsuo, S; Nakayama, M; Sakamoto, N; Sano, T; Sasaki, H, 1994)	0.96
"Treatment with enalapril alone (R, n = 8) reversed systemic hypertension, prevented a further increase in proteinuria, and significantly reduced glomerulosclerosis relative to the control group."	( Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Han, DC; Hwang, SD; Jin, SY; Lee, HB; Lee, SK, 1993)	0.9
"Treatment with enalapril decreased blood pressure but not renal alpha 2-adrenergic receptor density in both male and female SHR."	( Sex influence on renal alpha 2-adrenergic receptor density in the spontaneously hypertensive rat. Dobin, A; Gong, G; Johnson, ML; McArdle, S; Pettinger, WA; Sun, L, 1994)	0.63
"Rats treated with enalapril alone or in combination with the diuretic hydrochlorothiazide or rats treated with nitrendipine alone served as controls."	( Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Helmchen, U; Schoeppe, W; Schwietzer, G; Wenzel, UO, 1994)	0.92
"Cotreatment with enalapril reduced interstitial fibrosis (VvInt, 14 +/- 1%) and maintained VG (2.23 +/- 0.08 x 10(6) mu 3) and GFR (2.56 +/- 0.08 mL/min) at near-normal values in Group 3."	( The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. Lafayette, RA; Mayer, G; Meyer, TW, 1993)	0.61
"Treatment with enalapril significantly lowered both the systolic and diastolic blood pressures."	( Effect of chronic treatment with enalapril on glucose tolerance and serum insulin in non-insulin-resistant Japanese patients with essential hypertension. Baba, T; Ishizaki, T; Kodama, T, 1993)	0.91
"Treatment with enalapril decreased MA in diabetic groups A (no MA at rest) and B (MA at rest) during exercise and postexercise, and also decreased MA in group B while at rest."	( Decrease of exercise-induced microalbuminuria in patients with type I diabetes by means of an angiotensin-converting enzyme inhibitor. Daccordi, H; Ferder, L; Inserra, F; Ippolito, JL; Romano, L; Zelechower, H, 1996)	0.63
"Treatment with enalapril resulted in an absolute risk reduction of 42% for nephropathy to develop during 7 years (95% confidence interval, 15% to 69%; P < .001, Student's t test)."	( Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Lang, R; Lishner, M; Rachmani, R; Ravid, M, 1996)	0.63
"Treatment with enalapril on day 4 through day 8 or on day 6 through day 10 significantly reduced the elevated mRNA levels of these compounds in the obstructed kidney."	( Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Ishidoya, S; Klahr, S; McCracken, R; Morrissey, J, 1996)	0.94
"Mice treated with enalapril maintained small intestine weight, measured 4 h postburn, and ileal mucosal height was preserved, whereas burned untreated animals lost intestinal weight and mucosal height."	( Effects of the angiotensin converting enzyme inhibitor enalapril on bacterial translocation after thermal injury and bacterial challenge. Alexander, JW; Babcock, GF; Boyce, ST; Cornaggia, M; Gennari, R; Lilly, N, 1996)	0.86
"The treatment with enalapril at 3 mg/kg/day did not reduce the left ventricular weight or the systolic blood pressure in the aortic banding rats."	( Chronic low-dose treatment with enalapril induced cardiac regression of left ventricular hypertrophy. Hata, T; Makino, N; Sugano, M; Taguchi, S; Yanaga, T, )	0.73
"Treatment with enalapril was started 5 minutes before reperfusion by intravenous infusion of enalapril at a dosage of 5 mg/kg/h."	( Angiotensin-converting enzyme inhibition by enalapril: a novel approach to reduce ischemia/reperfusion damage after experimental liver transplantation. Anthuber, M; Farkas, S; Jauch, KW; Menger, MD; Messmer, K; Rihl, M; Schildberg, FW, 1997)	0.9
"Treatment with enalapril for 10 weeks, but not 4 weeks, significantly reduced the ACE activity in aortic tissue in association with the reductions in the elevated Ang II level and the atherosclerotic plaque area of the aortic tissue."	( Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Nishida, M; Tada, M; Yamashita, N, 1997)	0.86
"Treatment with enalapril for 3 months lowered the mean arterial pressure from 94+/-2 to 84+/-4 mm Hg in control rats and from 146+/-3 to 89+/-3 mm Hg in TGR."	( Enalapril and pressure-diuresis in hypertensive rats transgenic for mouse renin gene. Ganten, D; Springate, J; Van Liew, J, 1997)	2.08
"Treatment with enalapril (250 mg/l) and quinapril (200 mg/l in drinking water) was started 3 days before the shunt and sham surgery."	( ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy. Lear, W; Leenen, FH; Ruzicka, M, 1997)	0.64
"Treatment with enalapril had no significant effect on FMD (p=0.67) or response to the endothelial-independent dilator GTN (p=0.45)."	( Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study. Bull, T; Clarkson, P; Deanfield, JE; Donald, AE; Furuno, T; Mullen, MJ; Powe, AJ; Thomson, H; Thorne, SA, 1998)	1.04
"Treatment with enalapril prevented an increase in the blood pressure and the heart weight."	( Effect of long-term treatment with enalapril in streptozotocin diabetic and DOCA hypertensive rats. Bangaru, RA; Gandhi, TP; Goyal, RK; Satia, MC, 1998)	0.92
"Treatment with enalapril initiated 2 h after AMI prevented left ventricular dilation by limiting infarct expansion. "	( Early angiotensin converting enzyme inhibitor therapy after experimental myocardial infarction prevents left ventricular dilation by reducing infarct expansion: a possible mechanism of clinical benefits. Alhaddad, IA; Ali, SM; Brown, EJ; Nallapati, SR, 1998)	0.65
"Treatment with enalapril normalized blood pressure and muscle sympathetic-nerve activity (at 23+/-10 bursts per minute) in the patients and shifted the baroreflex curve to the left, reflecting normal blood-pressure levels, without significantly changing sensitivity (-2.3+/-1.8 bursts per minute per mm Hg, P=0.96)."	( Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. Blankestijn, PJ; Boomsma, F; Dijkhorst-Oei, LT; Klein, IH; Koomans, HA; Ligtenberg, G; Oey, PL; van Huffelen, AC; Wieneke, GH, 1999)	0.91
"Treatment with enalapril (EN) (50 mg/l in drinking water) was started 9 days prior to surgery."	( [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure]. Ciechanowicz, A, 1999)	0.89
"Treatment with enalapril (0.5 mg/kg, p.o., q 24 h) significantly reduced blood pressure in normotensive healthy cats and cats with ADPKD, and resulted in predictable changes in RAAS enzyme activities and hormone concentrations."	( Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease. DiBartola, SP; Lehmkuhl, LB; Miller, RH; Radin, J; Smeak, DD, 1999)	1.05
"Treatment with enalapril was associated with a greater reduction in albuminuria than with nifedipine in the entire patient group, and especially in those with microalbuminuria."	( Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Chan, JC; Cheung, MY; Cheung, RC; Cockram, CS; Critchley, JA; Ko, GT; Leung, DH; Nicholls, MG; So, WY; Swaminathan, R, 2000)	0.65
"Treatment with enalapril maleate led to a statistically significant decrease of von Willebrand's factor in plasma and ex vivo platelet aggregation whereas flow-mediated dilatation increased."	( [Effect of enalapril maleate on vascular endothelial function and platelet-endothelial interactions in patients with essential hypertension]. Iakovlev, VM; Il'iunykh, LN; Iudin, SM; Korennova, OIu; Kudriashov, IL; Nazarov, AG; Potapov, VV; Semenkin, AA, 2000)	1.04
"Treatment with enalapril maleate may lead to normalisation of endothelial function and decrease of platelet activity."	( [Effect of enalapril maleate on vascular endothelial function and platelet-endothelial interactions in patients with essential hypertension]. Iakovlev, VM; Il'iunykh, LN; Iudin, SM; Korennova, OIu; Kudriashov, IL; Nazarov, AG; Potapov, VV; Semenkin, AA, 2000)	1.04
"Treatment with enalapril attenuated the development of proteinuria, ameliorated morphological damage, decreased leukocyte infiltration, and prevented a rise in renal mRNA levels of growth factors and cytokines in kidney grafts in a rat model of chronic renal allograft rejection."	( Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Antus, B; Hamar, P; Heemann, U; Lutz, J; Philipp, T; Schleimer, K; Szabo, A, 2000)	0.66
"Pretreatment of enalapril and losartan did not prevent the reduction in GFR, indicating that angiotensin II was not involved."	( Mechanism of reduced GFR in rabbits with ischemic acute renal failure. Cho, SI; Jung, JS; Kim, BS; Kim, SJ; Kim, YK; Lim, YT; Woo, JS, 2000)	0.64
"Treatment with enalapril was associated with a significantly higher incidence of cough (P = 0.006) and a rise in serum uric acid (P = 0.002) compared with losartan."	( Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Bélanger, A; Godin, C; Hallé, JP; Lacourcière, Y; Marion, J; Ross, S; Wright, N, 2000)	0.92
"Treatment with enalapril, 5 mg, reduced Hb levels more markedly than treatment with losartan, 50 mg, in patients with PTE."	( Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Goh, J; Lam, CW; Li, PK; Lui, SF; Wang, AY; Yu, AW; Yu, LM, 2002)	0.96
"Treatment with enalapril was also associated with a comparable reduction in the risk of the development of HF requiring medical therapy and the composite end point of death or development of HF in black and white patients."	( Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. Cooper, RS; Drazner, MH; Dries, DL; Strong, MH, 2002)	0.65
"Treatment with Enalapril decreased the reflection of the retinal arterial wall significantly and reduced the narrowing of arteries and arterio-venous crossing phenomena non-significantly."	( Hypertensive retinal vascular changes: relationship to left ventricular hypertrophy and arteriolar changes before and after treatment. Dahlöf, B; Hansson, L; Stenkula, S, 1992)	0.62
"Pretreatment with enalapril from 4-9 weeks reduced the hypertension of SHR at 14 and 20 weeks by 38% and abolished all baroreceptor-HR reflex differences between the two strains."	( Characterization of the baroreceptor heart rate reflex during development in spontaneously hypertensive rats. Adams, MA; Head, GA, 1992)	0.61
"Treatment with enalapril can reduce the rate of decline in kidney function in patients with diabetic nephropathy more than equally effective antihypertensive treatment with metoprolol."	( Renal protective effect of enalapril in diabetic nephropathy. Aurell, M; Björck, S; Johnsen, SA; Mulec, H; Nordén, G, 1992)	0.92
"Treatment with enalapril reduces the degree of proteinuria in these patients, suggesting that glomerular capillary hypertension may be a pathogenic factor in sickle cell nephropathy."	( Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. Falk, RJ; Jennette, JC; Johnson, A; Orringer, E; Phillips, G; Scheinman, J, 1992)	0.62
"Treatment with enalapril resulted in significant improvement in 11 of the 34 items, and a tendency for another 4 items to improve."	( Crossover trial comparison of enalapril maleate and trichlormethiazide in the treatment of essential hypertension: emphasis on the quality of life. Hayashi, H; Ishizaka, K; Kisamori, K; Kobayashi, A; Yamazaki, N, 1992)	0.91
"Treatment with enalapril (10 mg/kg per day) and trandolapril (1 mg/kg per day) lowered systolic blood pressure, left ventricular weight and left ventricular angiotensin II content."	( Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. Higaki, J; Higashimori, K; Katahira, K; Mikami, H; Moriguchi, A; Nagano, M; Nakamaru, M; Nakamura, F; Ogihara, T; Tabuchi, Y, 1991)	0.62
"Treatment with enalapril (10 mg/day, adjusted between 5 and 40 mg, if necessary) or atenolol (50 mg/day, adjusted between 25 and 100 mg if necessary) titrated against a target fall in diastolic blood pressure to less than 95 mm Hg or of greater than 10 mm Hg, or both."	( Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. Apperloo, AJ; de Jong, PE; de Zeeuw, D; Sluiter, HE, 1991)	0.94
"Treatment with enalapril was started with a daily dose of 10 mg."	( Comparison of the antihypertensive effects of delapril and enalapril. Rahn, KH, 1991)	0.86
"Treatment with enalapril for 10 days reduced UalbV and FCalb in nephrotic rats fed either LP or HP."	( Differing actions of dietary protein and enalapril on renal function and proteinuria. Hutchison, FN; Jones, H; Kaysen, GA; Martin, VI, 1990)	0.88
"Treatment with enalapril alone for 4-6 days did not reduce SNGFR and SNPF; however, delta P decreased."	( Acute and subacute prostaglandin and ANG II inhibition on glomerulotubular dynamics in rats. Blantz, RC; Tucker, BJ, 1990)	0.62
"Treatment with enalapril (40 mg.kg-1.day-1) 1) prevented the striking rise in plasma renin activity in rats fed the low-NaCl K-free diet, 2) led to complete blockade of the pressor response to a 50-ng injection of angiotensin I but not ANG II, 3) did not affect daily water intake in rats consuming the control salt diet, 4) did not reduce basal water intake in rats fed the low-NaCl K-free diet below values measured in control animals, and 5) did not abolish water intake in response to osmotic stimulation."	( Converting-enzyme inhibition abolishes polydipsia induced by dietary NaCl and K depletion. McKay, AJ; Peterson, LN; Poirier, CD, 1990)	0.62
"Treatment with enalapril (n = 7) during pacing reduced the decrease in aortic flow by 33% and prevented changes in plasma urea, potassium, and sodium."	( Converting enzyme inhibition by enalapril in experimental heart failure. Bassenge, E; Holtz, J; Munzel, T; Sommer, O, 1990)	0.9
"Treatment with enalapril normalized BP, corrected electrolyte abnormalities, and reduced proteinuria."	( Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome. Battaglia, C; Remuzzi, A; Remuzzi, G; Schieppati, A, 1989)	0.62
"Treatment with enalapril in these patients usually continued without interruption for the length of the particular protocol."	( High-risk patients treated with enalapril maleate: safety considerations. Irvin, J; Rucinska, EJ; Small, R, 1989)	0.9
"The treatment with enalapril was well tolerated and tolerance improved remarkably in the patients, whose previous treatment had caused intolerance."	( The effects of enalapril on hypertension and quality of life. A large multicenter study in Belgium. de Lame, PA; Droussin, AM; Thomson, M; Verhaest, L; Wallace, S, 1989)	0.95
"Treatment with enalapril decreased plasma aldosterone and increased plasma renin activity (PRA), epinephrine and norepinephrine, but did not affect serum glucose, plasma insulin or basal plasma K."	( Potassium homeostasis during angiotensin-converting enzyme inhibition with enalapril. Izzo, JL; McKenna, BA; Ornt, DB; Pabico, RC; Radke, KJ; Scandling, JD, 1989)	0.85
"Treatment with enalapril was associated with significant increases in levels of HDL cholesterol (mean, 23%; P less than 0.001) and apoprotein A (mean, 11%; P less than 0.01), largely because of the increase in the subfraction HDL2 (mean, 43%; P less than 0.001), although the subfraction HDL3 also rose (mean, 14%; P less than 0.005)."	( Increase in plasma HDL-cholesterol in hypertensive patients treated with enalapril. Bongarzoni, A; Finardi, G; Martignoni, A; Muggia, C; Perani, G; Radaelli, A; Testa, F, 1987)	0.84
"Treatment with enalapril, in the absence of frusemide, was associated with a fall in mean blood pressure from 89 +/- 5 mmHg to 85 +/- 4 mmHg (P less than 0.02) and a rise in renal blood flow from 424 +/- 202 ml min-1 to 494 +/- 225 ml min-1 (P less than 0.02), but cardiac output and glomerular filtration rate were again unchanged."	( The effects of frusemide and angiotensin-converting enzyme inhibitors and their combination on cardiac and renal haemodynamics in heart failure. Cleland, JG; Dargie, HJ; Gillen, G, 1988)	0.61
"Treatment with enalapril reduced the degree of proteinuria at three months (36.4 +/- 3.0 mg/24 h, p less than 0.05)."	( Diabetic nephropathy in the rat: differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor. Jackson, B; Whitty, MR, 1988)	0.61
"Treatment with enalapril alone produced no changes in plasma catecholamine levels compared to control."	( Rest and exercise hemodynamic and adrenergic responses to enalapril, hydrochlorothiazide, and combination treatment in patients with systemic hypertension. Charlap, S; Frishman, W; Saltzberg, S; Shamoon, H; Stroh, JA; Weinberg, P, 1985)	0.85
"Treatment with enalaprilat was accompanied by significant reductions in heart preload and afterload and in plasma hormone concentrations."	( Plasma concentrations of angiotensin II and aldosterone during acute left ventricular failure in the dog. Effect of converting enzyme inhibition. Hall, C; Karlberg, BE, 1986)	0.61

Excerpt	Reference	Relevance
" Significantly fewer adverse events were experienced on lisinopril and metoprolol than on diuretic treatment."	( Quality of life, side effects and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. Bech, P; Frimodt-Moeller, J; Kornerup, HJ; Poulsen, DL, 1991)	0.28
" In clinical trials, adverse experiences in patients treated with a lisinopril-hydrochlorothiazide combination were dizziness (7."	( Review of international safety data for lisinopril-hydrochlorothiazide combination treatment. Murray, NH, 1991)	0.28
" A comparison of the double-blind studies demonstrated that quinapril has a lower incidence of adverse events and/or withdrawals than reported for captopril or enalapril."	( The safety and tolerability of quinapril. Frank, GJ; Knapp, LE; McLain, R; Posvar, E; Rieger, MM; Singer, R, 1990)	0.48
" The most frequently reported adverse reactions were headache, dizziness, and edema in the isradipine group, and cough, headache, and chest pain in the enalapril group."	( A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension. Eisner, GM; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR; Vargas, R; Zemel, M, 1991)	0.71
"Data from the lisinopril-captopril comparison trial (6), as well as other data (1, 8, 14, 10) indicate that both long- and short-acting ACEI are effective and safe for the treatment of CHF."	( Comparison of lisinopril and captopril in the treatment of left ventricular congestive heart failure--influence of duration of action on efficacy and safety. Giles, TD, 1991)	0.28
" Treatment was well tolerated and the profile of adverse events was similar to the pattern found with other nonsulfydryl angiotensin converting enzyme inhibitors."	( The antihypertensive effect and safety of lisinopril in patients with mild to moderate essential hypertension. A Belgian multicenter study. De Lame, PA; Droussin, AM; Lame, PA; Thomson, M, 1990)	0.28
" The number of patients experiencing clinical adverse effects was significantly greater in the nifedipine group than in the enalapril group [33 (48."	( Comparative efficacy and safety of enalapril and sustained-release nifedipine in patients with mild to moderate hypertension. The Enalapril vs Nifedipine French Study Group. Artigou, JY; Benichou, M; Berland, J; Fressinaud, P; Grollier, G; Gueret, P; Nguyen, CD, 1990)	0.76
" Quinapril was well tolerated in all trials, with the incidence of adverse events and withdrawals tending to be lower with quinapril than with enalapril or captopril."	( The safety and efficacy of quinapril in the treatment of mild to moderate essential hypertension. Frishman, WH, 1990)	0.48
" The period of sensitivity of fetuses to the toxic effects of enalapril was found to be limited to middle-to-late gestation (Gestational Days 14-27)."	( Maternotoxicity and fetotoxicity of an angiotensin-converting enzyme inhibitor, enalapril, in rabbits. Bagdon, WJ; Bokelman, DL; MacDonald, JS; Minsker, DH; Robertson, RT, 1990)	0.75
" In the hypertensive population, the most frequent clinical adverse experiences on lisinopril alone were headache, dizziness, cough, and diarrhea."	( The safety and tolerability of lisinopril in clinical trials. Merrill, DD; Rush, JE, 1987)	0.27
" The incidence of adverse reactions resulting in discontinuation of treatment was comparable to that observed with other standard antihypertensive therapies in patients with milder forms of disease."	( High-risk patients treated with enalapril maleate: safety considerations. Irvin, J; Rucinska, EJ; Small, R, 1989)	0.56
" It is concluded that lisinopril 5 mg is a safe starting dose for elderly patients who are not on diuretics, and that once-daily lisinopril monotherapy reduces BP safety without affecting heart rate."	( Safety and efficacy of lisinopril in elderly patients with mild to moderate hypertension. De Vriese, G; Marlier, R; Vandepapelière, P, 1989)	0.28
"The results of more than 1600 patient years of experience with the new angiotensin converting enzyme (ACE) inhibitor, quinapril, suggest that it is safe for the treatment of hypertension and congestive heart failure."	( Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects? Frank, GJ, 1989)	0.28
" Here we compare the clinical and laboratory adverse experiences in younger (under 55 years old) and older (at least 55 years old) patients treated with lisinopril monotherapy."	( Safety and tolerability of lisinopril in older hypertensive patients. Lyle, PA; Rush, JE, 1988)	0.27
" Unlike those reported in younger patients, all but one of the adverse drug reactions occurred 8 h or more after the first dose."	( Evaluation of the safety of enalapril in the treatment of heart failure in the very old. Bowes, SG; Denham, MJ; Dobbs, RJ; Dobbs, SM; Hunt, WB; O'Neill, CJ; Royston, JP; Sullens, CM, 1988)	0.57
"Although converting-enzyme inhibition is of established value in the management of patients with severe chronic congestive heart failure, troublesome adverse reactions occur frequently during the course of treatment and may cause physicians to interrupt effective therapy."	( Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Gottlieb, SS; Kessler, PD; Packer, M, 1986)	0.27
" Adverse effects are reviewed as those associated with sulfhydryl compounds and as those considered class-specific adverse effects of angiotensin converting enzyme inhibitors."	( Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. Irvin, JD; Viau, JM, 1986)	0.5
" Enalapril has a good safety profile as measured by frequency of clinical and laboratory adverse experiences."	( The efficacy and safety of enalapril in moderate to severe essential hypertension. Kramsch, DM; Kulaga, SF; Walker, JF, 1984)	1.47
" Apart from class-typical effects, such as edema for calcium antagonists, and cough for angiotensin-converting enzyme inhibitors, both drugs were equally well tolerated, with few adverse effects of clinical significance."	( A double-blind, long-term, comparative study on quality of life, safety, and efficacy during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicenter study. Eide, I; Herland, OB; Midha, R; Omvik, P; Thaulow, E; Turner, RR, 1993)	0.49
" We conclude that enalapril monotherapy is effective in adolescents with SEH and exerts a beneficial influence on sodium and purine balance and no adverse effect on the lipid profile."	( [Evaluation of the efficacy and safety of monotherapy for significant essential hypertension in adolescents with use of enalapril]. Cichocka, E; Januszewicz, P; Kawalec, W; Wyszyńska, T, 1995)	0.83
" Overall, losartan, whether administered alone or in combination with a low dose of hydrochlorothiazide (HCTZ), was effective and well-tolerated in these clinical trials, with an incidence of adverse experiences similar to that of placebo."	( Efficacy and safety of losartan. Goldberg, A; Sweet, C, 1995)	0.29
" The side-effect score for edema was lower with ISR plus diuretics than with other combinations, whereas the ACE inhibitor was associated with a higher score for cough."	( Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. Lüscher, TF; Waeber, B, 1993)	0.29
" Three patients in each group experienced adverse reactions requiring withdrawal of 1 patient in each group."	( Comparison of the safety and efficacy of delapril with enalapril in patients with congestive heart failure. Acanfora, D; Furgi, G; Nicolino, A; Papa, A; Picone, C; Rengo, C; Rengo, F; Vitale, DF, 1995)	0.54
" Safety was evaluated by monitoring the adverse reactions, laboratory tests, and blood pressure."	( Safety and efficacy study of delapril versus enalapril in patients with congestive heart failure. Dalla-Volta, S, 1995)	0.55
" Other reasons for discontinuation and adverse events not leading to discontinuation were also comparable."	( Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. Baiker, W; Baumann, G; Frick, MH; Haehl, M; Krayenbühl, HP; Nehmiz, G; Remme, WJ, 1994)	0.5
" Reported adverse events were mostly not study drug-related and were similar to those with placebo except for headache, which was more frequent with spirapril than placebo (5."	( A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. UK Study Group of Spirapril in Hypertension. Fairhurst, GJ, 1994)	0.29
" The most commonly reported adverse effects were cough (13-17%), dizziness, headache and insomnia."	( Efficacy and safety of spirapril, a new ace-inhibitor, in elderly hypertensive patients. Ekman, K; Honkanen, T; Järveläinen, V; Kantola, I; Kataja, M; Terént, A, 1996)	0.29
" Losartan was well tolerated in this trial, with an adverse event profile similar to placebo and enalapril."	( An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Bradstreet, TE; Byyny, RL; Merrill, DD; Sweet, CS, 1996)	0.74
" Nor have previous studies compared commonly used quality of life instruments for consistency, or investigated whether improvement or worsening of quality of life correlates with adverse events or blood pressure reduction."	( Antihypertensive therapy and quality of life. Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Adegbile, IA; Alemayehu, D; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1996)	0.29
" Angiotensin-converting enzyme inhibitors in low dose are a safe and effective long-term therapy for postrenal transplant erythrocytosis."	( Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. Briggs, JD; Junor, BJ; MacGregor, MS; Rodger, RS; Rowe, PA; Watson, MA, 1996)	0.29
" Hyponatraemia has previously been described as an adverse effect to fluoxetine and paroxetine, but not to citalopram."	( [Adverse effects of selective serotonin uptake inhibitors. Hyponatremia caused by Schwartz-Bartter syndrome]. Almdal, TP; Christensen, O; Sørensen, HA, 1996)	0.29
" Secondary variables included the change in DBP and SBP after 6 weeks of therapy, the BP normalization rates at 3 and 6 weeks and, concerning tolerability, the rates of adverse events after 6 weeks of therapy."	( Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor. Griebenow, R; Mueller, E; Mutschler, E; Pittrow, DB; Weidinger, G; Welzel, D, 1997)	0.3
" Patient demographic and baseline characteristics, systolic and diastolic blood pressures, adverse events reported, and data quality were recorded as the outcome measures."	( A prospective comparison of four study designs used in assessing safety and effectiveness of drug therapy in hypertension management. Hamet, P; Jolain, B; Levine, MA; Novosel, S, 1997)	0.3
" Drug-related adverse events were relatively infrequent, often transient, usually mild, and apparently not dose related."	( Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. Enalapril-Felodipine ER Factorial Study Group. Cutler, NR; Davis, PJ; Gradman, AH; Michelson, EL; Robbins, JA; Weiss, RJ; Wood, BC, )	0.37
" Most adverse experiences reported throughout the study were mild or moderate in both treatment groups."	( Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Gavras, H; Gavras, I, 1999)	0.59
" Eprosartan was well tolerated; the overall incidence of adverse events was comparable to that in the enalapril group."	( Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Sega, R, 1999)	0.52
" Telmisartan, a new angiotensin receptor blocker, is a safe and effective drug to use in combination for the treatment of patients with severe hypertension and proved at least as effective as the enalapril combination."	( The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Neutel, JM; Reilly, PA; Smith, DH, )	0.57
" The primary criterion for tolerability was the incidence of adverse experiences."	( Efficacy and safety of valsartan compared with enalapril at different altitudes. Blanco, M; Botero, R; Del Portillo, H; María, E; Matiz, H; Orejarena, H; Velez, JR, 2000)	0.56
" Adverse events irrespective of relationship to trial drug were reported by 12 patients (18."	( Efficacy and safety of valsartan compared with enalapril at different altitudes. Blanco, M; Botero, R; Del Portillo, H; María, E; Matiz, H; Orejarena, H; Velez, JR, 2000)	0.56
"To study the effect of losartan potassium in the treatment of mild to moderate hypertension and to compare its efficacy and adverse effect profile with enalaparil maleate."	( Evaluation of efficacy and safety of losartan potassium in the treatment of mild to moderate hypertension as compared to enalapril maleate. Babu, A; Bhaduri, J; Kamath, S; Kumar, TR; Raju, BS; Rao, M; Shobha, JC, 2000)	0.51
"A persistent, chronic dry cough is the most common adverse effect of angiotensin converting enzyme (ACE) inhibitors therapy."	( The influence of inhaled furosemide on adverse effects of ACE-inhibitors in airways. Franova, S, 2001)	0.31
"The results showed the protective effect of inhaled furosemide against the respiratory adverse effects induced by ACE-inhibitors administration."	( The influence of inhaled furosemide on adverse effects of ACE-inhibitors in airways. Franova, S, 2001)	0.31
" The overall incidence of adverse events (40."	( A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambula Aguilera, MT; Calvo, C; Coca, A; de la Sierra, A; García-Puig, J; Gil-Extremera, B; Marín, R; Martín-Hidalgo, A, 2002)	0.53
" Based on the number of treatment-related adverse events, irbesartan was better tolerated than enalapril."	( A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambula Aguilera, MT; Calvo, C; Coca, A; de la Sierra, A; García-Puig, J; Gil-Extremera, B; Marín, R; Martín-Hidalgo, A, 2002)	0.75
" Adverse events occurred in 12 (26."	( Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. Baumelou, B; Chanard, J; Hannedouche, T, 2001)	0.56
" Adverse events were carefully recorded throughout the study."	( A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. Frame, V; Herrera, P; Shahinfar, S; Shaw, W; Soffer, B; Wells, T; Zhang, Z, 2002)	0.54
" Fewer patients experienced adverse events in the valsartan group (50%) than in the enalapril group (63%), although statistically non-significant."	( Safety and efficacy of valsartan versus enalapril in heart failure patients. Gordon, A; Helmers, C; Löfdahl, P; Pantev, E; Rydberg, E; Willenheimer, R, 2002)	0.81
" Adverse effects were recorded."	( An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. Adhikari, PM; Bhat, P; Chowta, KN; Chowta, MN, 2002)	0.54
" Adverse events reported with losartan were mild."	( An open comparative clinical trial to assess the efficacy and safety of losartan versus enalapril in mild to moderate hypertension. Adhikari, PM; Bhat, P; Chowta, KN; Chowta, MN, 2002)	0.54
"Presented is an unusual case of a 66-year-old-resident of a long-term care facility, who manifested severe dysgeusia and impaired quality of life attributed to the angiotensin-converting enzyme (ACE) inhibitor enalapril; not realized at the time was the fact that he had an adverse reaction-cough-just weeks earlier from another ACE inhibitor in the same class, quinapril, thus illustrating different adverse effects to two antihypertensives in the same class."	( If it is not cough, it must be dysgeusia: differing adverse effects of angiotensin-converting enzyme inhibitors in the same individual. Dharmarajan, TS; Murakonda, P; Unnikrishnan, D, )	0.32
"A persistent, chronic dry cough is the most common adverse effect of angiotensin converting enzyme (ACE) inhibitors therapy."	( Enalapril and diltiazem co-administration and respiratory side effects of enalapril. Antosová, M; Franová, S; Nosál', S; Nosál'ová, G, 2005)	1.77
" The adverse events related with the treatment were significantly less frequent with E/N than with a (19."	( [Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg]. de la Figuera-von Wichman, M; de la Sierra-Iserte, A; Delgadillo-Duarte, J; Luque-Otero, M; Marín-Iranzo, R; Oliván-Martínez, J; Pontes-García, C; Redón-Mas, J; Roca-Cusachs, A, 2005)	0.56
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Effects on systolic blood pressure, heart rate, biochemical variables, adverse events and quality of life were studied as secondary efficacy parameters."	( Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomis Borrild, N; Rasmussen, S; Vang Andersen, J, 2006)	0.54
" The incidences of adverse events were similar in the low-dose bendroflumethiazide groups, with significantly higher incidences in the enalapril and amlodipine groups."	( Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomis Borrild, N; Rasmussen, S; Vang Andersen, J, 2006)	0.74
" The adverse effects included dry cough (seven [19."	( Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Lee, KO; Liew, CF; Lim, P; Mukherjee, JJ; Tan, F, 2010)	0.36
"Dual blockade of the RAAS is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy."	( Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Lee, KO; Liew, CF; Lim, P; Mukherjee, JJ; Tan, F, 2010)	0.36
"Thus, ACE inhibitor treatment of heart failure symptoms in patients with a systemic right ventricle is safe and reduces NT-proBNP levels significantly as a marker for ventricular overload."	( Safety and efficiency of chronic ACE inhibition in symptomatic heart failure patients with a systemic right ventricle. Bertram, H; Meyer, GP; Schieffer, B; Tutarel, O; Wessel, A; Westhoff-Bleck, M, 2012)	0.38
" We conclude that ACEI use in the early post-transplant period can be safe but patients must be carefully selected and monitored for elevations in serum creatinine and potassium."	( Angiotensin converting enzyme inhibitor use soon after renal transplantation: a randomized, double-blinded placebo-controlled safety study. Coco, M; Glicklich, D; Gordillo, R; Solorzano, C; Supe, K; Tapia, R; Woroniecki, R, )	0.13
" We also assessed the relations between dose levels and baseline variables or adverse events."	( Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Follath, F; Funck-Brentano, C; Goulder, M; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R, 2011)	0.62
" For both study drugs, the dose level reached was associated with baseline characteristics and adverse events."	( Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Follath, F; Funck-Brentano, C; Goulder, M; van de Ven, LL; van Veldhuisen, DJ; Willenheimer, R, 2011)	0.62
"The RCT on phosphocreatine found no differences in overall survival, mortality due to heart failure, echocardiographic cardiac function and adverse events between treatment and control group."	( Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Caron, HN; Cheuk, DK; Kremer, LC; Postma, A; Sieswerda, E; van Dalen, EC, 2011)	0.37
"A fixed-dose combination (FDC) of enalapril and lercanidipine has been shown to be effective and safe in reducing blood pressure in randomized clinical trials."	( Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Bramlage, P; Kreutz, R; Scholze, J; Trenkwalder, P, 2011)	0.88
" Treatment was associated with a low incidence of adverse events (3."	( Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Bramlage, P; Kreutz, R; Scholze, J; Trenkwalder, P, 2011)	0.6
" Data obtained with the prophylactic protocol of treatment might indicate that individuals under treatment with ACE inhibitors are less susceptible to the toxic effects of APAP."	( Effects of treatment with enalapril on hepatotoxicity induced by acetaminophen in mice. Betto, MR; Campos, MM; Driemeier, D; Lazarotto, LF; Leite, CE; Watanabe, TT, 2012)	0.68
" Adverse effects were seen in only one patient (0."	( Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal. Maldonado, J; Pereira, T; Tavares, A, 2014)	0.67
" No other adverse effects were reported."	( Efficacy and safety of lercanidipine/enalapril fixed combination in Lebanon: a prospective observational study. Arnaout, S, 2015)	0.69
"The RCT on phosphocreatine found no differences in overall survival, mortality due to heart failure, echocardiographic cardiac function, and adverse events between treatment and control groups."	( Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cheuk, DK; Kremer, LC; Postma, A; Sieswerda, E; van Dalen, EC, 2016)	0.43
" We determined the proportion of exposed infants who developed adverse events, including death, hypotension requiring pressors, hyperkalemia, and elevated serum creatinine."	( Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit. Benjamin, DK; Clark, RH; Hornik, CP; Ku, LC; Smith, PB; Zimmerman, K, 2017)	0.86
" Therefore, we have examined dementia-related adverse effects (AEs) in PARADIGM-HF and placed these findings in the context of other recently conducted HFrEF trials."	( Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Cannon, JA; Chen, F; Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shen, L; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR, 2017)	0.46
" The rate of adverse events was comparable between the enalapril and sacubitril-valsartan groups, although the absolute rates are likely underestimated due to the entry criteria and run-in period."	( The safety of sacubitril-valsartan for the treatment of chronic heart failure. Teerlink, JR; Tyler, JM, 2017)	0.7
" Adverse drug reactions (ADRs) were monitored."	( Comparison of Effect of Enalapril and Losartan Monotherapy on Quality of Life and Safety of Stage 1 Hypertensive Patients. Gupta, LK; Maharshi, V; Rehan, HS; Yadav, M, 2016)	0.74
" Secondary: changes of a) LV-FS from baseline, b) blood pressure, c), heart rate and autonomic function in ECG and Holter-ECG, e) cardiac biomarkers and neurohumeral serum parameters, f) quality of life, and g) adverse events."	( Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. Dittrich, S; Ebinger, F; Graf, E; Heilmann, A; Khalil, M; Kirschner, J; Korenke, C; Lange, M; Motz, R; Müller-Felber, W; Neudorf, U; Pattathu, J; Pozza, RD; Schara, U; Schröder, R; Stiller, B; Trollmann, R; von Au, K; von der Hagen, M; Weiss, K; Wiechmann, N; Wilichowski, E, 2019)	0.77
" As a single, yet important adverse event, the reversible deterioration of walking abilities of one DMD patient during the run-in period was observed."	( Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial. Dittrich, S; Ebinger, F; Graf, E; Heilmann, A; Khalil, M; Kirschner, J; Korenke, C; Lange, M; Motz, R; Müller-Felber, W; Neudorf, U; Pattathu, J; Pozza, RD; Schara, U; Schröder, R; Stiller, B; Trollmann, R; von Au, K; von der Hagen, M; Weiss, K; Wiechmann, N; Wilichowski, E, 2019)	0.77
"Intravenous (IV) hydralazine, enalapril and labetalol are oftentimes used without indication for the treatment of asymptomatic hypertension in the hospital setting and have been shown to have substantial adverse effects that are associated with increased morbidity and mortality, as well as longer length of stay."	( Improving the use of intravenous antihypertensive medications in the hospital setting: a quality improvement initiative for patient safety. Chams, N; Gjeka, R; Kumar, S; Peterson, D; Ross, I; Salman, A; Salman, J; Tegeltija, V, 2019)	0.8
" Data including demographics, drug administration, hemodynamic monitoring, laboratory measurements, adverse events, and survival were extracted from the public use data set and compared between the placebo and enalapril-treated groups."	( Safety of Enalapril in Infants: Data from the Pediatric Heart Network Infant Single Ventricle Trial. Aydin, SI; Hsu, DT; Lamour, JM; Mathur, K, 2020)	1.15
" There was a high frequency of serious adverse events in both groups."	( Safety of Enalapril in Infants: Data from the Pediatric Heart Network Infant Single Ventricle Trial. Aydin, SI; Hsu, DT; Lamour, JM; Mathur, K, 2020)	0.96
"9%) and adverse events (78."	( Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study. Aggarwal, RK; Billa, G; Jain, AR; Kumar, S; Rao, NS, )	0.38
" Sacubitril/valsartan was well tolerated with fewer study drug discontinuations due to adverse events, although the sacubitril/valsartan group had a higher proportion of patients with hypotension."	( Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study. Desai, AS; Guo, W; Iimori, T; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Saito, Y; Sakata, Y; Tsutsui, H; Yamamoto, K, 2021)	0.62
"In Japanese patients with HFrEF, there was no difference in reduction in the risk of CV death or HF hospitalization between sacubitril/valsartan and enalapril, and sacubitril/valsartan was safe and well tolerated."	( Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction　- Results From the PARALLEL-HF Study. Desai, AS; Guo, W; Iimori, T; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Saito, Y; Sakata, Y; Tsutsui, H; Yamamoto, K, 2021)	0.82
" However, it is recognised that a significant side effect is cardiotoxicity; anthracyclines can cause irreversible damage to cardiac cells and ultimately impaired cardiac function and heart failure, which may only be evident years after exposure."	( Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT). Akhter, N; Austin, D; Chang, L; Cresti, N; Graham, J; Graham, R; Hancock, HC; Haney, S; Humphreys, A; Kasim, AS; Maddox, J; Maier, RH; Ogundimu, E; Oxenham, H; Plummer, C; Stewart, M; Vahabi, S; Verrill, M; Wardley, A, 2022)	0.72
" Enalapril could be a safe alternative to steroids in the treatment of keloid and hypertrophic scars."	( Safety and efficacy of intralesional injection of enalapril versus triamcinolone acetonide in the treatment of keloids. Eltahlawy, S; Hamada Mohamed, B; Marzouk, WA; Mohamad, NE, 2023)	2.07

Excerpt	Reference	Relevance
"This review compares the metabolism and pharmacokinetic profiles of captopril, the first orally active angiotensin-converting enzyme (ACE) inhibitor, and 2 newer ACE inhibitors, enalapril and quinapril."	( Comparative pharmacokinetics of captopril, enalapril, and quinapril. Haynie, R; Vertes, V, 1992)	0.74
" Pharmacokinetic parameters including area under the serum concentration-time curve (AUC), peak serum concentration (Cmax) and time to peak concentration (tmax), as well as renal function, blood pressure, and plasma renin activity (PRA) and aldosterone levels, were determined on the first and last days of the study."	( Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Cutler, RE; Ford, NF; Parmer, RJ; Sica, DA, 1991)	0.51
"Co-administration of drugs with complementary action is a rational approach to the treatment of hypertension provided that the drugs are free of mutual pharmacokinetic interactions."	( The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Swaisland, AJ, 1991)	0.28
" Similar differences have been reported for such patient groups when the drugs were administered separately, indicating an absence of pharmacokinetic interaction."	( The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Connell, PA; Hosie, J; Laher, MS; Mulkerrins, E; Smith, RP; Swaisland, AJ, 1991)	0.28
"The acute hemodynamic, hormonal, and pharmacokinetic responses to the oral angiotensin-converting enzyme (ACE) inhibitor spirapril were studied in 15 patients with moderate to severe congestive heart failure in a baseline controlled dose-ranging study."	( The acute hemodynamic, hormonal, and pharmacokinetic properties of oral spirapril in patients with moderate to severe heart failure. de Graeff, PA; Hillege, H; Lie, KI; van Bruggen, A; van den Broek, SA; van Gilst, WH; Wesseling, H, 1991)	0.28
" However, when given with HCT, the mean AUC and Cmax of enalaprilat were reduced up to 20 per cent compared with enalapril administered alone."	( Pharmacokinetic comparison of a combination tablet of enalapril and hydrochlorothiazide with enalapril and hydrochlorothiazide tablets administered together and separately. Broadbear, J; Conway, EL; Drummer, OH; Howes, LG; Louis, WJ; Phillips, PA, )	0.63
"The pharmacokinetic and pharmacodynamic profiles of oral enalapril (20 mg), in absence and in presence of probenecid pretreatment (1 g twice daily for 5 days), were investigated in 12 healthy volunteers on normal salt intake (150 mmol/24 hr)."	( Pharmacokinetic and pharmacodynamic actions of enalapril in humans: effect of probenecid pretreatment. Lant, AF; McNabb, WR; Noormohamed, FH, 1990)	0.78
" The elimination half-life of enalaprilat was related to renal function."	( The pharmacokinetics of enalapril in patients with compensated liver cirrhosis. Baba, T; Murabayashi, S; Takebe, K; Tomiyama, T, 1990)	0.87
"The acute hemodynamic, hormonal, and pharmacokinetic aspects of treatment with the angiotensin-converting enzyme (ACE) inhibitor lisinopril were assessed in two studies in 24 patients with chronic stable congestive heart failure (CHF)."	( Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. Dickstein, K, 1987)	0.27
" The influence of renal function and cardiac failure on lisinopril clearance has been confirmed using a population pharmacokinetic analysis technique."	( Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. Kelly, JG; Thomson, AH; Whiting, B, 1989)	0.28
"In an open, crossover study, the pharmacokinetic and pharmacodynamic profiles of lisinopril and enalapril, administered alone and in combination with propranolol, were evaluated in 12 volunteers."	( Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. Bendtsen, F; Henriksen, JH, 1989)	0.73
"The pharmacokinetic and pharmacodynamic profiles of two angiotensin-converting enzyme (ACE) inhibitors, enalapril (a prodrug) and lisinopril (directly acting), were compared in eight patients with hepatic cirrhosis and 10 healthy controls."	( Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function. Bouchier, IA; Hayes, PC; Plevris, JN, 1989)	0.81
"In a pharmacokinetic drug interaction study, the purpose is to determine whether the coadministration of a drug A with a second drug B alters the absorption/distribution/metabolism/elimination profile of either drug."	( The statistical evaluation of a three-period two-treatment crossover pharmacokinetic drug interaction study. Bolognese, JA; Ciminera, JL; Gregg, MH, 1987)	0.27
" Traditionally, separate groups of patients, each with different underlying disease, are given the drug and then detailed studies are performed to assess which groups have significantly different pharmacokinetic parameters and therefore require an adjustment in dose."	( Population pharmacokinetics of lisinopril in hypertensive patients. Thomson, AH; Whiting, B, 1987)	0.27
" In patients with severe renal failure the peak concentrations were higher, the decline in serum concentration was slower and the time to peak concentration was extended."	( Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function. Geyskes, GG; Porsius, AJ; van der Wouw, PA; van Rooij, HH; van Schaik, BA, 1988)	0.27
" The accumulation half-life averages 12."	( Pharmacokinetics of lisinopril. Beermann, B, 1988)	0.27
" It is therefore possible to study their pharmacokinetics as well as their pharmacodynamic effects in man."	( Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Ajayi, AA; Campbell, BC; Howie, C; Kelman, AW; Meredith, PA; Reid, JL, 1985)	0.52
" The pharmacokinetic differences observed are likely to be related to an age dependent decline in renal function as well as changes in body composition."	( Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Ajayi, AA; Hockings, N; Reid, JL, 1986)	0.5
"The effect of age on the pharmacodynamic responses to converting enzyme inhibitors, enalapril and enalaprilat was investigated in nine young (22-30 years) and nine sex-matched elderly (65-73 years), healthy volunteers."	( Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Ajayi, AA; Hockings, N; Reid, JL, 1986)	0.73
" The effective half-life is 10 hours."	( [Pharmacokinetics of enalapril]. Billaud-Mesguich, E, 1986)	0.59
" It is concluded that the presence of CHF does not appreciably alter the pharmacokinetic behaviour of enalapril."	( Pharmacokinetics of enalapril in congestive heart failure. Dickstein, K, 1986)	0.81
" We conclude that the presence of CHF does not appreciably alter the pharmacokinetic behaviour of enalapril."	( The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. Aarsland, T; Abrahamsen, AM; Dickstein, K; Gomez, HJ; Gregg, H; Hichens, M; Kristianson, K; Till, AE; Tjelta, K, 1987)	0.8
" An average effective half-life for accumulation of approximately 11h was calculated from urine data."	( Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Bolognese, JA; Brooks, BA; Gomez, HJ; Hichens, M; Lant, AF; McNabb, WR; Noormohamed, F; Till, AE, )	0.38
" We assessed pharmacokinetic and pharmacodynamic interactions of the ACE inhibitor cilazapril and the beta-blocker propranolol in healthy volunteers and patients with essential hypertension."	( Review of studies on the clinical pharmacodynamics of cilazapril. Belz, GG; Breithaupt, K; Erb, K, 1994)	0.29
" However, there was no evidence of accumulation of spiraprilat in any of the groups as determined by the pharmacokinetic parameters derived after single and multiple doses."	( Pharmacokinetics of spirapril in renal impairment. Elliott, HL; Grass, P; Guitard, C; Meredith, PA, 1994)	0.29
" Regression analysis of pharmacokinetic parameters C(max)ss (the maximum steady-state drug concentration in plasma during a dosing interval), Cl/f (total plasma clearance) and k (elimination rate constant) of spirapril on creatinine clearance (Clcr) showed that the pharmacokinetics of spirapril were not significantly influenced by the degree of renal impairment."	( Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure. Grass, P; Haufe, CC; Jansa, U; Sierakowski, B; Stein, G; Weidinger, G, 1994)	0.29
" After intravenous infusion, the disposition of spirapril is monophasic with a terminal half-life of 20-50 minutes."	( Spirapril: pharmacokinetic properties and drug interactions. Gerbeau, C; Grass, P; Kutz, K, 1994)	0.29
"The conventional pharmacokinetic profile of the angiotensin converting enzyme (ACE) inhibitor, enalapril, is a lipid-soluble and relatively inactive prodrug with good oral absorption (60 to 70%), a rapid peak plasma concentration (1 hour) and rapid clearance (undetectable by 4 hours) by de-esterification in the liver to a primary active diacid metabolite, enalaprilat."	( Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. Elliott, HL; MacFadyen, RJ; Meredith, PA, 1993)	1.95
"00 h-1 in control subjects) while the elimination half-life of spiraprilat was not different."	( Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. Grass, P; Krähenbühl, S; Kutz, K; Reichen, J; Surve, A, 1993)	0.29
"The pharmacokinetic parameters obtained for each formation were the area under the time-concentration curve from 0 to 24 h (AUC[0-24]), maximum concentration Cmax and the time at which it occurred (tmax)."	( Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach. de Nucci, G; Martins, AR; Mendes, GB; Moreno, H; Muscará, MN; Ribeiro, W, 1996)	0.59
"The results show that complete bioequivalence of the two formulations can be concluded from serum total enalapril concentration data, and that serum ACE activity is not a suitable pharmacodynamic variable for assessing bioequivalence."	( Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach. de Nucci, G; Martins, AR; Mendes, GB; Moreno, H; Muscará, MN; Ribeiro, W, 1996)	0.8
" To test this hypothesis, we conducted three randomized, double-masked, placebo-controlled studies to evaluate how coadministration of tamsulosin would affect the pharmacodynamic profiles of nifedipine, enalapril, and atenolol."	( Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Lowe, FC, )	0.32
" Based upon this study performed on normal dogs given a single dose, no pharmacokinetic advantage or disadvantage is apparent for any ACEi except captopril, which, at the dosage used, decreased ACE levels to a much lesser degree and shorter time."	( Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. Hamlin, RL; Nakayama, T, )	0.13
" Pharmacokinetic parameters of KD3-671 were not influenced by repeated dosing."	( Antihypertensive activity and pharmacokinetics of KD3-671, a nonpeptide AT1-receptor antagonist, in renal hypertensive dogs. Kato, H; Mochizuki, S; Suzaka, H; Tajima, S; Takata, Y; Tomiyama, A, 1998)	0.3
" Cumulative urinary recovery of free enalaprilat (active metabolite of enalapril) and the serum maximum concentration of free enalaprilat (Cmax) were the primary pharmacokinetic parameters used to determine bioequivalence in this study."	( Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. Chiou, R; Cylc, D; Goldberg, MR; Hesney, M; McCrea, JB; Shadle, CR; Yuan, AS, 2000)	2.02
" Cmax of serum enalaprilat was also similar between the wafer and conventional tablet formulations (arithmetic mean 85."	( Enalapril in RAPIDISC (wafer formulation): pharmacokinetic evaluation of a novel, convenient formulation. Chiou, R; Cylc, D; Goldberg, MR; Hesney, M; McCrea, JB; Shadle, CR; Yuan, AS, 2000)	2.1
" The median effective half-life for accumulation ranged from 14."	( The pharmacokinetics of enalapril in children and infants with hypertension. Blowey, D; Delucchi, A; Hand, E; Hogg, R; Lo, MW; Panebianco, D; Rippley, R; Sakarcan, A; Shahinfar, S; Shaw, W; Vogt, B; Walson, P; Wells, T, 2001)	0.62
" The present paper reviews pharmacokinetic and pharmacodynamic aspects of enalapril that are physiologically important during pregnancy and intrauterine development in humans and in experimental animal species with the aim of better understanding the comparability of the manifestations of enalapril developmental toxicity in animals and humans."	( Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. A review. Kimmel, CA; Tabacova, SA, )	1.8
" Zofenopril exhibited a complete and a more rapid hydrolysis rate compared to enalapril, which is reflected by the higher metabolite to parent drug ratio of Cmax and AUCss, tau showed by this compound."	( Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Crivelli, F; Dal Bo, L; Giusti, A; Ismaili, S; Marzo, A; Mazzucchelli, P; Monti, NC; Uhr, MR, 2002)	0.78
" These plasma concentrations and blood pressure measurements were applied to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of both enalapril and enalaprilat."	( Determination of enalapril and enalaprilat by enzyme linked immunosorbent assays: application to pharmacokinetic and pharmacodynamic analysis. Arafat, T; Hamad, M; Jehanli, A; Matalka, K, 2002)	0.85
"5 mg/kg PO did not demonstrate significant availability, pharmacodynamic effect, or substantial suppression of ACE activity."	( Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses. Atkins, CE; Gardner, SY; Papich, MG; Sams, RA; Schwabenton, AB, )	0.34
"Most of the pharmacokinetic (PK) parameters for enalapril and enalaprilat were established following determination of the drug and its metabolite, using angiotensin converting enzyme (ACE) inhibition assays."	( Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. Al-Nasan, A; Arafat, T; Awad, R; Azzam, R; Hamad, M; Jehanli, A; Matalka, K, 2005)	0.84
"6 ng h/mL, Cmax values were 313."	( Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. Al-Nasan, A; Arafat, T; Awad, R; Azzam, R; Hamad, M; Jehanli, A; Matalka, K, 2005)	0.58
" This article utilized the physiologically based pharmacokinetic (PBPK) liver model and its extension that include heterogeneity in enzymes and transporters to illustrate how in vitro uptake and metabolic data from zonal hepatocytes on transport and enzymes may be used to predict the kinetics of removal in the intact liver; binding data were also necessary."	( An integrated approach to model hepatic drug clearance. Liu, L; Pang, KS, 2006)	0.33
" The HPLC-MS/MS method herein described was fully validated and successfully applied to the pharmacokinetic study of enalapril maleate capsules in 20 healthy male volunteers after oral administration."	( Simultaneous quantification of enalapril and enalaprilat in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. Jiang, K; Li, F; Lu, S; Lu, X; Qin, F, 2009)	0.85
" There is evidence that enalapril may be an organic anion-transporting polypeptide 1B1 (OATP1B1) substrate, suggesting that genetic polymorphisms of the OATP1B1 gene may play a role in causing the interindividual pharmacokinetic differences of this drug."	( Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Han, L; Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S, 2011)	0.88
" The pharmacokinetic parameters of enalapril and enalaprilat were then compared according to genotype groups, using 1-way ANOVA, except for T(max) in which the Mann-Whitney test or Kruskal-Wallis test was used."	( Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Han, L; Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S, 2011)	0.85
" Following single doses of ACT-178882, t1/2 and tmax varied from 18."	( Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. Binkert, C; Dingemanse, J; Nicolas, L, 2013)	0.39
" ACT-077825 pharmacokinetics on days 1 and 7 were characterized by dose-proportional increases in Cmax and AUCτ."	( Pharmacokinetics, pharmacodynamics, and tolerability of ACT-077825, a new direct renin inhibitor after multiple-ascending doses in healthy subjects. Binkert, C; Dingemanse, J; Gutierrez, M; Nicolas, LB, 2013)	0.39
" Colesevelam (3750mg once daily) was dosed throughout the pharmacokinetic sampling period."	( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.62
"For all six test drugs, 90% CIs for geometric least-squares mean ratios of AUC and Cmax for the measured analytes were within specified limits, indicating no interaction between the test drug and colesevelam."	( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.62
" Although the phenytoin study indicated no pharmacokinetic interaction, phenytoin should continue to be taken ≥4h before colesevelam in accordance with current prescribing information."	( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.62
" The CES1 genotype had no significant effect on the enalaprilat to enalapril AUC0-∞ ratio or on any other pharmacokinetic or pharmacodynamic parameters of enalapril or enalaprilat."	( Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Backman, JT; Holmberg, MT; Launiainen, T; Neuvonen, PJ; Niemi, M; Tarkiainen, EK; Tornio, A, 2015)	0.88
" The terminal half-life of enalaprilat was significantly longer in group 6 compared with the control group (26."	( The Pharmacokinetics of Enalapril in Relation to CES1 Genotype in Healthy Danish Volunteers. Bjerre, D; Dalhoff, K; Ferrero-Miliani, L; Guski, LS; Jürgens, G; Lyauk, YK; Rasmussen, HB; Stage, C; Thomsen, R, 2017)	1.06
"There have been no animal experiments and clinical studies on the pharmacokinetic interaction between rivaroxaban and enalapril."	( Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC-MS/MS and Its Application to A Pharmacokinetic Interaction Study. Guo, J; Luo, SB; Mei, YB; Tong, LJ; Ye, XY; Zhang, Q; Zheng, S, 2019)	0.98
"The UPLC-MS/MS method was successfully applied to simultaneous determination of rivaroxaban and enalapril in rat plasma and applied to study the pharmacokinetic interaction between rivaroxaban and enalapril."	( Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC-MS/MS and Its Application to A Pharmacokinetic Interaction Study. Guo, J; Luo, SB; Mei, YB; Tong, LJ; Ye, XY; Zhang, Q; Zheng, S, 2019)	0.99
"Comparative pharmacokinetic (PK) data analysis of drugs administered using developed child-appropriate and market authorized dosage formulation is sparse and is important in pediatric drug development."	( Model-dependent pharmacokinetic analysis of enalapril administered to healthy adult volunteers using orodispersible minitablets for use in pediatrics. Burckhardt, BB; Cawello, W; Faisal, M; Laer, S, 2019)	0.78
" This quality control system identified 15 % bioanalytical runs as non-compliant to the predefined specifications and ensured the reliable quantification of 940 pharmacodynamic samples."	( A quality control system for ligand-binding assay of plasma renin activity: Proof-of-concept within a pharmacodynamic study. Burckhardt, BB; Feickert, M; Gangnus, T; Makowski, N; Suessenbach, FK; Tins, J, 2020)	0.56
"Evidence-based pharmacotherapy with carvedilol and enalapril in children suffering from heart failure is insufficient owing to limited pharmacokinetic data."	( Low-volume LC-MS/MS method for the pharmacokinetic investigation of carvedilol, enalapril and their metabolites in whole blood and plasma: Application to a paediatric clinical trial. Burckhardt, BB; Gangnus, T, 2021)	1.1

Excerpt	Reference	Relevance
" L/HCTZ appears to be a well-tolerated combination with efficacy on once-daily dosing superior to that of C/HCTZ."	( Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. Graham, RD, 1991)	0.28
"In an open, crossover study, the pharmacokinetic and pharmacodynamic profiles of lisinopril and enalapril, administered alone and in combination with propranolol, were evaluated in 12 volunteers."	( Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. Bendtsen, F; Henriksen, JH, 1989)	0.73
" In conclusion, nicardipine, alone or in combination with enalapril, is an effective and well tolerated drug for use in treatment of hypertension secondary to chronic renal disease."	( [Nicardipine, alone or in combination with enalapril, in the therapy of arterial hypertension secondary to chronic nephropathy]. Feriozzi, S; Mavrikakis, G; Morabito, S; Pecci, G; Pierucci, A; Roscia, E; Simonetti, BM, 1989)	0.78
" Enalapril, either alone or in combination with hydrochlorothiazide, effectively controlled blood pressure."	( Effects of enalapril alone, and in combination with hydrochlorothiazide, on renin-angiotensin-aldosterone, renal function, salt and water excretion, and body fluid composition. Bauer, JH; Gaddy, P, 1985)	1.57
" Subsequently, 10 patients received 20 mg enalapril per day and 10 patients 15 mg altizide combined with 25 mg spironolactone in the same tablet."	( [Efficacy and tolerability of enalapril compared to altizide combined with spironolactone in patients with moderate arterial hypertension]. Baudouy, M; Camous, JP; Durand, P; Gibelin, P; Morand, P, 1986)	0.82
"Semotiadil fumarate, a novel benzothiazine calcium antagonist, was given alone or in combination with either enalapril or trichlormethiazide to conscious, spontaneously hypertensive, rats daily for 2 weeks."	( Antihypertensive effects of a novel calcium antagonist, semotiadil fumarate (SD-3211), alone and in combination with enalapril or trichlormethiazide in spontaneously hypertensive rats. Akashi, S; Ichikawa, M; Koida, M; Machidera, Y; Manno, K; Nakamuta, H; Ohtsuji, T; Wanaka, M, 1994)	0.71
"The antihypertensive effects and the tolerability of losartan and enalapril given alone or in combination with hydrochlorothiazide (HCTZ) were compared in a multicenter, double-blind, randomized, parallel-group, 16-week clinical trial."	( Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Edelman, JM; Haggert, B; Liss, C; Townsend, R, )	0.63
" It is concluded that protein restriction in combination with ACEI treatment improve IR and the associated dyslipoproteinaemia and proteinuria."	( Dietary protein restriction in combination with angiotensin converting enzyme inhibitor improves insulin resistance in patients with chronic renal disease. Dzúrik, R; Gazdíková, K; Krivosíková, Z; Spustová, V; Stefíková, K, 1997)	0.3
"Enalapril combined with an extended-release formulation of diltiazem was evaluated in a 12-week multicenter trial of 112 patients with Stages 3-4 essential hypertension."	( Evaluation of enalapril combined with diltiazem ER in patients with stage 3-4 essential hypertension. Chrysant, SG; Conradi, E; Gavras, H; Goldstein, R; Marbury, TC; Niederman, AL, 1998)	2.1
"The effects on plasma angiotensin-converting enzyme activity and renin activity of the two long-acting angiotensin-converting enzyme inhibitors, lisinopril and enalapril, alone and in combination with propranolol were studied."	( Effects on plasma angiotensin-converting enzyme activity and circulating renin of lisinopril and enalapril alone and in combination with propranolol in healthy volunteers. Bendtsen, F; Hansen, EF; Henriksen, JH, 1999)	0.72
" A dose finding study of enalapril ranging from 3 to 300 microg showed that 30 microg of enalapril in combination with AT-II infusion produced the best improvement in tumor uptake of 99Tc-HSA without altering 201Tl distribution, suggesting that the increase of vascular permeability was caused by enalapril."	( Persistent distension and enhanced diffusive extravasation of tumor vessels improved uniform tumor targeting of radioimmunoconjugate in mice administered with angiotensin II and kininase inhibitor. Aburano, T; Hiramatsu, T; Kawashima, A; Kinuya, S; Konishi, S; Michigishi, T; Shuke, N; Takayama, T; Tega, H; Tonami, N; Watanabe, N; Yamamoto, W; Yokoyama, K, 1998)	0.6
" An anaphylactoid reaction induced by an AN69 membrane during continuous, extracorporal treatment in combination with ACE inhibition has not been reported so far."	( Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? Kammerl, MC; Krämer, BK; Riegger, GA; Schaefer, RM; Schreiber, M; Schweda, F, 2000)	0.31
" Four variants of the course treatment were used: 1) monotherapy with enalapril maleate (2 mg twice a day); 2) enalapril maleate (5 mg twice a day) in combination with NSAID; 3) monotherapy with lisinopril (10 mg once a day); 4) lisinopril (10 mg once a day in combination with NSAID."	( [Antihypertensive effect of enalapril and lisinopril administered in combination with nonsteroid anti-inflammatory agents]. Brodskaia, SA; Ivanov, SN; Savenkov, MP, 2001)	0.84
" The results suggest that hydrochlorothiazide does not interact in the fixed combination with the pharmacokinetics of spirapril and vice versa."	( Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide. A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-lay Amschler, S; Erb, K; Hermann, R; Junge, K; Krupp, S; Schäfer, HF; Schulz, HU; Schürer, M, 2003)	0.32
" We wished to determine the cardioprotective actions of an aminopeptidase P inhibitor, apstatin alone and in combination with enalapril/lisinopril/ramipril in an in vivo rat model of acute ischemia (30 min) and reperfusion (4 h)."	( Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction. Akula, A; Kota, MK; Routhu, KV; Veeravalli, KK, 2003)	0.76
" Although the participation of the particular transporters in observed drug-drug interactions can be difficult to confirm in humans, this review focuses mainly on pharmacokinetic interactions of clinically important drugs."	( Transporter-mediated Drug Interactions. Tsuji, A, 2002)	0.31
" The aims of the present study were to investigate, in the New Zealand genetically hypertensive (GH) rat model, the effects of treatment with simvastatin, alone or in combination with valsartan or enalapril, on blood pressure (BP) and structural remodelling of mesenteric resistance arteries (MRA) and of the basilar artery, an artery that plays a major role in the regulation of cerebral resistance."	( Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model. Laverty, R; Ledingham, JM, )	0.55
"The present study investigates the effects of chronic administration of ACEIs (angiotensin-converting-enzyme inhibitors; either zofenopril or enalapril) in combination with a diruetic (hydrochlorothiazide) on BP (blood pressure) increase and renal injury induced by L-NAME (NG-nitro-L-arginine methyl ester), an inhibitor of NO (nitric oxide) synthesis."	( Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats. Alcaraz, A; Atucha, NM; Evangelista, S; García-Estañ, J; Navarro, EG; O'Valle, F; Ortiz, MC; Vargas, F, 2006)	0.54
"In this study quadropril (Spirapril, Pliva) was given for 2 months to patients with arterial hypertension combined with chronic obstructive pulmonary disease."	( [Clinical application of spirapril in patients with arterial hypertension combined with chronic obstructive pulmonary disease]. Barbarash, OL; Kondrikova, NV; Smakotina, SA, 2006)	0.33
" This study examined the effects of treatment with Ran alone and in combination with metoprolol (Met) or enalapril (Ena) on LV function and remodeling in dogs with HF."	( Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC, 2008)	0.86
"59 patients with bronchial asthma (BA) combined with hypertension have been observed."	( [Level of steroid hormones in patients with bronchial asthma combined with hypertension and their dynamics after using antihypertensive medications]. Altunina, NV; Lyzohub, VH, )	0.13
" This antiihypertensve effect was considerably potentiated, when kardos was administered in combination with enalapril."	( Pharmacodynamics of kardos administered as monotherapy and in combination with hypothiazide and enalapril in grade I-II arterial hypertension. Bakumov, PA; Epshtein, OI; Kachanova, MV; Petrov, VI; Sabanov, LB; Sergeeva, SA; Zabolotneva, YA; Zernyukova, EA, 2009)	0.78
"To investigate the efficacy of enalapril combined with folic acid in lowering both blood pressure and plasma total homocysteine (Hcy) in essential hypertensive patients."	( [Efficacy of enalapril combined with folic acid in lowering blood pressure and plasma homocysteine level]. Fu, J; Mao, GY; Qin, XH; Tang, GF; Tang, HQ, 2009)	1.01
"As compared to enalapril alone, enalapril combined with folic acid showed a better efficacy in reducing both blood pressure and plasma Hcy level in hypertensive subjects."	( [Efficacy of enalapril combined with folic acid in lowering blood pressure and plasma homocysteine level]. Fu, J; Mao, GY; Qin, XH; Tang, GF; Tang, HQ, 2009)	1.08
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"Epo in combination with enalapril caused additive reduction of cardiac fibrosis and microvessel disease in 5/6 nephrectomized rats presumably by decreasing myocardial oxidative stress."	( Erythropoietin combined with ACE inhibitor prevents heart remodeling in 5/6 nephrectomized rats independently of blood pressure and kidney function. Aldebssi, F; Bekeredjian, R; Gross-Weissmann, ML; Gut, N; Piecha, G; Ritz, E; Schaefer, S; Schirmacher, P, 2013)	0.7
" Enalapril alone or in combination with benznidazole did not change the number of circulating parasites, but reduced cardiac leukocyte recruitment and total collagen in the cardiac tissue."	( Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi. de Paula Costa, G; Horta, AL; Leite, AL; Natali, AJ; Neves, CA; Penitente, AR; Shrestha, D; Talvani, A, 2015)	2.77
" We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-β protein precursor (AβPP, thereafter APP mice)."	( Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. Aboulkassim, T; Hamel, E; Imboden, H; Nicolakakis, N; Ongali, B; Tong, XK, 2016)	2.11
" The effect of losartan and enalapril alone and in combination with sodium valproate on seizures, cognition, cardiac histopathology, and serum brain-derived neurotropic factor (BDNF) levels were determined."	( Effects of enalapril and losartan alone and in combination with sodium valproate on seizures, memory, and cardiac changes in rats. Arava, S; Gupta, YK; Joshi, D; Katyal, J, 2019)	1.2
" Sodium valproate alone or in combination with losartan or enalapril prevented kindled seizures."	( Effects of enalapril and losartan alone and in combination with sodium valproate on seizures, memory, and cardiac changes in rats. Arava, S; Gupta, YK; Joshi, D; Katyal, J, 2019)	1.15
" In this study, we evaluated the efficacy of firibastat in combination with enalapril, an angiotensin I-converting enzyme inhibitor, and hydrochlorothiazide (HCTZ), in conscious hypertensive deoxycorticosterone acetate (DOCA)-salt rats, which display high plasma arginine-vasopressin levels, low circulating renin levels and resistance to treatment by systemic RAS blockers."	( Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats. Balavoine, F; De Mota, N; Hmazzou, R; Llorens-Cortes, C; Marc, Y, 2021)	1.12
"To systematically evaluate the clinical efficacy and safety of Tanshinone Ⅱ_A Sodium Sulfonate Injection combined with enalapril in the treatment of patients with acute exacerbation of pulmonary heart disease."	( [Systematic review and sequential analysis of Tanshinone Ⅱ_A Sodium Sulfonate Injection combined with enalapril in treatment of acute exacerbation of pulmonary heart disease]. Ma, T; Mu, LT; Tian, XT; Yang, J; Zhao, YQ, 2022)	1.15
"Vinpocetine treatment and its combination with enalapril decreased the glucose levels compared to diabetic rats."	( Effect of vinpocetine alone and in combination with enalapril in experimental model of diabetic cardiomyopathy in rats: possible involvement of PDE-1/TGF-β/ Smad 2/3 signalling pathways. Arava, SK; Arora, T; Kaur, T; Kumar, N; Shah, S; Singh, AP; Vishwakarma, VK; Yadav, HN; Yadav, RK; Yadav, S, 2023)	1.42

Excerpt	Reference	Relevance
" Parent drug absorption and diacid bioavailability in the rat were higher than for enalapril, and the inhibition of plasma ACE of longer duration."	( Biological properties of the angiotensin-converting enzyme inhibitor cilazapril. Brewster, M; Budd, J; Francis, RJ; Klevans, LR; Natoff, IL; Nixon, JS; Patel, AT; Wenger, J; Worth, E, )	0.36
" Lisinopril bioavailability (approximately 25%) is not significantly affected by food, age, or coadministration of hydrochlorothiazide (HCTZ), propranolol, digoxin, and glibenclamide."	( The clinical pharmacology of lisinopril. Cirillo, VJ; Gomez, HJ; Moncloa, F, 1987)	0.27
" This study did not take bioavailability into consideration."	( Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Alicea, M; Colucci, RD; Greenstein, R; Halpern, NA, 1989)	0.58
" Its bioavailability is approximately 25% and is not affected by food."	( Lisinopril: a new angiotensin-converting enzyme inhibitor. Chase, SL; Sutton, JD, 1989)	0.28
" Although hydralazine had no effect on the bioavailability of enalapril, significantly increased bioavailability was observed with lisinopril."	( Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine. Drummer, OH; Froomes, P; McLean, AJ; McNeil, JJ; Smith, HJ, 1989)	0.8
" Possible mechanisms include poor drug permeability, a pH effect whereby the zwitterionic form of the drug is more rapidly absorbed, and esterase cleavage of moexipril to the poorly absorbed moexipril diacid."	( Evidence for site-specific absorption of a novel ACE inhibitor. Grass, GM; Morehead, WT, 1989)	0.28
" During the 4 h monitoring period enalapril was poorly absorbed in non-fasted rats as compared to fasted animals."	( Absorption of oral enalapril in germ-free and microbially-associated rats. Pelkonen, K; Ylitalo, P, )	0.74
" Compound 2 is well absorbed from rat jejunum, whereas lisinopril absorption is relatively low."	( Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852. Amidon, GL; Friedman, DI, 1989)	0.28
" The prodrug enalapril is well absorbed from rat jejunum, whereas the parent drug, enalaprilat, is poorly absorbed."	( Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril. Amidon, GL; Friedman, DI, 1989)	0.85
"The angiotensin-converting enzyme inhibitor, lisinopril, has an oral bioavailability of 25 percent +/- 4 percent, which is unaffected by food."	( Pharmacokinetics of lisinopril. Beermann, B, 1988)	0.27
" Although there were no statistically significant differences in lisinopril pharmacokinetics during single or combined treatment, serum and urinary parameters suggest that bioavailability may be enhanced slightly during combined treatment."	( A study of the potential pharmacokinetic interaction of lisinopril and digoxin in normal volunteers. Dews, IM; Kelly, JG; Marks, C; Morris, F; Stephens, JD; Vandenburg, MJ, 1988)	0.27
" Enalapril is a prodrug that is well absorbed from the gastrointestinal tract, with 60 to 70% of an oral dose being absorbed."	( Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. Cody, RJ; Kubo, SH, )	1.04
" Administration with food does not affect the bioavailability of enalapril; excretion of enalapril and enalaprilat is primarily renal."	( Enalapril: a review of human pharmacology. Cirillo, VJ; Gomez, HJ; Irvin, JD, 1985)	1.95
" Drug disposition studies in rats, dogs, and monkeys have demonstrated that the method can be readily adapted to any ACE inhibitor and is suitable for determining drug bioavailability and pharmacokinetics."	( Radioenzymatic assay of angiotensin-converting enzyme inhibitors in plasma and urine. Alpaugh, WC; Stauber, KL; Swanson, BN; Weinstein, SH, 1985)	0.27
" The only known interaction is with propranolol, which reduces by one-third the bioavailability of enalapril."	( [Clinical pharmacology of enalapril]. Giudicelli, JF, 1985)	0.79
" A population pharmacokinetic analysis approach applied to a few concentration-time data points in each of a relatively large number of subjects provided average population parameter estimates of the absorption rate constant, volume of distribution and clearance which correspond closely with the limited published data based on conventional pharmacokinetic approaches."	( Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Ajayi, AA; Campbell, BC; Howie, C; Kelman, AW; Meredith, PA; Reid, JL, 1985)	0.52
"A randomized, two-way, crossover study was performed on 18 normal volunteers to assess the influence of food on the bioavailability of lisinopril, (1-[N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline), a long-acting nonsulfhydryl angiotensin converting enzyme inhibitor."	( Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. Clementi, RA; Ferguson, RK; Hoholick, C; Mojaverian, P; Rocci, ML; Vlasses, PH, 1986)	0.27
" Enalapril bioavailability is unaffected by food, whereas captopril availability is suppressed by food."	( Pharmacology of angiotensin converting enzyme inhibitors. A review. Nelson, EB; Pool, JL; Taylor, AA, 1986)	1.18
" Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%."	( Pharmacokinetics of enalapril in congestive heart failure. Dickstein, K, 1986)	0.59
" Mean absorption for the oral dose was 69%, hydrolysis 55%, bioavailability 38%, urinary recovery 77% and estimated first-pass effect 10%."	( The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure. Aarsland, T; Abrahamsen, AM; Dickstein, K; Gomez, HJ; Gregg, H; Hichens, M; Kristianson, K; Till, AE; Tjelta, K, 1987)	0.58
" Designed as a prodrug to improve the bioavailability Hoe 498 has to be deesterified to its active moiety Hoe 498-diacid to develop full inhibitory potency."	( Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498). Becker, RH; Metzger, M; Schölkens, BA; Schulze, KJ, 1984)	0.27
"Enalapril, a long-acting, non-sulfhydryl, angiotensin converting enzyme (ACE) inhibitor, is well absorbed after oral administration, and hydrolised to its bioactive form, enalaprilic acid (EA)."	( The clinical pharmacology of enalapril. Cirillo, VJ; Gomez, HJ; Jones, KH, 1983)	2
"N-[1-(S)-carboxy-3-phenylpropyl]-L-alanyl-L-proline (MK-422), is a potent angiotensin I-converting enzyme (ACE) inhibitor, but as a diacid is poorly absorbed in laboratory animals."	( The physiological disposition and metabolism of enalapril maleate in laboratory animals. deLuna, FA; Duncan, AE; Tocco, DJ; Ulm, EH; Vassil, TC, )	0.39
" In rats, but not in dogs, the diacid inhibitor was poorly absorbed, whereas MK-421 was well absorbed in both species."	( Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. Backlund, EP; Bohn, DL; Gross, DM; Morris, AA; Stone, CA; Sweet, CS; Ulm, EH; Vassil, TC; Weitz, D; Wenger, HC, 1981)	0.26
" The bioavailability of orally administered spirapril was 50% whereas the bioavailability of orally administered spiraprilat was virtually zero."	( Spirapril: pharmacokinetic properties and drug interactions. Gerbeau, C; Grass, P; Kutz, K, 1994)	0.29
" In contrast, the bioavailability of spiraprilat, the metabolite responsible for the pharmacological action of spirapril, was significantly reduced in patients (AUC 820 micrograms."	( Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease. Grass, P; Krähenbühl, S; Kutz, K; Reichen, J; Surve, A, 1993)	0.29
"Two different conventional release enalapril maleate tablet formulations were evaluated for their relative bioavailability (Eupressin tablets 10 mg, Biosintética as the test formulation vs Renitec tablets 10 mg Merck Sharp & Dhome, as the reference formulation)."	( Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach. de Nucci, G; Martins, AR; Mendes, GB; Moreno, H; Muscará, MN; Ribeiro, W, 1996)	0.86
" However, no difference in either the extent or the rate of absorption were observed when serum total enalapril vs time curves were analysed."	( Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach. de Nucci, G; Martins, AR; Mendes, GB; Moreno, H; Muscará, MN; Ribeiro, W, 1996)	0.8
" Valacyclovir, a water soluble amino acid ester prodrug of acyclovir has been reported to increase the oral bioavailability of acyclovir but its absorption mechanism is unknown."	( 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Amidon, GL; Covitz, KM; de Vrueh, RL; Han, H; Lee, CP; Oh, DM; Rhie, JK; Sadée, W; Smith, PL, 1998)	0.3
" This study examined the relative bioavailability of enalapril suspension (10 mg) (S) compared with 10-mg marketed VASOTEC tablets (T) in 16 healthy adult subjects."	( Pharmacokinetic assessment of an oral enalapril suspension for use in children. Boyle, J; Bradstreet, TE; Connor, J; Hand, E; Lo, MW; Murphy, MG; Rippley, RK, 2000)	0.83
"We investigated whether augmentation of bradykinin (BK) bioavailability with angiotensin-converting enzyme (ACE) inhibition is associated with reduced exercise-induced myocardial ischemia in hypertension."	( Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension. Mincemoyer, R; Prasad, A; Quyyumi, AA, 2001)	0.31
" The effects of eprosartan on RPF are mediated, at least in part, by an increased bioavailability of nitric oxide in the renal vasculature."	( Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Delles, C; Fleischmann, I; Jacobi, J; John, S; Schmieder, RE, 2002)	0.7
" Bioavailability was evaluated on the basis of plasma concentrations of enalapril and its main active metabolite, enalaprilat and hydrochlorothiazide."	( Comparative bioavailability of two immediate release tablets of enalapril/hydrochlorothiazide in healthy volunteers. Caturla, MC; Filipe, AE; Goncalves, NJ; Maya, MT; Morais, JA; Rovira, M; Silva, NE, )	0.6
" This may be related to the improvement of endothelial NO bioavailability with the reduction of plasma ADMA levels."	( Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Chang, MS; Chen, JW; Hsu, NW; Lin, SJ; Wu, TC, 2002)	0.31
"To compare the relative bioavailability and bioequivalence of 2 enalapril tablet formulations in healthy volunteers under fasting conditions."	( Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteers. Daftsios, AC; Nikolaidis, N; Niopas, I, 2003)	0.83
"From the results of the present study, it is concluded that the test and reference tablet formulations of enalapril are bioequivalent for both the extent and the rate of absorption and therefore the 2 products can be considered to be interchangeable in clinical practice."	( Bioequivalence study of two brands of enalapril tablets after single oral administration to healthy volunteers. Daftsios, AC; Nikolaidis, N; Niopas, I, 2003)	0.8
"The pharmacokinetic and relative bioavailability studies of 20-mg enalapril tablets, the test product manufactured by Biolab, Thailand compared to the reference product (Merck Sharp & Dohme, USA) was conducted in 14 healthy Thai male volunteers following a single dose, two-period, crossover design."	( Relative bioavailability study of 20-mg enalapril tablets in healthy male volunteers. Lohitnavy, M; Lohitnavy, O; Polnok, S; Taytiwat, P, 2003)	0.82
" A potential mechanism is the correction of endothelial dysfunction (ED) leading to reduced production of reactive oxygen species and enhanced bioavailability of nitric oxide (NO), a potent apoptosis inducer."	( Synergistic interaction between enalapril, L-arginine and tetrahydrobiopterin in smooth muscle cell apoptosis and aortic remodeling induction in SHR. deBlois, D; Der Sarkissian, S; Duguay, D; Marchand, EL, 2004)	0.61
" These drugs also increased the bioavailability of CSA."	( Comparative interaction of few antihypertensive drugs with cyclosporine-A in rats. Inamdar, MN; Kumar, NP; Venkataraman, BV, 2007)	0.34
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" We investigated the effect of a combination of eplerenone, a selective aldosterone antagonist, and enalapril, an angiotensin-converting enzyme inhibitor, on NO bioavailability and spontaneous atherosclerotic changes."	( Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Tsujioka, H; Yoshida, K, 2008)	0.56
" The optimized formulation was evaluated for preclinical bioavailability and antihypertensive efficacy using albino rat model."	( Transdermal therapeutic system of enalapril maleate using piperidine as penetration enhancer. Ahmad, FJ; Ali, MM; Aqil, M; Chowdhary, I; Sultana, Y; Talegaonkar, S, 2008)	0.63
"We investigated the effects of co-administration of an angiotensin-converting enzyme inhibitor (ACEI) and angiotensin type 1 receptor blocker (ARB) on nitric oxide (NO) bioavailability in genetically hyperlipidemic rabbits with our newly developed NO sensor."	( Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits. Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Yoshida, K, 2008)	0.35
"5mg/kg PO, q24h) is either poorly absorbed in the horse or is inadequately converted to the active form of the drug, enalaprilat."	( Chronic oral therapy with enalapril in normal ponies. Ely, JJ; McDonnell, SM; Reef, VB; Sleeper, MM, 2008)	0.86
" Oral administration of RB150 in conscious spontaneously hypertensive rats inhibited brain aminopeptidase A activity, demonstrating the central bioavailability of RB150 and its ability to generate EC33 into the brain."	( Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Balavoine, F; Gao, J; Llorens-Cortes, C; Marc, Y; Michaud, A; Roques, BP, 2012)	0.38
" Bioavailability experiment was carried out by administering the pulsatile release pellets to rats compared with marketed rapid release tablets Yisu."	( A novel pulsatile drug delivery system based on the physiochemical reaction between acrylic copolymer and organic acid: in vitro and in vivo evaluation. Li, X; Qi, X; Wu, Z; Xing, J; Zhang, Z; Zhu, X, 2014)	0.4
"The low bioavailability of enalapril maleate associated to its instability in solid state motivated the development of a polyelectrolyte-drug complex between enalapril maleate and the cationic polymethacrylate Eudragit E100."	( Enhanced intestinal permeability and oral bioavailability of enalapril maleate upon complexation with the cationic polymethacrylate Eudragit E100. Manzo, RH; Olivera, ME; Ramírez-Rigo, MV; Rubio, M, 2014)	0.94
" The effect of food on the bioavailability of enalapril oral solution was also assessed."	( Bioequivalence of enalapril oral solution for treatment of pediatric hypertension and enalapril tablets. Colabuono, P; DiSanto, AR; Espinosa, O; Hou, J; Moffett, BS, 2014)	0.99
" These findings suggest that increased NO bioavailability may account for the enhanced hypotensive effects of propofol in ACEi-treated patients."	( Angiotensin converting enzyme inhibitors enhance the hypotensive effects of propofol by increasing nitric oxide production. Ferreira, GC; Garcia, LV; Garcia, WNP; Lacchini, R; Oliveira-Paula, GH; Pinheiro, LC; Tanus-Santos, JE, 2018)	0.48
" No other differences were observed in absorption, elimination, and relative bioavailability of drug between the three treatment arms."	( Model-dependent pharmacokinetic analysis of enalapril administered to healthy adult volunteers using orodispersible minitablets for use in pediatrics. Burckhardt, BB; Cawello, W; Faisal, M; Laer, S, 2019)	0.78
" In order to support the clinical evaluation of this new formulation in children, a relative bioavailability study was performed in healthy adults, comparing the bioavailability of enalapril in the ODMT with that of a reference product (RP) Renitec, a registered standard enalapril tablet formulation."	( Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults. Breitkreutz, J; Burckhardt, BB; de Hoon, J; Herbots, M; Khalil, F; Klingmann, I; Laeer, S; Lagler, FB; Van Hecken, A, 2020)	1.04
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The dosage was titrated upward until the goal blood pressure was achieved."	( Enalapril and verapamil in the treatment of isolated systolic hypertension in the elderly. Bruner, DE; Davis, JR; Espinel, CH; Williams, JL, )	1.57
"To investigate whether the compensatory rise in renin and plasma angiotensin I in response to repeated angiotensin converting enzyme (ACE) inhibitor treatment results in a partial escape of ACE inhibition over a 24-h dosing interval."	( Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? Admiraal, PJ; Boomsma, F; Derkx, FH; Man in 't Veld, AJ; Ritsema van Eck, HJ; Schalekamp, MA; van den Meiracker, AH, 1992)	0.28
" At the end of dosing interval angiotensin II had returned to values seen under placebo with the 12."	( Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? Admiraal, PJ; Boomsma, F; Derkx, FH; Man in 't Veld, AJ; Ritsema van Eck, HJ; Schalekamp, MA; van den Meiracker, AH, 1992)	0.28
" This escape also affects the antihypertensive response in the second half of the dosing interval."	( Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? Admiraal, PJ; Boomsma, F; Derkx, FH; Man in 't Veld, AJ; Ritsema van Eck, HJ; Schalekamp, MA; van den Meiracker, AH, 1992)	0.28
"0 microgram/kg) and a dose-response curve relating receptor activity to bradykinin was elicited."	( Responses of airway rapidly adapting receptors to bradykinin before and after administration of enalapril in rabbits. Hargreaves, M; Kappagoda, CT; Ravi, K; Senaratne, MP, 1992)	0.5
"01) from baseline over the 24 h dosing interval."	( Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. Dunne, B; Glazer, N; Kostis, JB; Miller, WE; Rector, DJ; Tresznewsky, ON; Whelton, A, 1992)	0.52
" Systolic BP (SBP) and mean arterial pressure (MAP) were significantly lower in spirapril-treated rats, and the dose-response curve to ANGI was shifted to the right."	( Effect of spirapril on left ventricular hypertrophy due to volume overload in rats. Hof, RP; Novosel, D; Pedersen, B; Robertson, E; Rudin, M; Umemura, K; Zierhut, W, 1992)	0.28
" More patients on hydrochlorothiazide attained a diastolic blood pressure of less than 90 mmHg while less patients required doubling of dosage compared to timolol and enalapril."	( The efficacy of hydrochlorothiazide, timolol and enalapril in Ethiopians with essential hypertension. Habte, B, 1992)	0.73
" Comparison of dose-response curves to ANG I, II, and III showed that all three had similar maximum pressor effects (27 +/- 3 mmHg), with ANG I being four times less potent than ANG II, and ANG III as potent as ANG II."	( Hemodynamic effects of central angiotensin I, II, and III in conscious rabbits. Head, GA; Williams, NS, 1992)	0.28
" In conclusion, enalapril at a dosage of 10-20 mg per day does not provoke any augmentation of the increase in plasma potassium during exercise."	( Enalapril and exercise-induced hyperkalemia. A study of patients randomized to double-blind treatment with enalapril or placebo after acute myocardial infarction. Böttcher, M; Bøtker, HE; Frost, L; Kristensen, SD; Nørgaard, A, 1992)	2.07
" Forty-eight patients achieved diastolic blood pressures less than 90 mm Hg on concomitant therapy; 44 patients completed 8 weeks of maintenance dosing with a mean blood pressure of 134/85 mm Hg."	( Transdermal clonidine as an adjunct to enalapril: an evaluation of efficacy and patient compliance. Cook, E; Dillard, D; Lewin, A; Wallin, JD; Weidler, D, 1992)	0.55
" After a 2 week placebo, the examinees were administered either L in increasing dose of 10, 20, or 40 mg per day (amount necessary to achieve normotension), or C in a dosage of 25, 50, or 100 mg per day."	( [Comparison of captopril and lisinopril in the treatment of mild and moderate hypertension]. Janezic, A; Knezević, S; Lijić, J; Marinković, M; Rumboldt, Z; Simunić, M, )	0.13
" An evaluation of reduction in blood pressure, and of response rate and side-effects suggests that an initial dose of 10 mg lisinopril once daily is sufficient, and that this dosage will control blood pressure in the majority of patients."	( [Treatment of hypertension with the ACE inhibitor lisinopril. A multicenter study of patients with mild to moderate hypertension in general practice]. Fagerthun, HE; Landmark, K; Larsen, S; Tellnes, G, 1991)	0.28
" L/HCTZ appears to be a well-tolerated combination with efficacy on once-daily dosing superior to that of C/HCTZ."	( Treating mild-to-moderate hypertension: a comparison of lisinopril-hydrochlorothiazide fixed combination with captopril and hydrochlorothiazide free combination. Graham, RD, 1991)	0.28
" Dosing with hydrochlorothiazide alone resulted in a mean peak serum concentration of 53 ng/ml, 2-6 hours post dose."	( The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Swaisland, AJ, 1991)	0.28
" The pharmacokinetic behaviour of lisinopril and hydrochlorothiazide given together to elderly and renally impaired hypertensive patients suggests that a fixed dose combination is appropriate and that no changes to the dosage regimen additional to those used for the individual agents are necessary."	( The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. Connell, PA; Hosie, J; Laher, MS; Mulkerrins, E; Smith, RP; Swaisland, AJ, 1991)	0.28
" Examination of the dosing regimen used, however, suggests that insufficient daily dosage of captopril or the inadequate schedule of administration, or both, might be responsible for different degrees of angiotensin-converting enzyme inhibition between the enalapril and captopril groups and hence for the difference in mortality."	( Difference in mortality between patients treated with captopril or enalapril in the Xamoterol in Severe Heart Failure Study. Oakley, C; Pouleur, H; Rousseau, MF; Rydén, L, 1991)	0.7
" Fenoldopam caused an acute fall in blood pressure which lasted approximately 3 h after dosing and was associated with a reflex tachycardia."	( A single dose study of the effects of fenoldopam and enalapril in mild hypertension. Freestone, S; Jeffrey, RF; Lee, MR; MacDonald, TM, 1991)	0.53
" Doxazosin produced rightward shifts of the PE pressor dose-response curves but had no effect on responses to AII."	( Vascular pressor responses in treated and untreated essential hypertension. Donnelly, R; Elliott, HL; Howie, CA; Reid, JL; Sumner, DJ, 1990)	0.28
" During consecutive dosing of lisinopril, its antihypertensive effects were sustained for greater than or equal to 12 h with less diurnal variation of BP."	( Pharmacokinetics and antihypertensive effects of lisinopril in hypertensive patients with normal and impaired renal function. Abe, Y; Ebina, T; Gotoh, E; Ishii, M; Matsukawa, T; Minamisawa, K; Shionoiri, H; Sugimoto, K; Ueda, S, 1990)	0.28
"Enalapril (Renitec, Merck-Sharp-Dohne, Rahway, USA) administered alone (Group I), or in combination (Group II) in a dosage normalizing blood pressure (BP) was investigated for its ability to inhibit adrenergic and serotonergic systems in a one-year study."	( Modulation of serotonergic and adrenergic systems by long-term antihypertensive treatment with enalapril. Balazovjech, I; Dzúrik, R; Jurecková, K; Raucinová, M; Sebeková, K, 1991)	1.94
" Significant decreases from baseline in supine and standing diastolic blood pressures were seen in all dosage groups at end point."	( Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial. Mroczek, WJ, 1991)	0.51
" Allergen (Southern Grass Mix) was administered intradermally 2 h after last drug dosage and the surface areas of the immediate wheal-and-flare-reactions were measured 15 min later."	( Effect of enalapril on allergen-induced cutaneous hypersensitivity reaction. Snyman, JR; Sommers, DK, 1991)	0.68
" The average daily dosage of captopril was 41 +/- 3 mg given in three divided doses (08:00, 12:00, and 17:00 h)."	( Circadian rhythm of blood pressure in congestive heart failure and effects of ACE inhibitors. Dietz, R; Lemmer, B; Osterziel, KJ, 1991)	0.28
" Dosage was titrated for six weeks on the basis of blood pressure (BP) response and was then maintained for the remainder of the study."	( A multicenter comparison of the safety and efficacy of isradipine and enalapril in the treatment of hypertension. Eisner, GM; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR; Vargas, R; Zemel, M, 1991)	0.52
" For the 47 patients randomized, data were collected for 25 patients switched to an equal milligram dosage of lisinopril and for 21 patients who continued to receive a constant dosage of enalapril."	( Cost of switching hypertensive patients from enalapril maleate to lisinopril. Goodfriend, TL; Lindgren-Furmaga, EM; Schuna, AA; Wolff, NL, 1991)	0.73
" Dosage of spirapril was increased from 12 mg to 48 mg once daily."	( Digoxin pharmacokinetics and spirapril, a new ace inhibitor. Flemming, J; Johnson, BF; Johnson, J; Wilson, J, 1991)	0.28
" Adequate precision was obtained to reliably verify drug dosage levels."	( Rapid verification of identity and content of drug formulations using mid-infrared spectroscopy. Brooks, MA; Compton, DA; Compton, SV; Ryan, JA, 1991)	0.28
"This randomised, double-blind, crossover study compared enalapril 5 mg, and atenolol 50 mg, each dosed once daily for 4 weeks, and investigated casual and diurnal BP changes using 24 hour ambulatory BP monitoring."	( Effect of atenolol or enalapril on diurnal changes of blood pressure in Japanese mild to moderate hypertensives: a double-blind, randomised, crossover trial. Hara, H; Ishida, Y; Kobayashi, K; Nakamura, S; Ohta, H; Takabatake, T; Takakuwa, H; Yamamoto, Y, 1991)	0.84
" The predicted responses (before dosing and 4 h after dosing) were in close agreement with the responses observed after 6 weeks."	( Prediction of the antihypertensive response to enalapril. Donnelly, R; Elliott, HL; Howie, CA; Meredith, PA; Reid, JL, 1990)	0.54
" The patients' BP and heart rate were evaluated biweekly by trained observers unaware of the treatment status, and drug dosage was titrated (up to 400 mg twice a day of labetalol or 40 mg daily of enalapril) to achieve a standing diastolic BP of less than 90 mm Hg and a decrease of 10 mm Hg from baseline."	( Comparison of labetalol versus enalapril as monotherapy in elderly patients with hypertension: results of 24-hour ambulatory blood pressure monitoring. Applegate, WB; Borhani, N; DeQuattro, V; Due, DL; Kaihlanen, PM; Oishi, S; Sirgo, MA, 1991)	0.76
" This combination is well tolerated, probably due to an adequate enalapril/HCTZ dosage ratio."	( [Comparative study of enalapril, hydrochlorothiazide and their combination in the treatment of essential hypertension]. Delage, Y; Poggi, L; Souchet, T; Vaisse, B, 1991)	0.83
" We concluded that enalapril in combination with hydrochlorothiazide is more effective and safe, and allows for lower dosing of enalapril than the drug as monotherapy in Korean hypertensives."	( Treatment of essential hypertension in Asians: enalapril as monotherapy versus combination therapy with hydrochlorothiazide. Jones, DW; Sands, CD, 1991)	0.87
" In conclusion this study shows antihypertensive therapy with enalapril during chronic renal insufficiency to be effective at low dosage (5-10 mg) in lowering blood pressure and to have a good safety profile."	( Enalapril in the treatment of hypertension associated with renal failure: results from a multicenter study. Acciarri, PM; Boggi, R; Capponi, E; Cecchini, F; Concetti, M; Greco, A; Mioli, V; Panichi, N; Radicioni, R; Trivelli, G, 1990)	1.96
" We studied 34 hypertensive patients, whose blood pressure levels were controlled by Enalapril at a mean dosage of 12."	( [The role of prostacyclin and thromboxane in the antihypertensive action of enalapril]. Castillo Ferrando, JR; Garrido Peralta, M; Oliván Martínez, J; Serrano Molina, J; Suárez Morano, J, 1990)	0.73
" In 14 patients the dosage was elevated to 40 mg once daily and, in 5 out of these, 12."	( [Hypertensive hypertrophy of the left ventricle: its regression in hypertensive patients with different profiles of plasma renin activity, treated with enalapril]. da Costa, JN; Nogueira, JB; Soares, Ade O, 1990)	0.48
" The administration of enalapril maleate was initiated with a 20 mg daily dosage and titrated up to a maximum of 40 mg daily, whenever DBP was maintained above 90 mmHg and no adverse experience occurred."	( [Effects of enalapril on left ventricular hypertrophy in patients with mild or moderate essential hypertension]. Armaganijan, D; Assef, JE; Batlouni, M, 1990)	0.97
" The dosage of enalapril was 20 mg/day for 11 patients and 40 mg/day for the other three."	( [Effects of enalapril on left ventricular hypertrophy in patients with mild or moderate essential hypertension]. Armaganijan, D; Assef, JE; Batlouni, M, 1990)	1.01
" The dose should be adjusted to the pretreatment GFR, and a decrease in dosage should be considered with prolonged treatment."	( Lisinopril in hypertensive patients with renal function impairment. Apperloo, AJ; de Jong, PE; de Zeeuw, D; Heeg, JE, 1990)	0.28
" A similar elimination profile was observed when the compound was dosed in its active form (FPL 63547 diacid), 87."	( Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Carr, RD; Cooper, AE; Hutchinson, R; Mann, J; O'Connor, SE; Robinson, DH; Wells, E, 1990)	0.28
" Lisinopril seems to be at least as effective as captopril in congestive heart failure, and it has over the latter the advantage of a once a day dosage therapy."	( [The value of lysinopril in cardiac insufficiency]. Lambert, M; Luccioni, R, 1990)	0.28
" At week 8, if the target diastolic pressure of less than 90 mm Hg was not achieved, the dosage of hydrochlorothiazide was increased to 50mg."	( Comparative efficacy and safety of enalapril and sustained-release nifedipine in patients with mild to moderate hypertension. The Enalapril vs Nifedipine French Study Group. Artigou, JY; Benichou, M; Berland, J; Fressinaud, P; Grollier, G; Gueret, P; Nguyen, CD, 1990)	0.56
" Initially, patients received enalapril 5 mg and the dosage was titrated upwards, according to response, to a maximum of 20 mg/day."	( A cooperative study to evaluate the efficacy and safety of enalapril in Puerto Rican patients with mild to moderate hypertension. Feliu, JF; Medina-Ruiz, A, 1990)	0.81
" The dosage of enalapril was increased from 10 to 20 mg daily in 12 patients; 8 required additional antihypertensive agents."	( Enalapril in the long-term treatment of elderly hypertensives. Cameron, A; Long, C; Mannering, D; Mondal, BK; Ranasinha, KW; Strouthidis, TM, 1990)	2.07
" A total of 22 patients completed the study, 11 treated with enalapril (mean dosage 25 +/- 10 mg/day) and 11 treated with captopril (mean dosage 77 +/- 26 mg/day)."	( [Comparison of enalapril and captopril in the treatment of chronic heart failure]. Greminger, P; Hess, OM; Jenni, R; Krayenbuehl, HP; Maire, R; Tjon-A-Meeuw, L, 1990)	0.87
" Blood pressure (BP) was lower with E after half the maximum dosage compared with V, but similar BP reductions were obtained after 2 months with the maximum dosage."	( Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study. Fagher, B; Henningsen, N; Hulthén, L; Katzman, P; Thulin, T, 1990)	0.55
" On repeated daily oral dosing to SHR, both compounds had a cumulative antihypertensive effect."	( Biological properties of the angiotensin-converting enzyme inhibitor cilazapril. Brewster, M; Budd, J; Francis, RJ; Klevans, LR; Natoff, IL; Nixon, JS; Patel, AT; Wenger, J; Worth, E, )	0.13
" Twenty and 40 mg enalapril lowered the blood pressure by 2 h after dosing in the hypertension group, and peak effects were seen 4-5 h after dosing."	( Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. Abernethy, D; Farmer, J; Mitchell, JR; Nelson, E; O'Meara, M; Pool, J; Schwartz, JB; Taylor, A; Young, J, )	0.73
"25 mg and increasing dosage until blood pressure was adequately controlled."	( Changes in the pathophysiologic profile of blood pressure determinants during short-term enalapril administration. Birkenhäger, WH; de Leeuw, PW, 1986)	0.49
"According to classic pharmacologic theory, agonist/antagonist competition can be used to quantify an antagonist's potency by measurement of agonist dose-response curves in the presence of varying doses of the antagonist."	( Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril. Belz, GG; Essig, J; Wellstein, A, 1987)	0.27
" The higher dosage reduced myocardial oxygen consumption (to 87 +/- 2% of control), mean arterial pressure (MAP) (to 90 +/- 1%) and coronary conduit artery tone (normalized delta diameter: +3."	( Dilation of epicardial arteries in conscious dogs induced by angiotensin-converting enzyme inhibition with enalaprilat. Bassenge, E; Busse, R; Holtz, J; Sommer, O, 1987)	0.49
" Arterial blood pressure was monitored continuously for 6 h following each dosage using an intraarterial cannula."	( Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure. Dickstein, K, 1987)	0.27
" After a 2-week run-in period, 130 patients receiving digoxin and/or diuretics were randomised to 12 weeks of treatment with lisinopril 5 mg daily (87 patients) or with placebo (43 patients), with an option to increase lisinopril dosage to 10 or 20 mg."	( Placebo-controlled study of lisinopril in congestive heart failure: a multicentre study. Chalmers, JP; Cyran, J; De La Torre, D; Englert, M; Kramar, M; Lewis, GR; Maranhao, MF; Myburgh, DP; Schuster, P; West, MJ, 1987)	0.27
" Two weeks of combined treatment with nicardipine and enalapril significantly reduced the predosing blood pressure, 12 h after the last dose of nicardipine (158/96 as compared with 172/106 with placebo), and there were further significant reductions in blood pressure during the subsequent dosage interval."	( An evaluation of the pharmacodynamics and pharmacokinetics of nicardipine combined with enalapril in essential hypertension. Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1987)	0.74
"5 mg orally, was given every 24 h initially; in six patients, dosage was decreased to an alternate or once-a-week schedule, because of a hypotensive effect during dialysis."	( Treatment of hypertension with lisinopril in end-stage renal failure. Bellucci, A; Küntziger, HE; Pouthier, D, 1987)	0.27
" Moreover, a question has arisen as to whether a once- or twice-daily dosing schedule is preferable."	( Long-term effects of a once-a-day versus twice-a-day regimen of enalapril for congestive heart failure. Francis, GS; Rucinska, EJ, 1989)	0.52
" A dose-response relation for most parameters was noted."	( Lisinopril for severe congestive heart failure. Amin, D; LeJemtel, T; Levine, TB; Liang, CS; Linnemaier, T; Shah, PK; Shaver, JA; Uretsky, BF; Walinsky, P, 1989)	0.28
" After 12 weeks of therapy with lisinopril, the dosage of which was titrated to produce optimal relief of symptoms of congestive heart failure (CHF), repeat hemodynamic studies revealed persistent significant reductions in baseline systemic arterial pressure, pulmonary artery wedge pressure, mean pulmonary arterial pressure and systemic vascular resistance."	( Hemodynamic effects of lisinopril after long-term administration in congestive heart failure. Amin, DK; Langendörfer, A; Liang, CS; Linnemeier, TJ; Rush, JE; Shah, PK; Snapinn, SM; Stone, CK; Uretsky, BF, 1989)	0.28
" Enalapril was then administered for 72 hours and 6 weeks, and the assessment of the Ang II dose-response relations was repeated."	( Prolonged converting enzyme inhibition in non-modulating hypertension. Dluhy, RG; Hollenberg, NK; Smith, K; Taylor, T; Williams, GH, 1989)	1.19
" The usual initial oral dosage of lisinopril is 10 mg once a day (range 20-40 mg/day)."	( Lisinopril: a new angiotensin-converting enzyme inhibitor. Chase, SL; Sutton, JD, 1989)	0.28
" Angiotensin I dose-response curves were derived by continuous infusion of angiotensin I in increasing dose steps; steady state was reached within 3 min."	( The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril. Belz, GG; Essig, J; Wellstein, A, 1989)	0.49
" Lisinopril treatment reduced supine and standing cuff clinic measurements of BP 24 h after dosing by (systolic/diastolic) 21."	( Assessment of the antihypertensive effect of lisinopril using 24-hour ambulatory monitoring. Conte, D; Herpin, D, 1989)	0.28
" These properties are consistent with once-daily dosing and uncomplicated clinical use in the treatment of hypertension and congestive heart failure."	( The clinical pharmacology of lisinopril. Case, DE, 1989)	0.28
" Therefore, if captopril therapy has to be used in a single daily dose an attempt should be made using an increased dosage or by employing the drug in some retarded pharmaceutical form."	( [Comparison of the efficacy of captopril and enalapril in single doses in the treatment of arterial hypertension. Evaluation by means of non-invasive ambulatory monitoring]. Canini, F; Gambini, G; Marinelli, M; Pinchi, G; Rossi, S; Valori, C, 1989)	0.54
" However, pharmacokinetic studies with the controlled-release dosage forms in humans produced plasma profiles with the same characteristics and time to peak as an immediate-release capsule."	( Evidence for site-specific absorption of a novel ACE inhibitor. Grass, GM; Morehead, WT, 1989)	0.28
" There was a linear dose-response relationship for both supine and erect blood pressure."	( Lisinopril dose-response relationship in essential hypertension. Chrysant, SG; Cirillo, VJ; Gomez, HJ; Gradman, AH; Leon, AS; MacCarthy, EP; Otterbein, ES; Rush, JE; Shaw, WC; Sromovsky, JA, 1989)	0.28
" In ex vivo dose-response and time-course studies, the inhibitory effects of the seven drugs on tissue ACEs and their relative distributions to SHR tissues were compared following oral administration."	( Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Cushman, DW; DeForrest, JM; Fung, WC; Grover, GJ; Harvey, CM; Mitch, SL; Scalese, RJ; Wang, FL, 1989)	0.28
"Sensory and behavioral performance of three normotensive and one renovascular hypertensive baboon was tested before, during and following chronic oral dosing with the angiotensin converting enzyme (ACE) inhibitor enalapril."	( Matching to sample, blood pressure and hormonal effects of chronic enalapril in baboons. Hienz, RD; Turkkan, JS, 1989)	0.7
" Thus, there is evidence that application of concentration-effect analysis is useful in predicting the steady-state antihypertensive effect from the first dose-response to the drug."	( Prediction of response to antihypertensive therapy with enalapril and nifedipine. Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1989)	0.52
"Nifedipine, in a slow release preparation, was given at a mean daily dosage of 47 +/- 4 mg to 12 patients with severe hypertension in whom arterial pressure was not satisfactorily controlled (mean arterial pressure 132 +/- 4 4 mm Hg) by the combination of a converting enzyme inhibitor and a diuretic."	( Effect of chronic nifedipine in patients inadequately controlled by a converting enzyme inhibitor and a diuretic. Mimran, A; Ribstein, J, 1985)	0.27
" A conversion rate of angiotensin I to angiotensin II calculated from the dose-response curves was 26."	( Presynaptic angiotensin II receptors and captopril-induced adrenergic transmission failure probably not via converting enzyme inhibition in guinea-pig pulmonary arteries. Kubo, T; Misu, Y; Shionoiri, H; Yasuda, G, 1987)	0.27
" Abundant data from controlled clinical trials and worldwide experience, particularly for captopril, indicate the safety and absence of subjective side effects when used alone in relatively low dosage or in combination with a diuretic."	( Angiotensin-converting enzyme inhibitors: are they all alike? Case, DB, 1987)	0.27
"The anti-anginal effect of the ACE inhibitor enalapril, at a dosage of 5 mg twice a day, was tested in a randomised, placebo-controlled double-blind trial on 12 normotensive patients with proven coronary-heart disease."	( [Anti-ischemia effect of enalapril in coronary heart disease. A randomized placebo-controlled double-blind study]. Kirsten, R; Rietbrock, N; Schneider, W; Thürmann, P, 1988)	0.84
" Thirty-one percent of older white patients attained normotension with a daily dosage of 5 mg, whereas only 4% of black patients in this age group did so."	( Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. Gavras, H; Gavras, I; Mulinari, R, 1987)	0.56
"If optimal dosage administration schedules are to be defined, the factors that influence the disposition of a drug in the population of patients who are likely to receive it should first be determined."	( Population pharmacokinetics of lisinopril in hypertensive patients. Thomson, AH; Whiting, B, 1987)	0.27
" The dosage of lisinopril was titrated upward to 40 mg daily according to BP response."	( Lisinopril treatment of hypertension in patients with impaired renal function. Cooper, WD; Donohoe, JF; Doyle, GD; Glover, DR; Laher, M; Long, C, 1987)	0.27
" After two weeks, the dosage was doubled (to 40 mg of enalapril and 100 mg of atenolol) in those patients with diastolic blood pressure higher than 95 mm Hg."	( The neglected time factor and antihypertensive therapy. A pitfall in evaluating side effects in a cross-over study. Baumgart, P; Edmonds, D; Greminger, P; Vetter, H; Vetter, W, 1988)	0.52
" Systolic blood pressure and heart rate were recorded once a week just before dosing and at varying time intervals up to 6 hr thereafter."	( Antihypertensive effect of spirapril and felodipine during repeated administration to spontaneously hypertensive rats. Forlani, A; Milani, S; Monopoli, A; Ongini, E, 1988)	0.27
" Prolonged duration of action of lisinopril allows once daily dosing, unlike captopril for which dosing is required every 8-12 hours or enalapril which may necessitate twice daily dosing."	( Lisinopril: a new angiotensin-converting enzyme inhibitor. Armayor, GM; Lopez, LM, 1988)	0.48
" The reported incidence of these side effects with the current recommended dosage of captopril is low."	( Lack of cross sensitivity between captopril and enalapril. Jackson, B; Johnston, CI; Maher, D; Matthews, PG; McGrath, BP, 1988)	0.53
" The changes were present up to 24 hours after dosing for most parameters."	( Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses Amin, D; LeJemtel, T; Levine, TB; Liang, CS; Linnemeier, T; Rush, JE; Shah, PK; Shaver, JA; Uretsky, BF; Walinsky, P, 1988)	0.27
" Removal of the respective ACE inhibitors revealed an apparent increase in total enzyme in the plasma of animals dosed chronically with BRL 36378 and enalapril."	( Acute and chronic effects of a novel dihydrobenzofuran analogue and enalapril on blood pressure and plasma and tissue angiotensin converting enzyme activity in the sodium deficient normotensive rat. Howlett, DR; Longman, SD, 1988)	0.71
"We evaluated the acute blood pressure lowering effect of enalapril in terms of dose-response curve and compared this effect with that on humoral parameters."	( Acute dose-response curve of enalapril in renovascular hypertensives. Arzilli, F; Giovannetti, R; Magagna, A; Nuccorini, A; Salvetti, A, 1988)	0.81
"Severe hypertension may be a difficult management issue, and it often requires therapy with multiple drugs at frequent dosing intervals."	( Clinical experience with labetalol and enalapril in combination in patients with severe essential and renovascular hypertension. Aydelotte, ME; White, WB, 1988)	0.54
" Lisinopril reduced systolic blood pressure and inhibited serum ACE activity in both normal and diabetic rats in a dose-response fashion."	( Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats. Hartmann, JF; Hayes, NS; Keegan, ME; Slater, EE; Szemplinski, M, 1988)	0.27
" These cases demonstrate that ACE inhibitors should not be instituted during extracellular volume depletion and their initial dosage should be low."	( [Severe complications during enalapril therapy for heart insufficiency]. Stäubli, M; Wieland, T, 1988)	0.57
" Thus, when verapamil is introduced or discontinued in patients on ciclosporin, close monitoring of ciclosporin levels and dosage adjustment are necessary."	( [Effect of enalapril, furosemide and verapamil on cyclosporin concentration in whole blood]. Angermann, CE; Anthuber, M; Kemkes, BM; Spes, CH; Theisen, K, 1988)	0.66
" Before treatment, after enalapril and placebo, mean blood glucose values, HbA1, daily insulin dosage were recorded as well as the number of clinical and biological (less than 3 mmol/l) hypoglycaemic episodes."	( [Absence of effect of enalapril on the glycemic control and peripheral sensitivity to insulin in 10 diabetic patients treated with subcutaneous continuous infusion of insulin]. Billault, B; Fisch, A; Leblanc, H; Passa, P; Porquet, D; Thote, A, 1988)	0.89
" The dosage must be adjusted according to renal function, in order to prevent accumulation and toxicity."	( [Angiotensin-converting enzyme inhibition: side effects and risks]. Scheler, F; Schilling, H, 1988)	0.27
" In patients not responding to this dosage regimen at the end of a 4-week treatment period, the dose was doubled."	( A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension. Akbary, MA; Rangoonwala, B; Rosenfeld, J; Schinzel, S; Zabludowski, J, 1988)	0.52
"The chemistry, pharmacology, pharmacokinetics, clinical use, adverse effects, and dosage of lisinopril are reviewed."	( Lisinopril: a nonsulfhydryl angiotensin-converting enzyme inhibitor. Murray, KM; Noble, TA, 1988)	0.27
" The design of dosage regimens of both lisinopril and enalapril for patients with severe renal impairment or chronic renal failure should take into consideration the use and effects of haemodialysis."	( Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis. Carmody, M; Cooper, WD; Doyle, GD; Glover, DR; Kelly, JG, 1988)	0.81
" After a placebo run-in period the patients received increasing dosages of medication every 2 weeks until the target diastolic blood pressure of 90 mm Hg or less was achieved on two consecutive visits, the maximum dosage was reached, or the patient withdrew because of adverse effects."	( Comparison of monotherapy with enalapril and atenolol in mild to moderate hypertension. The Canadian Enalapril Study Group. , 1987)	0.56
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of enalapril maleate, a nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor, are reviewed."	( Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. Conner, DP; Ferguson, RK; Larijani, GE; Vlasses, PH, )	1.79
" The therapeutic dosage was increased when the blood pressure (BP) was not controlled for more than 3 days."	( Effects of enalapril maleate (MK-421) on renovascular hypertension. Hara, A; Hirakawa, A; Kawai, C; Koide, H; Matsunaga, M; Nagai, H; Ogawa, K; Pak, CH, 1985)	0.66
" Both drugs reduced blood pressure without change in heart rate after acute dosing and after seven days."	( Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man. Ajayi, AA; Campbell, BC; Howie, CA; Reid, JL, 1985)	0.51
"The dose-response relationship of enalapril was evaluated in a double-blind, balanced, two-period, incomplete-block study in 91 patients with mild to moderate essential hypertension."	( Effective dose range of enalapril in mild to moderate essential hypertension. Berglund, G; Bergstrand, R; Bolognese, JA; Cirillo, VJ; Gomez, HJ; Herlitz, H; Johansson, S; Vedin, A; Wilhelmsson, C, 1985)	0.86
" Mouse PACE activity was determined with 14C-Hip-His-Leu as substrate one hour after oral dosing of 3 animals/group with 5 or 50 mumol ACE inhibitor per kg."	( Correlation between anti-hypertensive activity in rats and plasma angiotensin I-converting enzyme (ACE) inhibition in mice following oral administration of ACE inhibitors. Brooks, RR; Huang, CT; Moore, AF; Pong, SF, 1985)	0.27
" The dosage was increased when the blood pressure (BP) was not normalized for more than 3 days."	( Effects of enalapril maleate on plasma level of inactive renin in renovascular hypertension. Hara, A; Kawai, C; Matsunaga, M; Nagai, H; Ogawa, K; Pak, CH, 1985)	0.66
" The effective accumulation half-life following multiple dosing is 11 hours."	( Enalapril: a review of human pharmacology. Cirillo, VJ; Gomez, HJ; Irvin, JD, 1985)	1.71
") for 4 weeks, and were crossed over to the other dosage regimen after a 2-week washout period."	( Haemodynamic effects of enalapril, a new converting enzyme inhibitor, in hypertensive patients. Gómez, HJ; Hernández-Pieretti, O; Morillo, J; Pellicer, R; Ramirez, A; Silva, H; Urbina, A; Velasco, M, 1985)	0.58
" The commonest adverse reaction with enalapril was dizziness which occurred in two cases and resolved on dosage reduction."	( Enalapril maleate and atenolol combined with hydrochlorothiazide in moderate to severe essential hypertension. Gray, D; Moon, R; Musgrove, J; Pascoe, J, 1985)	1.98
" Population drug concentration data obtained in the course of early clinical evaluations of new drugs may provide a rational basis for dosage regimens with improved efficacy and, in particular, reduced concentration-related toxic effects."	( Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Ajayi, AA; Campbell, BC; Howie, C; Kelman, AW; Meredith, PA; Reid, JL, 1985)	0.52
" The therapeutic dosage range is 10-40 mg/d, maximum of 40 mg, given once or twice daily."	( Enalapril: a new angiotensin converting enzyme inhibitor. Cleary, JD; Taylor, JW, 1986)	1.71
" Further study of the usefulness of chronic dosing with angiotensin converting enzyme inhibitors in hypertension in the elderly is indicated."	( Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Ajayi, AA; Hockings, N; Reid, JL, 1986)	0.5
" The incidence of the main (but rare) side effects of hypotension in hypovolaemic patients and reduced renal function in certain patients with renovascular hypertension, which are also seen with captopril, might be reduced by careful dosage titration, discontinuation of diuretics, and monitoring of at-risk patients."	( Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Heel, RC; Todd, PA, 1986)	1.71
" After hydrochlorothiazide was added to patients not achieving 'target' blood pressure, the fall in systolic pressure was significantly greater in the enalapril group than in the atenolol group, despite similar dosage of hydrochlorothiazide in the two groups."	( Enalapril in moderate to severe hypertension: a comparison with atenolol. Burgess, J; Cooper, WD; Davidson, C; Fairhurst, G; Petrie, JC; Richardson, PJ; Robb, OJ; Trafford, J; Vandenburg, MJ; Webster, J, 1986)	1.91
" There was no evidence of a flat dose-response curve in the daily dose range of 12."	( Is low-dose hydrochlorothiazide effective? Freis, ED; Magee, PF, 1986)	0.27
"Nifedipine, in a slow release preparation, was given at a mean daily dosage of 47 +/- 4 mg to 12 patients with severe hypertension in whom arterial pressure was not satisfactorily controlled (mean blood pressure, 172 +/- 6/111 +/- 4 mmHg) by the association of a converting enzyme inhibitor and a diuretic."	( Effect of nifedipine in hypertension not controlled by converting enzyme inhibitor and diuretic. Mimran, A; Ribstein, J, 1986)	0.27
" Both drugs have a shallow dose-response curve and both produce comparable hormonal changes: an increase in plasma renin activity and a decrease in aldosterone levels."	( Angiotensin converting enzyme inhibitors in congestive heart failure. Overview in comparison of captopril and enalapril. Cohn, JN; Levine, TB; Olivari, MT, 1986)	0.48
" In patients with moderate renal impairment or in elderly people (creatinine clearance greater than 30 ml/min), plasma concentrations are slightly increased and there is no need for dosage adjustment."	( [Pharmacokinetics of enalapril]. Billaud-Mesguich, E, 1986)	0.59
" At the end of the study, drug-induced azotemia resolved after a reduction in the dosage of diuretics, despite unaltered treatment with captopril and enalapril."	( Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Kessler, PD; Lee, WH; Medina, N; Packer, M; Yushak, M, 1987)	0.7
" Monotherapy with enalapril in a single daily dosage regimen ranging between 5 and 40 mg resulted in normotension (in the sitting position) in 73% of the younger, 50% of the middle-aged, and 56% of the older patients."	( A multicenter trial of enalapril in the treatment of essential hypertension. Gavras, H, 1986)	0.92
" In patients with severe renal failure, adjustment of the dose or the dosing frequency to the degree of renal failure is recommended to avoid administration of doses in excess of those required to achieve adequate inhibition of converting enzyme."	( Lisinopril in hypertensive patients with and without renal failure. Boer, P; Geyskes, GG; van Schaik, BA, 1987)	0.27
" Renal failure was always reversible with interruption or dosage reduction of the drug."	( [Development of renal function in the transplanted patient with renal hypertension treated with enalapril]. Berthoux, F; Genin, C; Guerin, C; Leroy, G; Sabatier, JC; Toulon, J, 1987)	0.49
"001); however, this was not observed until after 4 weeks of treatment when the dosage was 30 and 150 mg X kg-1 X day-1, respectively."	( Systolic blood pressure responses to enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) and hydrochlorothiazide in conscious Dahl salt-sensitive and salt-resistant rats. Fernandez, PG; Kim, BK; Sharma, JN; Triggle, CR, 1984)	0.54
" In a randomized, double-blind study, 29 subjects (28 blacks and one white) received one of the following dosing regimens: hydrochlorothiazide (HCTZ), 25 mg twice a day (group 1; n = 12); enalapril, 10 mg twice a day (group 2; n = 12); or enalapril, 10 mg twice a day, with HCTZ, 25 mg twice a day (group 3; n = 5)."	( Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension. Bain, RP; Douglas, MB; Freier, PA; Hall, WD; Unger, DJ; Wollam, GL, 1984)	0.7
" Both acutely and chronically in patients with essential hypertension, enalapril reduced blood pressure with a rather flat dose-response curve."	( An overview of the clinical pharmacology of enalapril. Davies, RO; Gomez, HJ; Irvin, JD; Walker, JF, 1984)	0.76
" During long-term administration of enalapril, a similar relationship between the plasma enalaprilic acid level, ACE inhibition and the hypotensive effect was shown, although the dose-response curve for plasma enalaprilic acid to ACE inhibition was displaced to the right compared to the acute dose-response curve."	( Plasma enalapril levels and hormonal effects after short- and long-term administration in essential hypertension. Casley, D; Cubella, R; Jackson, BJ; Johnston, CI; Larmour, I, 1984)	1
" However, when compared to the acute response, the ACE inhibition dose-response line was shifted to the right after chronic enalapril therapy suggesting that enalapril may lead to ACE induction in humans."	( Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. Arnolda, L; Jackson, B; Johnston, CI; Matthews, G; McGrath, B, 1983)	0.74
" Serum profiles after chronic dosing of enalapril show little accumulation of the active diacid metabolite, enalaprilat."	( Kinetic and metabolic aspects of enalapril action. Lant, AF; McNabb, RW; Noormohamed, FH, 1984)	0.82
" The dose-response regression lines for the antihypertensive effect of each inhibitor, unlike those for ACE inhibition, were flat."	( Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats. Arbegast, PT; Blaine, EH; Gaul, SL; Gross, DM; Sweet, CS, 1981)	0.26
"In spontaneously hypertensive rats (SHR), after 1 day of dosing with an angiotensin-converting enzyme (ACE) inhibitor (captopril or enalapril) plus a diuretic (hydrochlorothiazide), a synergistic antihypertensive effect was observed when a second dose of the combination or ACE inhibitor alone but not the diuretic alone was given the next day."	( Acute antihypertensive synergism of angiotensin-converting enzyme inhibitors and diuretics. Cervoni, P; Chan, PS; Ronsberg, MA, 1984)	0.47
" The two dosages of MK-421 caused similar, significant falls in supine and standing blood pressure, which were maximum four to six hours after dosing (9."	( Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects. Bayliss, J; MacGregor, GA; Markandu, ND; Morton, JJ; Roulston, JE; Squires, M, 1981)	0.26
" Dose-response curves were generated in vitro by adding the diacid metabolite (DM) to serum (ID50 = to 6x10-9 M); l0-15% of initial activity was nonsuppressible."	( Angiotensin converting enzyme activity in human serum: relationship to enzyme inhibitor in vivo and in vitro. Dudash, M; Ferguson, RK; Hichens, M; Mojaverian, P; Swanson, BN; Vlasses, PH, 1981)	0.26
" During repeated dosing in the outpatient trial there was attenuation of the antihypertensive effect (12 to 24 hr after dosing) in eight of 10 patients."	( Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Ferguson, RK; Hichens, M; Huber, PB; Irvin, JD; Mojaverian, P; Swanson, BN; Vlasses, PH, 1982)	0.65
" Dose-response curves to angiotensin I, angiotensin II, and norepinephrine were established prior to and during continuous short-term (2 to 3 hours' duration) and long-term (24 hours' duration) inhibition of angiotensin converting enzyme activity by either captopril or enalapril."	( Modulation of angiotensin II pressor responsiveness by circulating levels of angiotensin II in pregnant sheep. Austin, JE; Clark, KE; Holroyd, JC; Siddiqi, TA, 1983)	0.44
" The reduction in blood pressure following enalapril was evident throughout the 12-hour dosing interval."	( Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination. Ferguson, RK; Irvin, JD; Koplin, JR; Lee, RB; Rotmensch, HH; Swanson, BN; Vlasses, PH, )	0.66
" All underwent a 4-wk washout-placebo phase and were then assigned to a dosing schedule of either 10 mg enalapril once daily, 5 mg enalapril twice daily, or placebo twice daily for 12 wk."	( Enalapril in low-renin essential hypertension. Dustan, HP; Oparil, S; Walker, JF; Wilkins, LH, 1983)	1.92
" Apart from the hydrochlorothiazide dosage which was fixed, the dosage of the other active drugs was titrated incrementally until the target blood pressure level was achieved."	( An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension. Fernandez, PG; Galway, AB; Kim, BK, 1984)	0.49
" Diuretic dosage was reduced in six patients and increased in one patient, one patient had died and another had been withdrawn from the study."	( Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Coxon, R; Hannan, SF; Murphy, J; Sharpe, DN, 1984)	1.71
" The daily dosage of enalapril was increased, if required, from 10 to 20 to 40 mg and that of nifedipine from 40 to 60 to 80 mg at 4-week intervals during the 12-week titration period."	( Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995)	0.86
" Urinary electrolytes and aldosterone were measured for the 24 h before dosing and for 24 h after dosing."	( Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man. Brunner, HR; Insuasty, J; MacFadyen, RJ; McIntyre, M; Menard, J; Meredith, PA; Reid, JL, 1995)	0.53
"A double blind randomised comparison of two angiotensin-converting enzyme (ACE) inhibitors was made in a study in which ambulatory blood pressure was monitored over a steady-state dosage interval and the subsequent 24-h period, the latter being designed to mimic a missed dose of drug."	( Differential effects of a missed dose of trandolapril and enalapril on blood pressure control in hypertensive patients. Boussac, J; Bouvier d'Yvoire, M; Dutrey-Dupagne, C; Elkik, F; Genes, N; Meredith, PA; Vaur, L, 1995)	0.54
" The dose-response curve for spirapril appears to be flat for doses of 6 to 24 mg once daily."	( Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Noble, S; Sorkin, EM, 1995)	0.29
"01), although the once-daily dosing of enalapril and the maximum dose of 20 mg might not have been optimal for this agent."	( Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Adegbile, IA; Alemayehu, D; Carr, AA; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1995)	0.56
" The dosage was increased if the average sitting diastolic blood pressure was > 90 mm Hg."	( A multicenter comparison of adverse reaction profiles of isradipine and enalapril at equipotent doses in patients with essential hypertension. Eisner, GM; Jain, AK; Johnson, BF; McMahon, FG; Rudd, P; Sowers, JR, 1995)	0.52
" We performed a dose-response study of enalapril to assess the level at which maximal suppression of intimal hyperplasia occurs."	( Pharmacologic suppression of intimal hyperplasia: a dose-response suppression by enalapril. Colburn, MD; Gelabert, HA; Law, MM; Moore, WS; Petrik, PV; Quinones-Baldrich, W, 1995)	0.79
"The objective of this study was to test the efficacy and tolerability of a precise dosage regimen of enalapril in general medical practice, in combination with conventional therapy, in patients with mild-to-moderate (NYHA classes II and III) congestive heart failure (CHF)."	( Enalapril in the treatment of mild-to-moderate heart failure in general medical practice: a prospective and multicentre study concerning 17,546 patients. Grolleau, R; Leclercq, F; Messner Pellenc, P; Rudnicki, A, 1995)	1.95
" In genetic and renal hypertensive rats, the antihypertensive effect induced after acute dosing of SR 47436 was similar to that observed after losartan and enalapril."	( Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. Canals, F; Cazaubon, C; Galindo, G; Lacour, C; Nisato, D; Segondy, D, 1994)	0.49
" These results indicate that combined daily dosing of semotiadil, especially with enalapril, each at relatively low doses may be able to control hypertension in a continuous manner."	( Antihypertensive effects of a novel calcium antagonist, semotiadil fumarate (SD-3211), alone and in combination with enalapril or trichlormethiazide in spontaneously hypertensive rats. Akashi, S; Ichikawa, M; Koida, M; Machidera, Y; Manno, K; Nakamuta, H; Ohtsuji, T; Wanaka, M, 1994)	0.72
") dosing in humans."	( Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans. Birnbock, H; Doig, JK; Jones, CR; MacFadyen, RJ; Reid, JL, 1995)	0.29
" In a further 7-week period the dosage level reached with the initial drug was halved, and titration with the second agent was carried out."	( Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients. Boutagy, J; Johnston, HJ; Marwood, JF; Monaghan, JC; Okoro, EO; Stokes, GS, 1994)	0.54
" An effective dosage of norepinephrine that increased MAP by 20 mmHg (EDNE 20) was thereafter calculated."	( Enhanced pressor responsiveness to norepinephrine in type II diabetes. Effect of ACE inhibition. Capelli, M; Ciavarella, A; Mustacchio, A; Ricci, C; Vannini, P, 1994)	0.29
"75, 10, and 30 mg) of cilazapril reduced diastolic blood pressure dose-dependently and shifted the angiotensin I dose-response curves to the right."	( Review of studies on the clinical pharmacodynamics of cilazapril. Belz, GG; Breithaupt, K; Erb, K, 1994)	0.29
" The dosage was titrated if necessary after 4 weeks of treatment."	( Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension. Chan, TY; Critchley, JA; Or, KK; Sanderson, JE; Tomlinson, B; Woo, J, 1994)	0.29
" If, after 4 weeks of treatment, CR-determined diastolic blood pressure (DBP) was still > 90 mm Hg, this dosage was doubled (n = 327) and, at week 8, pindolol at 5 mg or spirapril at 3 mg daily was added if necessary for blood pressure control."	( A multicenter study using causal readings, self-recordings, and ambulatory blood pressure monitoring to assess isradipine effects. AMICUS Study Group. Fitscha, P; Magometschnigg, D; Meisner, W, 1994)	0.29
"The AR described were classified by organs and systems, evaluating the age and the sex of the patient, the indication for the drug, dosage used, and the level of health care assistance received since notification."	( [Adverse reactions from angiotensin-converting enzyme inhibitor drugs reported by the yellow card]. Ferrer, JM; Morales-Olivas, FJ; Palop, V; Rubio, E, 1994)	0.29
" Significantly more patients were dosed on a twice daily regimen of enalapril than lisinopril."	( A multi-center analysis of the use of enalapril and lisinopril in elderly hypertensive patients. Cotsonis, G; Douglas, MB; Hall, WD; Hawkins, DW, 1994)	0.8
" Thus, compared with other agents, amlodipine with its relatively smooth concentration-time profile and long elimination half-life will be superior in maintaining blood pressure control both with perfect compliance and when dosage regimens are perturbed due to missed drug doses."	( Therapeutic coverage: reducing the risks of partial compliance. Elliott, HL; Meredith, PA, 1994)	0.29
" Regression analysis of pharmacokinetic parameters C(max)ss (the maximum steady-state drug concentration in plasma during a dosing interval), Cl/f (total plasma clearance) and k (elimination rate constant) of spirapril on creatinine clearance (Clcr) showed that the pharmacokinetics of spirapril were not significantly influenced by the degree of renal impairment."	( Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure. Grass, P; Haufe, CC; Jansa, U; Sierakowski, B; Stein, G; Weidinger, G, 1994)	0.29
" There were statistically significant differences between all active-treatment groups (except the 24-mg dose group) and placebo, but not among the spirapril groups at the end of the +24-hour dosing interval."	( A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. UK Study Group of Spirapril in Hypertension. Fairhurst, GJ, 1994)	0.29
" When blood pressures were measured at the end of the dosing interval (trough), all spirapril regimens had produced similar reductions in sitting systolic and diastolic blood pressures (siSBP/siDBP) which were significantly greater than those observed in placebo-treated patients."	( Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension. Alvisi, V; Boxho, G; Cocco, G; Franck, J; Guitard, C; Maibach, E; Mellein, B; Waite, R, 1994)	0.29
" The oral dosage should be much reduced in infants with congestive heart failure aged < 20 days compared with those aged > 20 days."	( The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. Chiba, K; Ishii, M; Ishizaki, T; Kato, H; Nakamura, H; Sugimura, T, 1994)	0.6
"The purpose of the present study was to quantify some of the short term responses of the renin-angiotensin system (RAS) to a recommended dosage of the angiotensin-converting enzyme inhibitor enalapril in clinically healthy dogs fed a normal-sodium and a low-sodium diet."	( Short term effects of acute inhibition of the angiotensin-converting enzyme on the renin-angiotensin system and plasma atrial natriuretic peptide in healthy dogs fed a low-sodium diet versus a normal-sodium diet. Bie, P; Flagstad, A; Jensen, AL; Koch, J; Pedersen, HD; Poulsen, K, 1994)	0.48
" Beginning at 5 mg once daily for enalapril and 30 mg once daily for nifedipine-ER, the dosage was titrated every 4 weeks for 16 weeks, up to a maximum of 40 mg for enalapril and 120 mg for nifedipine-ER."	( Efficacy and safety of enalapril versus extended-release nifedipine for the treatment of mild-to-moderate essential hypertension: a multicenter 22-week study. Multicenter Cooperative Study Group. Leon, AS, )	0.72
" In the first the effects of captopril on apomorphine-induced behaviour were compared with those of the classical neuroleptic haloperidol, and in the second dose-response curves for the effects of captopril and enalapril on apomorphine-induced behaviour were determined."	( The angiotensin converting enzyme inhibitors captopril and enalapril inhibit apomorphine-induced oral stereotypy in the rat. Banks, RJ; Dourish, CT; Mozley, L, 1994)	0.72
" The inhibition of ACE activity paralleled enalaprilat concentrations following both single and multiple dosing and the time of maximum inhibition of ACE activity was associated on both occasions with maximum concentration of enalaprilat."	( Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing. Edeki, T; Johnston, A; Li Kam Wa, E; Turner, P, 1994)	1.99
"3 years) of whom 89% (n = 510) received the standard dosage of 1 tablet daily."	( [Antihypertensive effectiveness of enalapril and hydrochlorothiazide as a combination drug]. Banyai, M; Pirich, C, 1993)	0.56
" Evaluation criteria were efficacy, clinical experience, safety, dosage interval, hepatic bioactivation, interactions, dosage forms and cost."	( Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors. Atienza Fernández, M; Carvajal Gragera, E; Piña Vera, MJ; Santos Ramos, B, 1993)	0.29
" The relationship of the profile of hormonal suppression seen with enalapril and drug dosage to observed beneficial effects on morbidity or mortality is unclear."	( Role of the circulating and tissue-based renin-angiotensin system in the development of heart failure: implications for therapy. MacFadyen, RJ, 1993)	0.52
"2 L/h)] results in significant accumulation of enalaprilat and necessitates dosage reduction."	( Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. Elliott, HL; MacFadyen, RJ; Meredith, PA, 1993)	1.99
" Group 2 (n = 5) was treated with enalapril at a dosage of 50 mg/l in drinking water starting at 6 weeks of age."	( Effects of an angiotensin II receptor antagonist on the progression of renal failure in hyperlipidemic Imai rats. Baba, N; Sakemi, T, 1993)	0.57
" Combination therapy, involving 16 patients and both drugs given at the original dosage schedule for 12 weeks, resulted in further reductions in systolic and diastolic blood pressures, and an improvement in left ventricular function; indices of diastolic function were not modified."	( Ketanserin alone and in combination with enalapril in the treatment of essential hypertension: assessment of the haemodynamic effects. Assogna, G; Celentano, A; Crivaro, M; de Divitiis, O; Galderisi, M; Garofalo, M; Palmieri, V; Tammaro, P; Zanna, C, )	0.4
" During maintenance, patients not at goal were "stepped up," and patients with uncontrolled DBP at maximum dosage were removed from the study."	( Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994)	0.57
" Symptom frequency differed little among the three dosage levels, becoming maximal by the second visit at the same dosage level."	( Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women. Bartels, DW; Benz, JR; Due, DL; Hall, WD; Kostis, JB; Peng, A; Perry, HM; Sirgo, M; Townsend, RR, 1994)	0.57
" At the end of the 4-week trial, patients in all six dosage groups had clinically and statistically significant reductions in supine diastolic blood pressure compared with baseline values."	( Comparison of ramipril and enalapril in patients with essential hypertension. Mroczek, WJ; Ruddy, MC, )	0.43
" In the three areas of efficacy that the study compared-24-hour post dose blood pressure, control of blood pressure over the dosing period with particular reference to the waking day and attenuation of systolic blood pressure on exercise-atenolol and the fixed combination demonstrated greater efficacy than enalapril."	( A double-blind crossover trial of atenolol, enalapril and the fixed combination of atenolol and nifedipine in mild and moderate hypertension. Brennand-Roper, D; Chapman, CM; Flora, HK; Gupta, S; Jackson, G; Jackson, PG; Manivannan, A; Taylor, DJ; Thirkettle, JL; Vella, R, )	0.57
" dosing schedule) oral treatment with isosorbide-5-mononitrate (IS-5-MN; 5 mg kg-1) indicative of the induction of tolerance to GTN but not to SIN-1."	( Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies. Mollace, V; Pistelli, A; Salvemini, D, 1993)	0.52
"We studied healthy volunteers dosed with placebo, enalapril and losartan 4-6 h before measurement of forearm blood flow by venous occlusion plethysmography."	( Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature. Cockcroft, JR; Goldberg, MR; Ritter, JM; Sciberras, DG, 1993)	0.54
" Oral dosing with active drugs led to different temporal responses."	( Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. Lees, KR; MacFadyen, RJ; Reid, JL; Squire, IB, 1993)	0.29
" Subchronic dosing at 7 PM significantly further decreased nighttime blood pressure followed by a slow increase during the day, with no effect on elevated afternoon values."	( Cardiovascular effects, pharmacokinetics, and converting enzyme inhibition of enalapril after morning versus evening administration. Hopf, R; Lehmann, K; Lemmer, B; Mutschler, E; Neubeck, M; Weisser, K; Witte, K, 1993)	0.51
" Many of these side effects are dose related, and can be controlled or eliminated by lowering the dosage of angiotensin-converting enzyme inhibitor, depending upon the clinical circumstances."	( Enalapril-associated erythema and vasculitis. Carrington, PR; Sanusi, ID; Winder, PR; Zahradka, S, 1993)	1.73
" One capsule was taken for three days and then the dosage was doubled for the remainder of a four-week period."	( Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Annett, MP; Culbert, JP; McCorvey, E; McKenney, JM; Proctor, JD; Wright, JT, 1993)	0.57
" The results of this study indicated that monotherapy with isradipine SRO at the recommended initial dosage of 5 mg once daily is appropriate in black patients with hypertension."	( A comparative study of isradipine SRO and enalapril in black patients with mild-to-moderate hypertension. Maharaj, B; van der Byl, K, 1993)	0.55
" The dose-response relationships for these last two effects of ET-1 were found to be biphasic with a maximum (corresponding to 80 to 200% increase) at 50 to 80 ng ET-1/kg/min, and were also dependent on the infusion rate."	( In vivo stimulation of aldosterone biosynthesis by endothelin: loci of action and effects of doses and infusion rate. Cozza, EN; de Bedners, ME; Gomez-Sanchez, CE; Lantos, CP; Pecci, A, 1993)	0.29
" The complication of cough was not related significantly to age, sex, underlying disease, drug dosage or smoking status."	( High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Nicholls, MG; Woo, KS, 1995)	0.29
" In spontaneously hypertensive rats (SHR), repeated daily oral dosing of XR510, losartan, and enalapril at 30 mg/kg/day decreased BP similarly."	( Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. Bernard, R; Crain, EJ; McCall, DE; Quan, ML; Saye, JM; Smith, RD; Watson, CA; Wexler, RR; Wong, PC; Zaspel, AM, 1995)	0.51
" Enalapril was administered at an average dosage of 10 mg/kg per day to 10- to 20-week-old hamsters with hypertrophic (Bio 14."	( Effects of enalapril on the collagen matrix in cardiomyopathic Syrian hamsters (Bio 14.6 and 53.58). Makino, N; Maruyama, T; Masutomo, K; Shimada, T; Yanaga, T, 1996)	1.59
" We conclude that although the pharmacokinetics of both enalaprilat and HCTZ are related to renal function, HCTZ has no significant effect on the pharmacokinetics of enalaprilat and that dosage adjustment for both regimens should be based on renal function."	( Effect of hydrochlorothiazide on the pharmacokinetics of enalapril in hypertensive patients with varying renal function. Carmody, M; Doyle, GD; Hersh, AD; Kelly, JG; Laher, MS, 1996)	0.79
" After clinical and laboratory evaluation without treatment for at least two weeks, the two groups were treated with enalapril 5-10 or 20 mg daily plus doxazosin at the dosage of 1-2-4- or 8 mg daily; they were observed for 24 weeks."	( [Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension]. Ansuini, R; Curnis, A; Gallucci, M; Malacco, E; Puddu, P; Pupita, F, 1995)	0.74
"001) linear dose-response relation."	( Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. Applegate, WB; Cohen, JD; Davis, A; Green, S; Wolfson, P, 1996)	0.54
" The mean daily dosage of enalapril was 13."	( Correction of post-renal transplant erythrocytosis by enalapril. Boisseau, M; Durand, D; Huyn, A; Rostaing, L, 1995)	0.84
" In contrast, the single dosing of all agents failed to show antinociceptive effect."	( Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Miyazaki, M; Okunishi, H; Song, K; Takai, S; Tanaka, T, 1996)	0.29
"Patients received either the dosage of enalapril-diltiazem ER that they were given during the double-blind phase, or were prescribed enalapril 5 mg-diltiazem ER 120 mg once/day."	( Long-term effectiveness of enalapril plus extended-release diltiazem in essential hypertension. Applegate, W; Cohen, JD; Davis, A; Green, S; Wolfson, P, )	0.7
" Treatment with enalapril was started 5 minutes before reperfusion by intravenous infusion of enalapril at a dosage of 5 mg/kg/h."	( Angiotensin-converting enzyme inhibition by enalapril: a novel approach to reduce ischemia/reperfusion damage after experimental liver transplantation. Anthuber, M; Farkas, S; Jauch, KW; Menger, MD; Messmer, K; Rihl, M; Schildberg, FW, 1997)	0.9
" The final dosage of enalapril was 40 +/- 23 mg/day of isosorbide dinitrate it was 153 +/- 127 mg/day."	( Reverse remodeling in heart failure with intensification of vasodilator therapy. Keteyian, SJ; Lesch, M; Levine, AB; Levine, TB; Narins, B, 1997)	0.62
" This study was aimed at: evaluating the magnitude and incidence of the inhibitory phenomenon; defining the minimal aspirin dosage that produces an antagonistic effect, as well as the possible reasons for a different individual susceptibility."	( [The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors]. Alimento, M; Campodonico, J; Celeste, F; Guazzi, M; Rossi, M; Santambrogio, G; Trabattoni, D, 1997)	0.3
"After 7 years of treatment with 20 mg of enalapril twice daily, regression of the initial left ventricular hypertrophy in a group of 24 patients with essential arterial hypertension was achieved: gradual reduction in the dosage to 10 or 5 mg twice daily caused no worsening of either blood pressure or ventricular structure or function."	( Effects on left ventricular mass and function of low doses of enalapril for systemic hypertension. Cabezas-Cerrato, J; Calvo Gómez, C; García-Acuña, JM; González-Juanatey, JR; Reino, AP; Varela Román, A, 1998)	0.81
" This study was designed to evaluate the incidence of the counteractive phenomenon and to define minimal aspirin dosage that causes an antagonistic effect."	( Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Alimento, M; Campodonico, J; Celeste, F; Guazzi, M; Guazzi, MD; Rossi, M; Santambrogio, G; Trabattoni, D, 1998)	0.3
" In patients whose blood pressure was not normalized (defined as DBP< or =90 mmHg) after 6 weeks of treatment, the dosage of either medication was doubled or, in the placebo group, was switched to the fixed combination."	( Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. Antlsperger, A; Pittrow, DB; Schardt, W; Wambach, G; Weidinger, G; Welzel, D, 1997)	0.3
" In contrast, the angiotensin II type 1 receptor antagonist losartan, at a dosage that did not lower blood pressure, did not attenuate the increase in urinary excretion of sodium."	( Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers. Hertenberg, F; Smits, P; Vervoort, G; Wetzels, JF, 1998)	0.3
"We evaluated the effects on cardiovascular structure of the angiotensin-converting enzyme (ACE) inhibitor enalapril and of the angiotensin II receptor blocker losartan, administered either at hypotensive or nonhypotensive dosage in spontaneously hypertensive rats (SHR)."	( Effects of losartan and enalapril on small artery structure in hypertensive rats. Agabiti Rosei, E; Bettoni, G; Castellano, M; Guelfi, D; Muiesan, ML; Mulvany, MJ; Pasini, G; Piccoli, A; Porteri, E; Rizzoni, D, 1998)	0.82
" ACE inhibitor dose-response analysis used the discharge dose of ACE inhibitor, converted to enalapril-equivalent doses and adjusted for renal function."	( Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Adelman, M; Forrest, A; Hawari, FI; Izzo, JL; Luzier, AB; Schentag, JJ, 1998)	0.52
"The stability of five drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied."	( Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded oral liquids. Allen, LV; Erickson, MA, 1998)	0.54
" In addition, endothelium-dependent and endothelium-independent relaxation was evaluated by dose-response curves to acetylcholine (in the presence or absence of a bradykinin-receptor blocker and of indomethacin) and sodium nitroprusside."	( Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. Bettoni, G; Castellano, M; Guelfi, D; Muiesan, ML; Pasini, G; Piccoli, A; Porteri, E; Rizzoni, D; Rosei, EA, 1998)	0.57
" The dose-response curves of vasoconstriction to phenylephrine and prostaglandin F2alpha were obtained in healthy male volunteers."	( Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity. Kimura, M; Kosuge, K; Nakashima, M; Nishimoto, M; Ohashi, K; Umemura, K, 1998)	0.3
"The ACEIs shifted the dose-response curve of phenylephrine to the right and raised the median effective dose (ED50; 189."	( Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity. Kimura, M; Kosuge, K; Nakashima, M; Nishimoto, M; Ohashi, K; Umemura, K, 1998)	0.3
"The pharmacokinetics of benazepril, enalapril, and their active metabolites (benazeprilat and enalaprilat) were compared after a single administration of each product by the oral route at the recommended dosage (0."	( Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. Concordet, D; Laroute, V; Lefebvre, HP; Toutain, PL, )	0.64
"A 26-week, multicenter, double-blind, parallel-group, dosage titration study."	( Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. Hermansson, K; Karlberg, BE; Lins, LE, 1999)	0.53
" The telmisartan dosage was increased from 20 to 40-80 mg and that of enalapril from 5 to 10-20 mg at 4-week intervals until trough supine diastolic blood pressure was < 90 mmHg."	( Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. Hermansson, K; Karlberg, BE; Lins, LE, 1999)	0.76
" Both regimens provided effective blood pressure lowering over the 24 h dosing interval, as determined by ambulatory blood pressure monitoring."	( Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. Hermansson, K; Karlberg, BE; Lins, LE, 1999)	0.53
" Stepwise reduction of the enalapril dosage from 40 to 30, 20, 10, and 5 mg/day during the eighth year caused no significant changes in BP, LV structure, LV systolic function, or QT dispersion, which all likewise remained unaltered during a further year of the 5-mg/day regimen."	( Maintenance of blood pressure control and left ventricular performance with small doses of enalapril. Cabezas-Cerrato, J; de la Peña, MG; García-Acuña, JM; González-Juanatey, C; González-Juanatey, JR; Reino, AP; Valdes, L, 1999)	0.82
" Patients received the maximum titrated dosage during the maintenance phase."	( Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Argenziano, L; Trimarco, B, 1999)	0.61
" Patients received the maximum titrated dosage during the maintenance phase."	( Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Gavras, H; Gavras, I, 1999)	0.59
" Patients received the maximum titrated dosage during the maintenance phase."	( Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Levine, B, 1999)	0.61
" Clinical inputs include agent efficacy, side effects, and compliance with dosing schedules."	( An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee. Neil, N; Perfetto, E; Ramsey, SD; Sullivan, SD, )	0.13
" Dosage was doubled after 4 weeks when diastolic blood pressure was > 90 mmHg in sitting position, the treatment was continued for 12 weeks."	( Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Armas de Hernández, MJ; Armas-Padilla, MC; Carvajal, AR; Guerrero-Pajuelo, J; Hernández-Hernández, R; Pacheco, B; Velasco, M, 1999)	0.6
"3% of hypertensive patients with an average dosage of 31."	( Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. Armas de Hernández, MJ; Armas-Padilla, MC; Carvajal, AR; Guerrero-Pajuelo, J; Hernández-Hernández, R; Pacheco, B; Velasco, M, 1999)	0.6
"We investigated 45 patients (age 55 +/- 10 years) with stable CHF who presented with a maintenance dosage of enalapril of either 5 mg given twice daily (E10; n = 16), 10 mg given twice daily (E20; n = 18), or 20 mg given twice daily (E40; n = 11)."	( Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Brunner-La Rocca, HP; Candinas, R; Follath, F; Kiowski, W; Maly, FE; Weilenmann, D, 1999)	0.76
" Thus patients with congestive heart failure may benefit from increasing dosage of ACE inhibitors."	( Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Brunner-La Rocca, HP; Candinas, R; Follath, F; Kiowski, W; Maly, FE; Weilenmann, D, 1999)	0.54
" A dose-response curve to norepinephrine was performed at cumulative concentrations in the presence or absence of low- and high-dose insulin."	( High-dose, not low-dose insulin increases the vasoconstrictor effect of norepinephrine in spontaneously hypertensive rats: effects of antihypertensive treatment. Castellano, M; Guelfi, D; Muiesan, ML; Pasini, G; Piccoli, A; Porteri, E; Rizzoni, D; Rosei, EA, )	0.13
" Stepwise reduction of the enalapril dosage from 40 to 30, 20, 10, and 5 mg/d during the eighth year caused no significant change in blood pressure, LV structure, LV systolic function, or QT dispersion, which all likewise remained unaltered during an additional 2-year period of the 5-mg/d regimen."	( Step-down of enalapril treatment for arterial hypertension. Cabezas-Cerrato, J; García-Acuña, JM; González-Juanatey, C; González-Juanatey, JR; Reino, AP; Valdes, L, 1999)	0.97
" To evaluate the dose-response relation between this pharmacological interference and dependent edema, a frequent side effect of CCBs during antihypertensive treatment, skin blood flow (laser Doppler flowmetry) at the dorsum of the foot, both supine and with the limb passively placed 50 cm below the heart level, and leg weight (Archimedes principle) were measured at baseline, during increasing doses of the dihydropyridine amlodipine (5 and 10 mg UID each for 2 weeks), and after drug withdrawal in 10 hypertensive men."	( Amlodipine, enalapril, and dependent leg edema in essential hypertension. Dell'Omo, G; Mariani, M; Melillo, E; Pedrinelli, R, 2000)	0.69
"To be listed for heart transplantation (HTx), optimization of the dosage of angiotensin converting enzyme (ACE) -inhibitors is recommended worldwide even though this issue has not been thoroughly investigated in the pre-transplantation cohort."	( ACE inhibitor dosage at the time of listing predicts survival. Berger, R; Frey, B; Kozanly, I; Kuchling, G; Pacher, R; Stanek, B, 2000)	0.31
" A normotensive four-sixths remnant-kidney model (Nx) was elaborated, compared with sham-operated (S) animals, and a subantihypertensive dosage of enalapril (E) was administered for 4 weeks of intensive kidney tissue proliferation (NxE)."	( Enalapril inhibits growth and proliferation of various tissues in rat normotensive four-sixths kidney ablation nephropathy. Dzúrik, R; Gajdos, M; Krivosíková, Z; Lajdová, I; Sebeková, K; Spustová, V, 2000)	1.95
" To prevent these objections, a normotensive 4/6 remnant kidney model was elaborated and a subantihypertensive dosage of enalapril was used to evaluate its antiproliferative action."	( Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat. Dzúrik, R; Krivosíková, Z; Lajdová, I; Sebeková, K; Spustová, V, 1999)	1.95
" These studies show that it is possible to detect the active ingredients in the intact dosage form, even where the substance comprises <1% of the total mass of the tablet."	( Evaluation of solid-state forms present in tablets by Raman spectroscopy. Langkilde, FW; Taylor, LS, 2000)	0.31
" Data are reviewed to demonstrate that ACE escape reflects inadequate ACE dosage rather than a decrease in ACE inhibition occurring with time."	( Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Berlowitz, M; Ennezat, PV; Le Jemtel, TH; Sonnenblick, EH, 2000)	0.31
" In conclusion, this reappraisal of the conflicting observations reported on ACE inhibitor effects on exercise capacity has highlighted a proposition that there is an optimal dosage of ACE inhibitors which will most enhance exercise capacity, and this will require further well designed cross-over studies to elucidate."	( Disparate results of ACE inhibitor dosage on exercise capacity in heart failure: a reappraisal of vasodilator therapy and study design. Cooke, GA; Tan, LB; Williams, SG; Wright, DJ, 2001)	0.31
" Dose-response curves to bradykinin (0."	( Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats. Calegari, V; do Prado, JF; Moreno, H; Paganelli, MO; Tanus-Santos, JE; Toledo, JC, 2001)	0.31
"We sought to describe the dosages of angiotensin-converting enzyme (ACE) inhibitor prescribed to elderly patients with heart failure at hospital discharge, the factors associated with dosing level, and the association of these dosages with 1-year outcomes."	( Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Chen, YT; Krumholz, HM; Radford, MJ; Wang, Y, 2001)	0.31
" We observed a dose-response relationship between higher doses and lower mortality."	( Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Chen, YT; Krumholz, HM; Radford, MJ; Wang, Y, 2001)	0.31
"The chemical stability of enalapril maleate in tablet dosage forms consisting of different formulation excipients has been studied in this work."	( Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. Abdelah, MK; Al-Omari, MM; Badwan, AA; Jaber, AM, 2001)	0.87
" In anaesthetized rabbits (treated or sham), arterial blood pressure and renal blood flow were measured and renal responsiveness tested by constructing dose-response curves to bolus doses of phenylephrine, angiotensin II and acetylcholine delivered directly into the renal artery."	( Chronic angiotensin converting enzyme inhibition enhances renal vascular responsiveness to acetylcholine in anaesthetized rabbits. Alcorn, D; Anderson, WP; Denton, KM; Lamden, M; Shweta, A, 2001)	0.31
" Response rates of 50% to 100% have been reported using twice-daily dosing of 5 to 32 mg/kg/d, achieving trough blood levels of 70 to 500 ng/mL."	( Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Brewer, ED; Chishti, AS; Kale, AS; Sorof, JM, 2001)	0.31
" The aim of this study was to assess the dose-response relationship of nitrendipine and enalapril alone or in fixed combination in the treatment of mild to moderate hypertension."	( Nitrendipine and enalapril combination therapy in mild to moderate hypertension: assessment of dose-response relationship by a clinical trial of factorial design. Calvo, G; Delgadillo, J; Horas, M; Ríos, J; Roca-Cusachs, A; Terán, M; Torres, F, 2001)	0.87
" In 3 periods of 8 days, separated by wash-outs of 6 days, each volunteer received 2 dosage levels of Aliskiren (low before high; 40 and 80 or 160 and 640 mg/d) and randomized placebo or 20 mg enalapril."	( Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Brunner, HR; Jensen, C; Nussberger, J; Wuerzner, G, 2002)	0.72
" We studied whether the dosage of enalapril in daily clinical practice is associated with drug accumulation of enalaprilat in chronic renal failure."	( High serum enalaprilat in chronic renal failure. Elung-Jensen, T; Heisterberg, J; Kamper, AL; Larsen, NE; Sonne, J; Strandgaard, S, 2001)	0.98
" The spectrophotometric and atomic absorption spectrometric procedures hold their accuracy and precision well when applied to the determination of ramipril and enalapril dosage forms."	( Spectrophotometric and AAS determination of ramipril and enalapril through ternary complex formation. Abdellatef, HE; Ayad, MM; Hosny, MM; Shalaby, AA, 2002)	0.76
" Telmisartan (40, 80, and 120 mg) provided greater decreases in mean hourly systolic and diastolic blood pressure throughout the 24-hour dosing interval, including the last 4 hours of the dosing period, than amlodipine (5 and 10 mg)."	( Comparative effects of telmisartan in the treatment of hypertension. White, WB, )	0.13
" During a 2-week, double-blind, randomized, dose-response period, patients were stratified by weight (< 50 kg or > or = 50 kg), then assigned to one of three dosing groups: low(0."	( A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. Frame, V; Herrera, P; Shahinfar, S; Shaw, W; Soffer, B; Wells, T; Zhang, Z, 2002)	0.54
"We studied the effects of a chronotherapeutic delivery system of verapamil (controlled-onset extended release [COER]-24 system) dosed at bedtime versus conventional morning administration of both enalapril and losartan on the blood pressure (BP), heart rate, and the heart rate systolic BP product during the first 4 hours after awakening in a placebo-controlled, forced-titration trial."	( Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Anders, RJ; Calhoun, D; Mansoor, GA; Sica, DA; White, WB, 2002)	0.7
"Bedtime administration of an agent designed to parallel the circadian rhythm of BP and heart rate led to significantly greater early morning hemodynamic effects compared with other conventional once-daily antihypertensive agents dosed in the morning."	( Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. Anders, RJ; Calhoun, D; Mansoor, GA; Sica, DA; White, WB, 2002)	0.51
" Additional prospective large studies are necessary to verify the relationship observed here between the optimal dosage as well as the duration of action of different ACEIs and their outcomes."	( Long-term survival of non-elderly patients with severe heart failure treated with angiotensin-converting enzyme inhibitors assessment of treatment with captopril and enalapril survival study (ACESS). Huang, CM; Young, MS, 2002)	0.51
" Doses were increased to 20 mg/day, 10 mg/day or 60 mg/day, respectively, if the office BP remained 160/90 mmHg or greater at the end of the dosing interval."	( Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril. Joyner, CD; Leenen, FH; Myers, MG; Toal, CB, 2002)	0.51
"On 24 h ambulatory BP monitoring, nifedipine-GITS caused a consistent decrease in BP throughout the 24 h dosing interval, whereas felodipine-ER caused a more marked fall in BP during the day, and enalapril's effects diminished during the night and had disappeared by the morning."	( Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril. Joyner, CD; Leenen, FH; Myers, MG; Toal, CB, 2002)	0.7
" The primary endpoint was the change from baseline in ambulatory DBP in the last 6 h of the 24-h dosing interval after 12 weeks' treatment."	( ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. Amerena, J; O'Shaughnessy, D; Ouellet, JP; Pappas, S; Williams, L, )	0.37
"As part of an open, randomized, controlled trial of the effect of high and low dosage of enalapril on the progression of renal failure, short-term blood pressure response was evaluated."	( Blood pressure response to conventional and low-dose enalapril in chronic renal failure. Elung-Jensen, T; Heisterberg, J; Kamper, AL; Sonne, J; Strandgaard, S, 2003)	0.79
"After a prior failure of the first-line treatment with either enalapril or nitrendipine, an evaluation was made of the possibilities of increasing dosage of the first-line treatment, changing the drug or administering the E/N combination."	( [Theoretical model of a cost-effectiveness analysis of combined enalapril-nitrendipine therapy for treating hypertension]. Abbas, I; Antoñanzas, F; Delgadillo, J; Pontes, C; Terán, M; Velasco, M, 2003)	0.8
"Although fitting orders to renal function avoids overdosage and therefore iatrogenic risk, dosage adjustment is rarely made."	( Assessing residents' prescribing behavior in renal impairment. Brücker, G; Deray, G; Launay-Vacher, V; Levu, S; Ravaud, P; Salomon, L, 2003)	0.32
" Although no adjustment to renal function was required, 28% of the residents decreased the dosage of amlodipine and ordered an underdose."	( Assessing residents' prescribing behavior in renal impairment. Brücker, G; Deray, G; Launay-Vacher, V; Levu, S; Ravaud, P; Salomon, L, 2003)	0.32
"Considering the iatrogenic risk related to the lack of dosage adjustment, attention should be drawn to increasing residents' awareness of dosage adjustment in renal impairment and to providing them with better information on patients' renal function."	( Assessing residents' prescribing behavior in renal impairment. Brücker, G; Deray, G; Launay-Vacher, V; Levu, S; Ravaud, P; Salomon, L, 2003)	0.32
" The method was successfully applied to the determination of enalapril maleate in dosage forms and biological fluids without interferences."	( Flow-injection chemiluminescence determination of enalapril maleate in pharmaceuticals and biological fluids using tris(2,2'-bipyridyl)ruthenium(II). Alarfaj, NA, 2003)	0.81
" Patients who received a full dosage of ACEI did not have to posses an increasing risk of C-ACEI."	( Angiotensin converting enzyme inhibitor induced cough: experience in Siriraj Hospital. Buranakitjaroen, P; Phoojaroenchanachai, M; Sangprasert, P; Saravich, S; Sriussadaporn, S, 2003)	0.32
" Comparing survivors, enalapril generated annual cost savings greater than the average wholesale price of the drug at Studies of Left Ventricular Dysfunction mean dosage levels."	( Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. Gregory, DD; Konstam, MA; Pereira, B; Salem, D; Sarnak, MJ, 2003)	0.63
"Patients with chronic AF for more than 3 months were assigned to receive either amiodarone (200mg orally 3 times a day; group I: n=75) or the same dosage of amiodarone plus enalapril (10mg twice a day; group II: n=70) 4 weeks before scheduled external cardioversion."	( Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Chan, KC; Chen, CY; Chen, SA; Lin, CS; Lin, MC; Tsai, CF; Tsai, TP; Ueng, KC; Wu, DJ; Yu, WC, 2003)	0.97
" Three decision trees for solid oral dosage forms or liquid suspensions are provided for evaluating when and how polymorphs of drug substances should be monitored and controlled in ANDA submissions."	( Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adams, RC; Furness, MS; Gill, DS; Holcombe, FO; Raw, AS; Yu, LX, 2004)	0.32
" The aim of the study was to investigate dosing of ACE inhibitors in patients discharged from the hospital after an acute myocardial infarction (AMI) and, furthermore, to compare these doses with the doses actually reached in clinical trials."	( The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction. Kvan, E; Reikvam, A, 2004)	0.32
" Outcome variables, including deaths and drug utilization with dosing after 6 months, were collected."	( The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction. Kvan, E; Reikvam, A, 2004)	0.32
" Enalapril/nitrendipine 10/20 mg produced a consistent antihypertensive effect that persisted for the entire 24-hour dosage interval as shown by ambulatory BP monitoring."	( Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension. Plosker, GL; Siddiqui, MA, 2004)	1.54
" Both synthetic mixtures and commercial dosage forms were assayed, and the results were compared to those obtained using the USP XXIV procedure and were both in close agreement."	( Quantitative analysis of enalapril by 1H NMR spectroscopy in tablets. Linares, M; Longhi, M; Zoppi, A, 2005)	0.63
" Since marked inter-patient variation in concentrations of enalaprilat has been shown in patients with renal failure despite equivalent dosage of enalapril, a direct comparison of the effect of high versus low plasma concentrations of enalaprilat on the progression of renal failure was undertaken."	( Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. Elung-Jensen, T; Heisterberg, J; Kamper, AL; Sonne, J; Strandgaard, S, 2005)	2.01
" Least square means (95% CI) of all observations during the first 6 h after dosing showed that diclofenac caused a reduction in GFR from 71 (64-78) to 59 (52-66) ml/min."	( Cyclooxygenase inhibition causes marked impairment of renal function in elderly subjects treated with diuretics and ACE-inhibitors. Björkman, S; Höglund, P; Juhlin, T, 2005)	0.33
" The pharmaceutical preparations used included atenolol 100 mg tablets, enalapril 20 mg tablets and acetylsalicylic acid (ASS) tablets of different dosage units."	( Quality control of tablets by Near Infrared (NIR)-Spectroscopy. Karas, M; Kaunzinger, A; Niemöller, A; Petri, J, 2005)	0.56
" No significant change was obtained in GFR after a 28-day period of dosing with tepoxalin and benazepril together."	( Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor. Debailleul, M; Desfontis, JC; Fusellier, M; Gautier, F; Gogny, M; Madec, S; Marescaux, L, 2005)	0.33
" After the dosage of enalapril had been reduced to 10 mg daily about 1(1/2) years before the current admission, he had developed persistent constipation."	( Pseudoaldosteronism due to the concurrent use of two herbal medicines containing glycyrrhizin: interaction of glycyrrhizin with angiotensin-converting enzyme inhibitor. Hosoya, T; Iida, R; Kuriyama, S; Matsumoto, K; Otsuka, Y, 2006)	0.65
" The suppression of urinary protein was statistically significant in surviving animals dosed with telmisartan."	( Renoprotective effects of telmisartan in the 5/6 nephrectomised rats. Chachin, M; Hayashi, N; Hayashi, T; Horie, Y; Konomi, A; Matsumaru, T; Ohmura, T; Seidler, R; Sumida, T; Tsunenari, I, 2007)	0.34
" The present post hoc analysis evaluated dipper/non-dipper status prospectively in a study on dosage of enalapril in progressive chronic kidney disease (CKD) stages 3-5."	( Longitudinal observations on circadian blood pressure variation in chronic kidney disease stages 3-5. Elung-Jensen, T; Kamper, AL; Strandgaard, S, 2008)	0.56
" RI was compared to the ARB, candesartan (3 mg/kg/day PO), and to the ACEI, enalapril (60 mg/kg/day PO) in a 4-week dosing paradigm."	( A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes. Carlson, T; Kowala, MC; Leadley, R; Major, TC; Okerberg, C; Olszewski, B; Ostroski, R; Rosebury, W; Schroeder, R, 2008)	0.58
" These methods hold their accuracy and precision well when applied to the determination of ramipril, enalapril maleate and fosinopril in their dosage forms."	( Spectrophotometric and atomic absorption determination of ramipril, enalapril maleate and fosinopril through ternary complex formation with molybdenum (V)-thiocyanate (Mo(V)-SCN). Abd-Alaty, NM; Baraka, MM; El-Sadek, M; Moussa, EM, 2008)	0.8
" In large, randomized trials, eprosartan (with or without hydrochlorothiazide [HCTZ]) demonstrated superior antihypertensive efficacy to that of placebo and, when administered at comparable dosage regimens, had similar blood pressure-lowering effects to enalapril."	( Eprosartan: a review of its use in hypertension. Plosker, GL, 2009)	0.53
"The administration of most angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) at bedtime results in a greater reduction of nighttime blood pressure (BP) than dosing upon awakening."	( Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Alonso, I; Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2010)	0.36
" Using the same dosing regimen, only perindopril inhibited the brain ACE activities by more than 50%, whereas imidapril and enalapril showed much less potent effects."	( Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Kanda, T; Nagata, Y; Shirakura, S; Suzuki, N; Takahashi, S; Takayama, M; Uchida, S; Yamada, K, 2010)	0.57
" Two simple, accurate, precise and fully validated analytical methods for the simultaneous determination of enalapril and lercanidipine in combined dosage forms have been developed."	( Determination of pK(a) values of some antihypertensive drugs by liquid chromatography and simultaneous assay of lercanidipine and enalapril in their binary mixtures. Gumustas, M; Ozkan, SA; Sanli, N; Sanlı, S, 2010)	0.78
" Change to a weekly dosage schedule with slow infusions has been tested, a strategy that requires more frequent hospital visits and increased storage resources[7,9]."	( Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Ahimastos, A; Anagnostopoulos, N; Galanopoulos, A; Georgakopoulos, P; Georgiakodis, F; Karavidas, A; Kyriakidis, M; Marinakis, T; Matsakas, E; Roussou, P; Zimeras, S, 2010)	0.62
" Experiment lasted 11 days and dosing was via oral route."	( Pharmacologic inhibition of the renin-angiotensin system did not attenuate hepatic toxicity induced by carbon tetrachloride in rats. Adesanoye, OA; Bamidele, TO; Ekor, M; Kale, OE; Odewabi, AO; Oritogun, KS, 2011)	0.37
" Oral dosing of aliskiren, enalapril or losartan provided a similar maximal reduction in MAP and duration of efficacy in telemetrised dTG rats."	( Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors. Auger, A; Binkert, C; Cromlish, W; Fischli, W; Harris, J; Hess, P; Liu, S; Percival, MD; Riendeau, D; St-Jacques, R; Steiner, B; Toulmond, S, 2011)	0.67
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" Pharmacokinetic data are lacking to provide adequate dosing and for pediatric pharmacotherapeutical trials it is imperative to minimize sample volume."	( Determination of enalapril and enalaprilat in small human serum quantities for pediatric trials by HPLC-tandem mass spectrometry. Läer, S; Ramusovic, S; Thielking, G, 2012)	0.72
"To detect clinical predictors of renal worsening in CHF patient population characterized by two types of ACE-inhibitor dosing regimens."	( ACE-inhibitor therapy at relatively high doses and risk of renal worsening in chronic heart failure. Ariano, C; Cantatrione, S; Ciccarelli, A; Cioppa, C; De Vecchis, R; Di Biase, G; Giasi, A; Pucciarelli, A, 2011)	0.37
" The purpose of this study was to determine the relative effects of these three modes of pharmacological RAS inhibition in reducing atherosclerosis by determining the dose-response relationships."	( Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. Balakrishnan, A; Cassis, LA; Charnigo, R; Daugherty, A; Howatt, DA; Liau, G; Lu, H; Wu, C, 2012)	0.38
"The results provide evidence that ACT-077825, with a pharmacokinetic profile consistent with a once-a-day dosing regimen, may represent an effective antihypertensive agent and pave the way toward a multiple-ascending dose study."	( Entry-into-humans study with a new direct renin inhibitor. Binkert, C; Dingemanse, J; Gutierrez, MM; Nicolas, LB, 2012)	0.38
" In this report, no significant correlations between dosage of hydrochlorothiazide and calciuria and no significant correlations between proteinuria and dosage of enalapril were detected."	( The long-term use of enalapril and hydrochlorothiazide in two novel mutations patients with Dent's disease type 1. Henriques, Ldos S; Igarashi, T; Koch, VH; Seki, G; Sekine, T; Vaisbich, MH, 2012)	0.89
" Following 2 further weeks of treatment, the reduction in msSBP was maintained in patients who were re-randomized to continue receiving the same dosage of valsartan but not in those re-randomized to placebo."	( Valsartan: in children and adolescents with hypertension. Croxtall, JD, 2012)	0.38
" In the multiple-ascending-dose part, subjects were dosed with midazolam on days -2, 2, and 12 to investigate interactions with CYP3A4."	( Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam. Binkert, C; Dingemanse, J; Nicolas, L, 2013)	0.39
" The main exposure variables were the proportion of days covered (PDC) by these drugs and the mean enalapril dosage (for enalapril users only)."	( Association of angiotensin-converting enzyme inhibitor therapy initiation with a reduction in hemoglobin levels in patients without renal failure. Berliner, S; Chodick, G; Leshem-Rubinow, E; Raz, R; Rogowski, O; Shalev, V; Steinvil, A; Zeltser, D, 2012)	0.6
" The in situ preparation of enalapril sodium salt (NaE) has been used to improve drug stability in dosage forms; however, gas release and product rejection ensue when the chemical reaction for obtaining the sodium salt is not completely finished before packaging."	( Effect of stearic acid on enalapril stability and dissolution from multiparticulate solid dosage forms. Cunha, TA; de Freitas, LA; de Oliveira, AP; Diniz, DG; Lima, EM; Marreto, RN; Nasser, LN; Serpa, RC; Taveira, SF, 2013)	0.98
"It was the aim of this study to examine the compatibility and the pharmacokinetics of the angiotensin converting enzyme inhibitor enalapril after oral application in racing pigeons and Amazons, and to contribute to a safe dosage regime of this drug in birds."	( [Examinations on the pharmacokinetics and compatibility of enalapril in racing pigeons]. Abraham, G; Krautwald-Junghanns, ME; Lierz, M; Pees, K; Pees, M; Ungemach, FR, 2013)	0.84
" Community and Hospital Pharmacists are often challenged to provide an oral liquid extemporaneous formulation for pediatric patients, because there are no appropriate dosage drugs to the specific needs of the child."	( Physicochemical stability of captopril and enalapril extemporaneous formulations for pediatric patients. Álvarez, J; Casas, M; Lucero, MJ, 2015)	0.68
" Colesevelam (3750mg once daily) was dosed throughout the pharmacokinetic sampling period."	( Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.62
" The present protocol describes a trial to test the efficacy of bedtime dosing of the ACE inhibitor enalapril on night time blood pressure and left ventricular mass in patients with type 1 diabetes."	( Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping of blood pressure during night time: protocol for a randomised, placebo-controlled, double-blind, two-way crossover study. Corinth, H; Hilsted, J; Hilsted, KL; Hjortkær, H; Jensen, T; Kofoed, K; Køber, L; Mogensen, U; Theilade, S, 2014)	0.62
"In a randomised, double-blind, two-way cross-over study, 24 normoalbuminuric patients with type 1 diabetes with CAN will be treated for 12 weeks with either morning or bedtime dosing of 20 mg enalapril, followed by 12 weeks of switched treatment regimen."	( Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping of blood pressure during night time: protocol for a randomised, placebo-controlled, double-blind, two-way crossover study. Corinth, H; Hilsted, J; Hilsted, KL; Hjortkær, H; Jensen, T; Kofoed, K; Køber, L; Mogensen, U; Theilade, S, 2014)	0.59
"A monitored dosage system (MDS) is a professionally prepared blister-type repackaging system used to improve medication adherence."	( Stability of enalapril repackaged into monitored dosage system. Braza, AJ; Lastra, CF; Loscertales, HR; Mariño, EL; Modamio, P; Tobaruela, G, 2015)	0.79
" The aim of this study was to assess whether appropriate dosage adjustments were made in hospitalized patients with renal impairment."	( Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. Getachew, H; Shibeshi, W; Tadesse, Y, 2015)	0.42
" Data regarding serum creatinine level, age, sex and prescribed drugs and their dosage was collected from the patients' medical records."	( Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. Getachew, H; Shibeshi, W; Tadesse, Y, 2015)	0.42
"The findings indicate that dosing errors were common among hospitalized patients with renal impairment."	( Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. Getachew, H; Shibeshi, W; Tadesse, Y, 2015)	0.42
" Moreover, we strongly suggest an up-to-date revision of the ACE-inhibitor dosing guidelines in pediatric patients to define unambiguously the safe upper limits of this class of drugs."	( Enalapril Associated with Furosemide Induced Acute Kidney Injury in an Infant with Heart Failure. A Case Report, a Revision of the Literature and a Pharmacovigilance Database Analysis. Carnovale, C; Clementi, E; Fabiano, V; Gentili, M; Mameli, C; Perrotta, C; Radice, S; Zuccotti, GV, 2016)	1.88
"This work aimed at developing enalapril maleate granules in order to improve its stability in solid dosage form."	( Fluidized Bed Hot Melt Granulation with Hydrophilic Materials Improves Enalapril Maleate Stability. Comelli, ACC; Cunha, TA; Freitas, LAP; Guimarães, TF; Marreto, RN; Tacón, LA, 2017)	0.98
"Three multivariate calibration spectrophotometric methods were developed for simultaneous estimation of Paracetamol (PARA), Enalapril maleate (ENM) and Hydrochlorothiazide (HCTZ) in tablet dosage form; namely multi-linear regression calibration (MLRC), trilinear regression calibration method (TLRC) and classical least square (CLS) method."	( Development and validation of multivariate calibration methods for simultaneous estimation of Paracetamol, Enalapril maleate and hydrochlorothiazide in pharmaceutical dosage form. Daharwal, SJ; Singh, VD, 2017)	0.88
" This pooled analysis investigates the dose-response relationship of fixed-dose lercanidipine + enalapril in patients with mild-to-moderate hypertension."	( Dose-response effect of the lercanidipine/enalapril combination: a pooled analysis. Rizzoni, D, 2016)	0.92
"This pooled analysis of four randomized studies shows evidence of a dose-response effect in BP reduction with different fixed combinations of lercanidipine + enalapril."	( Dose-response effect of the lercanidipine/enalapril combination: a pooled analysis. Rizzoni, D, 2016)	0.9
" We aimed to test if bedtime dosing (BD) versus morning dosing (MD) of the ACE inhibitor enalapril would affect the 24-hour BP profile in patients with type 1 diabetes (T1D), CAN and non-dipping."	( Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping: a randomised, placebo-controlled, double-blind cross-over trial. Corinth, H; Hilsted, J; Hilsted, KL; Hjortkjær, HØ; Jensen, T; Kofoed, KF; Køber, L; Mogensen, UM; Sigvardsen, PE; Theilade, S, 2016)	0.66
"With a great quantity of solid dosage tested by dissolution technology, developing a rapid and sensitive method to access the content of drug within dissolution media is highly desired by analysts and scientists."	( Rapid analysis of drug dissolution by paper spray ionization mass spectrometry. He, L; Lin, L; Liu, N; Liu, Y; Zhou, YN, 2017)	0.46
"Literature data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the marketing authorization of immediate-release, solid oral dosage forms containing enalapril maleate are reviewed."	( Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Abrahamsson, B; Cristofoletti, R; Dressman, JB; Groot, DW; Kanfer, I; Langguth, P; Löbenberg, R; Mehta, M; Parr, A; Polli, JE; Shah, VP; Verbeeck, RK, 2017)	0.88
" Our data suggest that compared with never smokers, ever smokers may require a higher dosage of folic acid to achieve a greater beneficial effect on stroke."	( Effect of Smoking and Folate Levels on the Efficacy of Folic Acid Therapy in Prevention of Stroke in Hypertensive Men. Cai, Y; Cheng, X; Dong, Q; He, M; Hou, FF; Huang, X; Huo, Y; Li, J; Li, Y; Liu, L; Qin, X; Song, Y; Tang, G; Wang, B; Wang, X; Wang, Y; Xu, X; Yin, D; Yu, Y; Zhang, Y; Zhao, M; Zhou, Z, 2018)	0.48
" In this study, a dilution method has been developed by dispersing the lowest dose strength ODMTs to enable flexible and precise EM dosing during the dose titration phase of the therapy."	( Flexible and precise dosing of enalapril maleate for all paediatric age groups utilizing orodispersible minitablets. Breitkreutz, J; Thabet, Y; Walsh, J, 2018)	0.77
" Until now, there are only a few products available for the paediatric population due to the lack of age appropriate dosage forms or studies proving the efficacy and safety of these products."	( Continuous manufacturing and analytical characterization of fixed-dose, multilayer orodispersible films. Breitkreutz, J; Lunter, D; Thabet, Y, 2018)	0.48
" This dynamic dosing system maintained the advantages of FDCs while providing a superior flexibility of dosing range, hence offering an optimal clinical solution to hypertension therapy in a patient-centric healthcare service."	( From 'fixed dose combinations' to 'a dynamic dose combiner': 3D printed bi-layer antihypertensive tablets. Abbadi, I; Alhnan, MA; Aziz, D; Isreb, A; Isreb, M; Sadia, M; Selo, A; Timmins, P, 2018)	0.48
"8% of participants were taking any diuretics (n = 6290 for loop diuretics, n = 496 for other diuretics); of those, recorded dosage data for loop diuretics were available on 5487 participants."	( Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Claggett, B; Desai, AS; Kachadourian, J; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR, 2019)	0.74
"Comparative pharmacokinetic (PK) data analysis of drugs administered using developed child-appropriate and market authorized dosage formulation is sparse and is important in pediatric drug development."	( Model-dependent pharmacokinetic analysis of enalapril administered to healthy adult volunteers using orodispersible minitablets for use in pediatrics. Burckhardt, BB; Cawello, W; Faisal, M; Laer, S, 2019)	0.78
"The development of orodispersible mini-tablets (ODMTs) for paediatric use has gained importance within recent years as European authorities set up regulations for developing suitable and palatable dosage forms for paediatric patients."	( New orodispersible mini-tablets for paediatric use - A comparison of isomalt with a mannitol based co-processed excipient. Breitkreutz, J; Luhn, O; Lura, A; Suarez Gonzales, J, 2019)	0.51
" Therefore, regulations for developing suitable and palatable dosage forms for pediatric patients have been established by WHO authorities."	( New Orodispersible Mini Tablets of Enalapril Maleate by Direct Compression for Pediatric Patients. Cianchino, VA; Cifuente, DA; Favier, LS; Ortega, CA, 2020)	0.84
" Whether initiation of sacubitril/valsartan limits the use and dosing of other elements of guideline-directed medical therapy for HFrEF is unknown."	( Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Bhatt, AS; Claggett, BL; Desai, AS; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Vaduganathan, M; Vardeny, O; Zile, MR, 2021)	0.9
" Orodispersible tablets are oral solid dosage forms which rapidly disintegrate after contact with saliva, leaving a liquid dispersion, which can be easily swallowed."	( Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets. Breitkreutz, J; Kokott, M; Lura, A; Wiedey, R, 2021)	0.62
" During the first 2 weeks, the dosage was titrated according to systolic blood pressure (SBP)."	( 3-Month Enalapril Treatment in Pediatric Fontan Patients With Moderate to Good Systolic Ventricular Function. Blom, NA; Harteveld, LM; Hazekamp, MG; Kuipers, IM; Rammeloo, LAJ; Ten Harkel, ADJ; Terol Espinosa de Los Monteros, C; van Dijk, JG, 2022)	1.16
" Rats were dosed orally with metformin alone (100 mg/kg) or in combination with enalapril (4 mg/kg)."	( Enalapril increases the urinary excretion of metformin in rats by inducing multidrug and toxin excretion protein 1 in the kidney. Gou, XY; Ma, YR; Ran, FL; Wu, XA; Wu, YF, 2022)	2.39
" This approach has also been applied to the quantification of enalapril in brain tissue from a rat dosed in vitro."	( Quantification of pharmaceutical compounds in tissue and plasma samples using selective ion accumulation with multiple mass isolation windows. Liang, Z; Prentice, BM, 2023)	1.15

Role	Description
prodrug	A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor	An EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
geroprotector	Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
dicarboxylic acid monoester	A monoester of a dicarboxylic acid.
dipeptide	Any molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	0.0631	0.0032	45.4673	12,589.2998	AID2517
endonuclease IV	Escherichia coli	Potency	0.0002	0.7079	12.4324	31.6228	AID2565
USP1 protein, partial	Homo sapiens (human)	Potency	39.8107	0.0316	37.5844	354.8130	AID504865
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	29.8493	0.0010	22.6508	76.6163	AID1224838
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	3.0107	0.0002	14.3764	60.0339	AID720691
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	11.8823	0.3758	27.4851	61.6524	AID743220
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	0.0144	0.0056	12.3677	36.1254	AID624032
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	39.8107	0.2512	15.8432	39.8107	AID504327
lamin isoform A-delta10	Homo sapiens (human)	Potency	1.5924	0.8913	12.0676	28.1838	AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Angiotensin-converting enzyme	Homo sapiens (human)	IC50 (µMol)	0.3536	0.0001	0.5336	10.0000	AID38853; AID38857; AID38860; AID39622; AID39750; AID39758; AID39767
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	2.7083	0.0000	1.6129	10.0000	AID1231572; AID37669; AID37781
Type-2 angiotensin II receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	1.2000	0.0010	0.3957	3.3000	AID39622
Succinyl-diaminopimelate desuccinylase	Haemophilus influenzae Rd KW20	IC50 (µMol)	1,000.0000	3.3000	3.3000	3.3000	AID467024
Solute carrier family 15 member 1	Homo sapiens (human)	IC50 (µMol)	9,750.0000	0.1800	0.1900	0.2000	AID679008; AID681608
Angiotensin-converting enzyme	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1400	0.0009	0.3322	3.0300	AID38089
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	500.0000	0.0100	2.7656	10.0000	AID721754
Angiotensin-converting enzyme 2	Homo sapiens (human)	IC50 (µMol)	0.1400	0.0004	2.2079	10.0000	AID39758
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier organic anion transporter family member 1A1	Rattus norvegicus (Norway rat)	Km	252.0000	0.0150	3.4996	7.0000	AID682027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
response to hypoxia	Angiotensin-converting enzyme	Homo sapiens (human)
kidney development	Angiotensin-converting enzyme	Homo sapiens (human)
blood vessel remodeling	Angiotensin-converting enzyme	Homo sapiens (human)
angiotensin maturation	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of renal output by angiotensin	Angiotensin-converting enzyme	Homo sapiens (human)
neutrophil mediated immunity	Angiotensin-converting enzyme	Homo sapiens (human)
antigen processing and presentation of peptide antigen via MHC class I	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Angiotensin-converting enzyme	Homo sapiens (human)
proteolysis	Angiotensin-converting enzyme	Homo sapiens (human)
spermatogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
female pregnancy	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of blood pressure	Angiotensin-converting enzyme	Homo sapiens (human)
male gonad development	Angiotensin-converting enzyme	Homo sapiens (human)
response to xenobiotic stimulus	Angiotensin-converting enzyme	Homo sapiens (human)
embryo development ending in birth or egg hatching	Angiotensin-converting enzyme	Homo sapiens (human)
post-transcriptional regulation of gene expression	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of gene expression	Angiotensin-converting enzyme	Homo sapiens (human)
substance P catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
bradykinin catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of smooth muscle cell migration	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
animal organ regeneration	Angiotensin-converting enzyme	Homo sapiens (human)
response to nutrient levels	Angiotensin-converting enzyme	Homo sapiens (human)
response to lipopolysaccharide	Angiotensin-converting enzyme	Homo sapiens (human)
mononuclear cell proliferation	Angiotensin-converting enzyme	Homo sapiens (human)
response to laminar fluid shear stress	Angiotensin-converting enzyme	Homo sapiens (human)
angiotensin-activated signaling pathway	Angiotensin-converting enzyme	Homo sapiens (human)
vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
hormone metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
hormone catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
eating behavior	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of apoptotic process	Angiotensin-converting enzyme	Homo sapiens (human)
peptide catabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of vasoconstriction	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of glucose import	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of synaptic plasticity	Angiotensin-converting enzyme	Homo sapiens (human)
lung alveolus development	Angiotensin-converting enzyme	Homo sapiens (human)
amyloid-beta metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
arachidonic acid secretion	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of neurogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
heart contraction	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of angiotensin metabolic process	Angiotensin-converting enzyme	Homo sapiens (human)
hematopoietic stem cell differentiation	Angiotensin-converting enzyme	Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesis	Angiotensin-converting enzyme	Homo sapiens (human)
cellular response to glucose stimulus	Angiotensin-converting enzyme	Homo sapiens (human)
response to dexamethasone	Angiotensin-converting enzyme	Homo sapiens (human)
cell proliferation in bone marrow	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of calcium ion import	Angiotensin-converting enzyme	Homo sapiens (human)
response to thyroid hormone	Angiotensin-converting enzyme	Homo sapiens (human)
blood vessel diameter maintenance	Angiotensin-converting enzyme	Homo sapiens (human)
regulation of hematopoietic stem cell proliferation	Angiotensin-converting enzyme	Homo sapiens (human)
negative regulation of gap junction assembly	Angiotensin-converting enzyme	Homo sapiens (human)
cellular response to aldosterone	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylation	Angiotensin-converting enzyme	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Angiotensin-converting enzyme	Homo sapiens (human)
monoatomic ion transport	Solute carrier family 15 member 1	Homo sapiens (human)
protein transport	Solute carrier family 15 member 1	Homo sapiens (human)
peptide transport	Solute carrier family 15 member 1	Homo sapiens (human)
dipeptide import across plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
tripeptide import across plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
proton transmembrane transport	Solute carrier family 15 member 1	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
amino acid import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine import across plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
proton transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transport	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
negative regulation of signaling receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
symbiont entry into host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cytokine production	Angiotensin-converting enzyme 2	Homo sapiens (human)
angiotensin maturation	Angiotensin-converting enzyme 2	Homo sapiens (human)
angiotensin-mediated drinking behavior	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Angiotensin-converting enzyme 2	Homo sapiens (human)
tryptophan transport	Angiotensin-converting enzyme 2	Homo sapiens (human)
viral life cycle	Angiotensin-converting enzyme 2	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of vasoconstriction	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of transmembrane transporter activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cell population proliferation	Angiotensin-converting enzyme 2	Homo sapiens (human)
symbiont entry into host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
receptor-mediated virion attachment to host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of inflammatory response	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of amino acid transport	Angiotensin-converting enzyme 2	Homo sapiens (human)
maternal process involved in female pregnancy	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane fusion	Angiotensin-converting enzyme 2	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Angiotensin-converting enzyme 2	Homo sapiens (human)
blood vessel diameter maintenance	Angiotensin-converting enzyme 2	Homo sapiens (human)
entry receptor-mediated virion attachment to host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of gap junction assembly	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cardiac conduction	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of L-proline import across plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
carboxypeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
metalloendopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
calmodulin binding	Angiotensin-converting enzyme	Homo sapiens (human)
peptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
metallopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
exopeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
tripeptidyl-peptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
peptidyl-dipeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
zinc ion binding	Angiotensin-converting enzyme	Homo sapiens (human)
chloride ion binding	Angiotensin-converting enzyme	Homo sapiens (human)
mitogen-activated protein kinase kinase binding	Angiotensin-converting enzyme	Homo sapiens (human)
bradykinin receptor binding	Angiotensin-converting enzyme	Homo sapiens (human)
mitogen-activated protein kinase binding	Angiotensin-converting enzyme	Homo sapiens (human)
metallodipeptidase activity	Angiotensin-converting enzyme	Homo sapiens (human)
heterocyclic compound binding	Angiotensin-converting enzyme	Homo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
peptide:proton symporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
tripeptide transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
dipeptide transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
virus receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
endopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
carboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallocarboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
peptidyl-dipeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
zinc ion binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
identical protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular region	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme	Homo sapiens (human)
lysosome	Angiotensin-converting enzyme	Homo sapiens (human)
endosome	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
external side of plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
basal plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
brush border membrane	Angiotensin-converting enzyme	Homo sapiens (human)
extracellular exosome	Angiotensin-converting enzyme	Homo sapiens (human)
sperm midpiece	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme	Homo sapiens (human)
plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
brush border	Solute carrier family 15 member 1	Homo sapiens (human)
membrane	Solute carrier family 15 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular region	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
endoplasmic reticulum lumen	Angiotensin-converting enzyme 2	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
cilium	Angiotensin-converting enzyme 2	Homo sapiens (human)
cell surface	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
apical plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
endocytic vesicle membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
brush border membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane raft	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular exosome	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID182947	In vivo inhibitory activity against Angiotensin I pressor response in normotensive rats after peroral administration	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID37781	Tested for 50% inhibition of Angiotensin converting enzyme(ACE) obtained from rabbit lung (in vitro)	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID192456	Effects of oral dosing (0.1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 1,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID19006	Calculated membrane partition coefficient (Kmemb)	2004	Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7	Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID176200	Effective dose to produce AcE inhibition in rat, administered intravenously	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID1698208	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in myocardial necrotic area at 2.86 mg/kg, po administered via gavage for 30 days	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID1698219	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as reduction in infarct survival area of myocardial cells at 2.86 mg/kg, po administered via gavage for 30 days by H and E staining bas	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID39762	In vivo inhibition of Angiotensin I converting enzyme in hog plasma after (po) administration of a dose of 0.3(mg/kg)	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID174577	Maximal changes in blood pressure recorded during the 4 day test period in spontaneous hypertensive rats, at 3 mg/kg peroral dose	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID1427531	Half life in Sprague-Dawley rat plasma at 1 uM by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Piperazines as nootropic agents: New derivatives of the potent cognition-enhancer DM235 carrying hydrophilic substituents.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID681152	TP_TRANSPORTER: uptake in Xenopus laevis oocytes	2002	Drug metabolism and pharmacokinetics, , Volume: 17, Issue:4	Transporter-mediated Drug Interactions.
AID186366	Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 3 mg/kg administered orally.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID190703	Activity against the bradykinin Response in anesthetized normotensive rat, administered intravenously at dose 0.0033 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID38110	Compound tested in vivo for inhibition of Angiotensin I converting enzyme in rat	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Angiotensin converting enzyme inhibitors: spirapril and related compounds.
AID598526	1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID678841	TP_TRANSPORTER: inhibition of PHA uptake (PHA: 1000uM) in mOat3-expressing oocytes	2004	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 32, Issue:5	Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
AID467024	Inhibition of Haemophilus influenzae recombinant DapE	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Inhibitors of bacterial N-succinyl-L,L-diaminopimelic acid desuccinylase (DapE) and demonstration of in vitro antimicrobial activity.
AID182948	In vivo inhibitory activity against Angiotensin I pressor response in normotensive rats by peroral administration, experiment 2	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID180807	Change in heart rate was determined at a dose 3 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID38853	Compound tested in vitro for inhibition of Angiotensin I converting enzyme	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Angiotensin converting enzyme inhibitors: spirapril and related compounds.
AID1353453	Half life in Sprague-Dawley rat plasma up to 1 uM by LC-MS/MS analysis	2018	European journal of medicinal chemistry, Mar-10, Volume: 147	Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID192447	Initial systolic blood pressure in spontaneously hypertensive rats after administration of 10 mg/kg of compound perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID481441	Aqueous diffusivity at 37C	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID170715	Percent change was determined in bradykinin depressor response in anesthetized normotensive rat, administered intravenously at dose 0.0033 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID189729	Effects of oral dosing (10 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 4,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID190638	The time required for the maximal fall in blood pressure after administration of the compound	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID481446	Effective permeability across human jejunum	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1698218	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as increase in organized myocardial cells at 2.86 mg/kg, po administered via gavage for 30 days by H and E staining based optical micro	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID184240	Maximum inhibitory effect on Angiotensin I induced pressor responses in anesthetized normotensive rats with 0.5 mg/Kg dose of compound given perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID1353452	Half life in human plasma up to 1 uM by LC-MS/MS analysis	2018	European journal of medicinal chemistry, Mar-10, Volume: 147	Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
AID681608	TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells	1999	Journal of pharmaceutical sciences, Mar, Volume: 88, Issue:3	CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.
AID170716	Percent change was determined in bradykinin depressor response in anesthetized normotensive rat, administered intravenously at dose 0.010 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID192451	Maximum effect on systolic blood pressure in spontaneously hypertensive rats after administration of 10 mg/kg of compound perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID170717	Percent change was determined in bradykinin depressor response in anesthetized normotensive rat, administered intravenously at dose 0.030 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID186541	Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 10 mg/kg administered orally at 4 hr.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID169034	Hypotensive activity was determined in low-sodium treated rat, dose 30 mg/kg administered orally at 5 hr	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID212097	Tested for 50% inhibition of thromboxane synthase (TxS) in human platelets (in vitro); Not active	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
AID194975	Maximum change in mean aortic blood pressure in conscious renal 2-kidney/1-clip goldblatt hypertensive rat at a dose 1.0 mg/kg administered orally at 8h; 4 animals tested	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID39622	Inhibition of Angiotensin I converting enzyme (ACE) in Bothrops jararaca venom	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery.
AID592683	Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID189734	Effects of oral dosing (1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 3,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID189736	Effects of oral dosing (1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 4,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID173534	Percent decrease in angiotensin I pressor response was measured in rat, administered intravenously at dose 0.010 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681004	TP_TRANSPORTER: inhibition of Glutarate uptake (Glutarate: 5 uM, Enalapril: 1000 uM) in Xenopus laevis oocytes	2002	Molecular pharmacology, Jul, Volume: 62, Issue:1	Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID170719	Percent change was determined in bradykinin depressor response n anesthetized normotensive rat, administered intravenously at dose 0.090 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID625277	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID189731	Effects of oral dosing (1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 1,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID26526	Compound was tested for its maximum lipophilicity.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
AID194994	Mean aortic base line blood pressure in conscious renal 2-kidney/1-clip goldblatt hypertensive rat at a dose 3.0 mg/kg administered orally	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID173214	Decrease in systolic blood pressure of Spontaneous Hypertensive Rats (SHR) pretreated with hydrochlorothiazide upon oral administration at 10 mm/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID37669	In vitro inhibitory activity against rabbit lung Angiotensin I converting enzyme at pH 8.3	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives.
AID174939	Time duration was determined for the actioni (determination of MAP in po administration) in rat	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID173422	Effect of perorally administered compound on systolic blood pressure and proteinuria was studied with a 5/6 renal ablated rat as a model of progressive injury	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	[(1H-imidazol-1-yl)methyl]- and [(3-pyridinyl)methyl]pyrroles as thromboxane synthetase inhibitors.
AID173536	Percent decrease in angiotensin I pressor response was measured in rat, administered intravenously at dose 0.090 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID186362	Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 1 mg/kg administered orally.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID171891	Change in systolic blood pressure	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID169030	Hypotensive activity was determined in low-sodium treated rat, dose 10 mg/kg administered orally at 2 hr	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID1698223	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in collagen volume fraction at 2.86 mg/kg, po administered via gavage for 30 days by Masson trichrome staining based micros	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID679885	TP_TRANSPORTER: uptake in OATP-expressing HeLa cells	2000	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 28, Issue:7	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes.
AID169031	Hypotensive activity was determined in low-sodium treated rat, dose 10 mg/kg administered orally at 5 hr	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID1647960	Prevention of heart failure in verapamil treated zebrafish AB assessed as efficacy on heart dilation at 10 ug/ml preincubated for 4.5 hrs followed by verapamil treatment and measured after 30 mins relative to verapamil alone
AID169033	Hypotensive activity was determined in low-sodium treated rat, dose 30 mg/kg administered orally at 2 hr	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID192469	Effects of oral dosing (10 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 3,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID173535	Percent decrease in angiotensin I pressor response was measured in rat, administered intravenously at dose 0.030 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID191053	Effect on vasopressor response caused by angiotensin I (AI) in anesthetized normotensive rat, administered intravenously at dose 0.27 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID592682	Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID177501	In vivo inhibition of angiotensin I induced pressor effect after po administration in rats	1988	Journal of medicinal chemistry, Jan, Volume: 31, Issue:1	(Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L -proline a novel orally active inhibitor of ACE.
AID37948	Time to inhibit maximum Angiotensin I converting enzyme in rabbit lung	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1408208	Stability of the compound in Sprague-Dawley rat whole blood assessed as parent compound remaining after 1 hr by LC-MS/MS analysis	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Synthesis and antibacterial evaluation of 13-substituted cycloberberine derivatives as a novel class of anti-MRSA agents.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID192454	Maximum effect on systolic blood pressure in spontaneously hypertensive rats after administration of 5 mg/kg of compound perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID192464	Effects of oral dosing (10 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 1,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID38860	In vitro inhibitory activity against Angiotensin I converting enzyme	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID682027	TP_TRANSPORTER: uptake in Oatp1-expressing HeLa cells	1998	Hepatology (Baltimore, Md.), Nov, Volume: 28, Issue:5	The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein.
AID192450	Initial systolic blood pressure in spontaneously hypertensive rats after administration of 5 mg/kg of compound perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID481439	Absolute bioavailability in human	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID189738	Predose systolic blood pressure in spontaneously hypertensive rats	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID192467	Effects of oral dosing (10 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 2,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID186360	Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 10 mg/kg administered orally.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID59371	In vivo inhibitory activity against Angiotensin I pressor response in normotensive dog after peroral administration, experiment 1	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID192468	Effects of oral dosing (10 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 3,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID680242	TP_TRANSPORTER: uptake in Oatp1-expressing HeLa cells	2000	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 28, Issue:7	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes.
AID186868	Maximum percent change in mean arterial pressure by the compound over control after po administration at 30 mg/kg dosage	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Angiotensin-converting enzyme inhibitors: new orally active 1,4-thiazepine-2,5-diones, 1,4-thiazine-2,5-diones, and 1,4-benzothiazepine-2,5-diones possessing antihypertensive activity.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID679584	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Enalapril: 50 uM) in MDR1-expressing LLC-PK1 cells	2002	Life sciences, Feb-15, Volume: 70, Issue:13	Interaction of digoxin with antihypertensive drugs via MDR1.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26306	Logarithm of the ratio of anionic to unionized species at pH 7.4	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
AID182327	% Inhibition of angiotensin-I induced pressor response in normotensive rats after peroral dosing of 1.5 umol/kg	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID183135	Inhibitory effect on Angiotensin I induced pressor responses in normotensive rats when given perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID598527	1-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID184239	Maximum inhibitory effect on Angiotensin I induced pressor responses in anesthetized normotensive rats with 0.2 mg/Kg dose of compound given perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID194993	Mean aortic base line blood pressure in conscious renal 2-kidney/1-clip goldblatt hypertensive rat at a dose 10 mg/kg administered orally	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID183141	Peroral dose required to inhibit angiotensin I induced vasopressor response in normotensive conscious rats	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives.
AID184241	Maximum inhibitory effect on Angiotensin I induced pressor responses in anesthetized normotensive rats with 1.0 mg/Kg dose of compound given perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID467611	Dissociation constant, pKa of the compound	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID174936	The duration time of the hypotensive effect showing statistically significant difference from initial value was determined	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID599064	Plasma protein binding in human	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
AID38089	Inhibition of rat Angiotensin I converting enzyme (ACE), using Hip-Gly-Gly as synthetic substrate.	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID194991	Mean aortic base line blood pressure in conscious renal 2-kidney/1-clip goldblatt hypertensive rat at a dose 0.3 mg/kg administered orally	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID193899	Antihypertensive activity was measured in spontaneously hypertensive rat (SHR) by measuring the blood pressure after 24 hours when administered orally at dose of 5 mg/kg	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
AID194978	Maximum change in mean aortic blood pressure in conscious renal 2-kidney/1-clip goldblatt hypertensive rat at a dose 10 mg/kg administered orally at 4 hr; 4 animals tested	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID189733	Effects of oral dosing (1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 2,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID39761	In vitro inhibition of Angiotensin I converting enzyme in Hog plasma	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID191050	Effect on vasopressor response caused by angiotensin I (AI) in anesthetized normotensive rat, administered intravenously at dose 0.010 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID174951	Time taken by the compound to change arterial pressure outside the control area at a dose of 30mg/kg, po	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Angiotensin-converting enzyme inhibitors: new orally active 1,4-thiazepine-2,5-diones, 1,4-thiazine-2,5-diones, and 1,4-benzothiazepine-2,5-diones possessing antihypertensive activity.
AID59373	Peroral dose required to inhibit angiotensin I induced vasopressor response in normotensive conscious dogs	1985	Journal of medicinal chemistry, Jan, Volume: 28, Issue:1	Angiotensin-converting enzyme inhibitors. New orally active antihypertensive (mercaptoalkanoyl)- and [(acylthio)alkanoyl]glycine derivatives.
AID25871	The acid dissociation constant, pKa was determined. 'a' represents value of C-terminus carboxylic acid.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Design, synthesis, and physicochemical properties of a novel, conformationally restricted 2,3-dihydro-1,3,4-thiadiazole-containing angiotensin converting enzyme inhibitor which is preferentially eliminated by the biliary route in rats.
AID679363	TP_TRANSPORTER: inhibition of Salicylate uptake (salicylate: 1 uM, Enalapril: 1000 uM) in Xenopus laevis oocytes	1998	FEBS letters, Jun-12, Volume: 429, Issue:2	Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.
AID57349	Diuretic activity (ip) was tested in dogs; NI-No Increase	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin-converting enzyme inhibitors. 9. Novel [[N-(1-carboxy-3-phenylpropyl)amino]acyl]glycine derivatives with diuretic activity.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID39763	Time to inhibit maximum Angiotensin I converting enzyme in Hog plasma	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID194987	Maximum change in mean aortic blood pressure in conscious renal 2-kidney/1-clip goldblatt hypertensive rat at a dose 3 mg/kg administered orally at 5h; 4 animals tested	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID174398	% decrease in mean arterial pressure in conscious renal hypertensive rats at a dose of 3 mg/Kg, administered perorally at MAP 190 mm Hg	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.
AID192458	Effects of oral dosing (0.1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 2,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID781326	pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X	2014	Pharmaceutical research, Apr, Volume: 31, Issue:4	Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID192470	Effects of oral dosing (10 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 4,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID481444	Octanol-water partition coefficient, log P of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1427532	Half life in PBS at 1 uM by LC-MS/MS analysis	2017	Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6	Piperazines as nootropic agents: New derivatives of the potent cognition-enhancer DM235 carrying hydrophilic substituents.
AID192461	Effects of oral dosing (0.1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 3,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID192463	Effects of oral dosing (0.1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 4,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID1647963	prevention of heart failure in verapamil treated zebrafish AB assessed as efficacy on blood flow velocity at 10 ug/ml preincubated for 4.5 hrs followed by verapamil treatment and measured after 30 mins relative to verapamil alone
AID190706	Activity against the bradykinin Response in anesthetized normotensive rat, administered intravenously at dose 0.090 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID1698216	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as increase in fractional shortening at 2.86 mg/kg, po administered via gavage for 30 days by echocardiography	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID186359	Baseline mean aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 0.3 mg/kg administered orally.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID38465	Compound tested in vivo for inhibition of angiotensin converting enzyme in rat	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Angiotensin converting enzyme inhibitors: spirapril and related compounds.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID38857	Compound was tested for its inhibitory potency against Angiotensin I converting enzyme	1991	Journal of medicinal chemistry, Feb, Volume: 34, Issue:2	Molecular and crystal structures of MDL27,467A hydrochloride and quinapril hydrochloride, two ester derivatives of potent angiotensin converting enzyme inhibitors.
AID194992	Mean aortic base line blood pressure in conscious renal 2-kidney/1-clip goldblatt hypertensive rat at a dose 1.0 mg/kg administered orally	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID192462	Effects of oral dosing (0.1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 4,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID189737	Effects of oral dosing (1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 4,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID182330	% Inhibition of angiotensin-I induced pressor response in normotensive rats after peroral dosing of 5 umol/kg	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID37931	In vitro inhibition of Angiotensin I converting enzyme in rabbit lung	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1698215	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as increase in ejection fraction at 2.86 mg/kg, po administered via gavage for 30 days by echocardiography	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID1459084	Metabolic stability in rat plasma assessed as compound remaining at 100 uM after 4 hrs incubation by LC-MS/MS analysis	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	New potent biaryl sulfate-based hepatitis C virus inhibitors.
AID25407	Half life was determined	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID39627	In vitro inhibitory activity against Angiotensin I converting enzyme in dog	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin-converting enzyme inhibitors. 9. Novel [[N-(1-carboxy-3-phenylpropyl)amino]acyl]glycine derivatives with diuretic activity.
AID189730	Effects of oral dosing (1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 1,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID1408207	Stability of the compound in Sprague-Dawley rat whole blood assessed as parent compound remaining after 0.5 hrs by LC-MS/MS analysis	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Synthesis and antibacterial evaluation of 13-substituted cycloberberine derivatives as a novel class of anti-MRSA agents.
AID190704	Activity against the bradykinin Response in anesthetized normotensive rat, administered intravenously at dose 0.010 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID192448	Initial systolic blood pressure in spontaneously hypertensive rats after administration of 1 mg/kg of compound perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID1698210	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in heart weight ratio at 2.86 mg/kg, po administered via gavage for 30 days	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID188135	The onset hour was determined in rat	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID173537	Percent decrease in angiotensin I pressor response was measured in rat, administered intravenously at dose 0.27 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID176216	Effective dose was determined to increase the vasoResponse in rat	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID37938	In vivo inhibition of Angiotensin I converting enzyme in rabbit lung after (po) administration of a dose of 0.3(mg/kg)	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID184766	Tested for percent inhibition of maximum angiotensin I (AI) pressor response in rats on oral administration of 300 mg/kg after 2 hr	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
AID467613	Volume of distribution at steady state in human	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1647962	prevention of heart failure in verapamil treated zebrafish AB assessed as efficacy on cardiac output at 10 ug/ml preincubated for 4.5 hrs followed by verapamil treatment and measured after 30 mins relative to verapamil alone
AID681825	TP_TRANSPORTER: uptake in Oatp2-expressing HeLa cells	2000	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 28, Issue:7	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes.
AID185740	Antihypertensive activity was measured in spontaneously hypertensive rat (SHR) by measuring the maximum blood pressure when administered orally at dose of 5 mg/kg after 3 h	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	Dual angiotensin converting enzyme/thromboxane synthase inhibitors.
AID1757327	Metabolic stability in rat plasma assessed as parent compound remaining at 100 nM measured after 60 mins by HPLC analysis	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID39767	Inhibitory activity against angiotensin I converting enzyme (ACE)	2000	Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3	Protease inhibitors: current status and future prospects.
AID1647961	prevention of heart failure in verapamil treated zebrafish AB assessed as efficacy on venous congestion at 10 ug/ml preincubated for 4.5 hrs followed by verapamil treatment and measured after 30 mins relative to verapamil alone
AID180806	Change in heart rate was determined at a dose 30 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID192453	Maximum effect on systolic blood pressure in spontaneously hypertensive rats after administration of 2 mg/kg of compound perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID588971	Substrates of transporters of clinical importance in the absorption and disposition of drugs, PEPT2	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID60629	Maximum percent decrease in blood pressure at the dose of 1.0 mg/kg ip	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin-converting enzyme inhibitors. 9. Novel [[N-(1-carboxy-3-phenylpropyl)amino]acyl]glycine derivatives with diuretic activity.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1698221	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as decrease in collagen in heart at 2.86 mg/kg, po administered via gavage for 30 days by Masson trichrome staining based microscopic m	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID182326	% Inhibition of angiotensin-I induced pressor response in normotensive rats after peroral dosing of 0.5 umol/kg	1988	Journal of medicinal chemistry, Jun, Volume: 31, Issue:6	Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
AID189735	Effects of oral dosing (1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 3,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID189732	Effects of oral dosing (1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 2,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID192452	Maximum effect on systolic blood pressure in spontaneously hypertensive rats after administration of 1 mg/kg of compound perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID39460	The time to 50% recovery of the angiotensin I response was measured after po administration at 0.08 mg/kg	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Angiotensin-converting enzyme inhibitors: new orally active 1,4-thiazepine-2,5-diones, 1,4-thiazine-2,5-diones, and 1,4-benzothiazepine-2,5-diones possessing antihypertensive activity.
AID186686	Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 3 mg/kg administered orally at 5 hr.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID191052	Effect on vasopressor response caused by angiotensin I (AI) in anesthetized normotensive rat, administered intravenously at dose 0.090 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID192466	Effects of oral dosing (10 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 2,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID171925	Antihypertensive activity was determined in spontaneously hypertensive rat at a dose of 3 mg/kg(po) administration	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID721753	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID467612	Fraction unbound in human plasma	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID39759	Time during which Angiotensin I converting enzyme inhibition is greater than or equal to 30% in Hog plasma	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID1231572	Inhibition of rabbit lung ACE assessed as hippuryl-histidyl-leucine hydrolysis after 30 mins by colorimetric method	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors.
AID481440	Dissociation constant, pKa of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID37642	In vitro inhibition of Angiotensin I converting enzyme activity in rabbit lung	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Angiotensin-converting enzyme inhibitors: new orally active 1,4-thiazepine-2,5-diones, 1,4-thiazine-2,5-diones, and 1,4-benzothiazepine-2,5-diones possessing antihypertensive activity.
AID39480	Percentage inactivation of the angiotensin I induced vasopressor response in normotensive conscious rats after po administration at dose 0.08 mg/kg; 80-85	1986	Journal of medicinal chemistry, May, Volume: 29, Issue:5	Angiotensin-converting enzyme inhibitors: new orally active 1,4-thiazepine-2,5-diones, 1,4-thiazine-2,5-diones, and 1,4-benzothiazepine-2,5-diones possessing antihypertensive activity.
AID1608226	Half life in Sprague-Dawley rat plasma at 1 uM by LC-MS/MS analysis
AID192465	Effects of oral dosing (10 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 1,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID191054	Effect on vasopressor response caused by angiotensin I (AI) in anesthetized normotensive rat, administered intravenously at dose 0.81 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID681025	TP_TRANSPORTER: inhibition of PAH uptake (PAH: 20 uM, Enalapril: 1000 uM) in OAT-expressing COS-7 cells	1999	The Journal of biological chemistry, Jan-15, Volume: 274, Issue:3	Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells.
AID173538	Percent decrease in angiotensin I pressor response was measured in rat, administered intravenously at dose 0.81 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID176941	Dose required to reduce systolic blood pressure by 30 mmHg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID192459	Effects of oral dosing (0.1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 2,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID180805	Change in heart rate was determined at a dose 10 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID37925	Time during which Angiotensin I converting enzyme inhibition is greater than or equa to 30% in rabbit lung	1990	Journal of medicinal chemistry, Jun, Volume: 33, Issue:6	Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
AID440466	Metabolic stability in Sprague-Dawley rat plasma at 10 uM by LC-MS/MS analysis	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	Hydroxamates: relationships between structure and plasma stability.
AID455986	Permeability across human Caco-2 cells	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID588970	Substrates of transporters of clinical importance in the absorption and disposition of drugs, PEPT1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID173216	Decrease in systolic blood pressure of Spontaneous Hypertensive Rats (SHR) pretreated with hydrochlorothiazide upon oral administration at 3 mm/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID39758	Inhibition of guinea pig angiotensin I converting enzyme	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID679952	TP_TRANSPORTER: inhibition of D-Phe-L-Gln uptake in Xenopus laevis oocytes	1998	Biochimica et biophysica acta, Aug-14, Volume: 1373, Issue:1	Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter.
AID169032	Hypotensive activity was determined in low-sodium treated rat, dose 3 mg/kg administered orally at 2 hr	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID186676	Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 1 mg/kg administered orally at 8 hr.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID192449	Initial systolic blood pressure in spontaneously hypertensive rats after administration of 2 mg/kg of compound perorally	1989	Journal of medicinal chemistry, Feb, Volume: 32, Issue:2	Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
AID440467	Metabolic stability in Sprague-Dawley rat plasma at 10 uM by LC-MS/MS analysis in presence of esterase inhibitor PMSF	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	Hydroxamates: relationships between structure and plasma stability.
AID186538	Maximum change aortic blood pressure in conscious renal (1clip/2kidney) hypertensive rats at dose 0.3 mg/kg administered orally at 5 hr.	1986	Journal of medicinal chemistry, Oct, Volume: 29, Issue:10	Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.
AID1608225	Half life in human plasma at 1 uM by LC-MS/MS analysis
AID194971	Maximum change in mean aortic blood pressure in conscious renal 2-kidney/1-clip goldblatt hypertensive rat at a dose 0.3 mg/kg administered orally at 5h; 4 animals tested	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and structure-activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids.
AID679008	TP_TRANSPORTER: inhibition of Gly-Sar uptake (Gly-Sar: 20 uM) in PEPT1-expressing CHO cells	1998	Pharmaceutical research, Aug, Volume: 15, Issue:8	5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.
AID481442	Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID190705	Activity against the bradykinin Response in anesthetized normotensive rat, administered intravenously at dose 0.030 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID192460	Effects of oral dosing (0.1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 3,at 24 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID169035	Hypotensive activity was determined in low-sodium treated rat, dose 3 mg/kg administered orally at 5 hr	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1353451	Half life in PBS up to 1 uM by LC-MS/MS analysis	2018	European journal of medicinal chemistry, Mar-10, Volume: 147	Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
AID39750	In vitro inhibitory activity against Angiotensin I converting enzyme from unpurified guinea pig serum	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID192457	Effects of oral dosing (0.1 mg/kg) on systolic blood pressure in spontaneously hypertensive rats, day 1,at 2 hr	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme.
AID59370	In vivo inhibitory activity against Angiotensin I pressor response in normotensive dog after peroral administration, ecperiment 2	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID191051	Effect on vasopressor response caused by angiotensin I (AI) in anesthetized normotensive rat, administered intravenously at dose 0.030 mg/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID173217	Decrease in systolic blood pressure of Spontaneous Hypertensive Rats (SHR) pretreated with hydrochlorothiazide upon oral administration at 30 mm/kg	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Synthesis and pharmacology of the potent angiotensin-converting enzyme inhibitor N-[1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanyl-(S)-pyroglutamic acid.
AID174575	Maximal changes in blood pressure recorded during the 4 day test period in spontaneous hypertensive rats, at 1 mg/kg peroral dose	1985	Journal of medicinal chemistry, Nov, Volume: 28, Issue:11	Angiotensin converting enzyme inhibitors: structure-activity profile of 1-benzazepin-2-one derivatives.
AID1698212	Cardioprotective activity in Sprague-Dawley rat model of LAD coronary artery ligation-induced cardiac fibrosis assessed as increase in left ventricular function by measuring reduction in LAD-induced anterior wall weakened at 2.86 mg/kg, po administered vi	2020	Journal of natural products, 10-23, Volume: 83, Issue:10	Discovery of Natural Compounds for Cardiac Fibrosis by a Transcriptome-Based Functional Gene Module Reference Approach.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345457	Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2))	1994	Journal of cardiovascular pharmacology, , Volume: 23 Suppl 4	Compared properties of trandolapril, enalapril, and their diacid metabolites.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1251 (21.25)	18.7374
1990's	2278 (38.69)	18.2507
2000's	1420 (24.12)	29.6817
2010's	791 (13.43)	24.3611
2020's	148 (2.51)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,924 (30.49%)	5.53%
Reviews	325 (5.15%)	6.00%
Case Studies	602 (9.54%)	4.05%
Observational	8 (0.13%)	0.25%
Other	3,452 (54.70%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (124)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect of Prophylactic Treatment With Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis Patients. [NCT03667131]	Phase 2	59 participants (Actual)	Interventional	2017-02-13	Completed
Prevention of Left Ventricular Dysfunction With Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies [NCT01110824]	Phase 3	90 participants (Actual)	Interventional	2008-04-30	Completed
ASP1585 Pharmacokinetic Interaction Study - Pharmacokinetic Interaction With Enalapril - [NCT01115946]	Phase 1	24 participants (Actual)	Interventional	2010-03-31	Completed
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Two-Period, Two-Cohort Crossover Study to Assess the Potential Interaction of Avanafil on the Pharmacokinetic and/or Hemodynamic Effects of Enalapril or Amlodipine in Male Subjects [NCT01117038]	Phase 1	48 participants (Actual)	Interventional	2010-04-30	Completed
Examination of Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With ENEAS®. [NCT01074281]		2,065 participants (Actual)	Observational	2008-06-30	Completed
The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II [NCT02281838]	Phase 2	270 participants (Anticipated)	Interventional	2011-08-01	Recruiting
A Randomized Controlled Trial Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period [NCT04236258]	Phase 4	94 participants (Actual)	Interventional	2020-01-24	Completed
A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction [NCT03066804]	Phase 3	2,572 participants (Actual)	Interventional	2017-08-22	Completed
A Multi-center, Prospective, Randomized, Double-blind Study to Assess the Impact of Sacubitril/Valsartan vs. Enalapril on Daily Physical Activity Using a Wrist Worn Actigraphy Device in Adult Chronic Heart Failure Patients [NCT02900378]	Phase 3	621 participants (Actual)	Interventional	2016-12-20	Completed
Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults [NCT02252692]	Phase 1	24 participants (Anticipated)	Interventional	2014-08-31	Active, not recruiting
Primary Prevention of Cardiovascular Disease in Pre-diabetic & Pre-hypertensive Subjects Using Multiple Risks Reduction Strategy: A Multi-center, Double-blind, Randomized Controlled Trial [NCT01364675]		8,900 participants (Anticipated)	Interventional	2012-01-31	Not yet recruiting
Safety and Efficacy of Maximally Tolerated RAAS Blockade and Spironolactone Therapy on Urinary Proteinuria and Progression of Type II Diabetic Nephropathy in African Americans and Other Patient Cohorts. [NCT03502031]	Phase 4	72 participants (Anticipated)	Interventional	2018-10-01	Recruiting
The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients [NCT01305850]	Phase 4	100 participants (Anticipated)	Interventional	2010-07-31	Recruiting
The Effect of NEPRIlysin (LCZ696) on EXercise TOLerance, Muscle Vasodilatation, Muscle Strength and Body Composition in Patients With Heart Failure - NEPRIExTol-HF Trial [NCT03190304]	Phase 4	52 participants (Actual)	Interventional	2017-06-14	Completed
A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954) [NCT00882440]	Phase 3	576 participants (Actual)	Interventional	1990-12-31	Completed
Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health- [NCT02970669]	Phase 4	140 participants (Actual)	Interventional	2016-12-16	Completed
The Effect of Continuing or Discontinuing ACE-I/ARBs Therapy on the Incidence of Contrast-induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Coronary Angiography; a Randomized Controlled Trial [NCT05271448]		600 participants (Anticipated)	Interventional	2021-06-01	Recruiting
A Randomized, Double-blind, Active-controlled Study to Assess the Effect of LCZ696 Compared With Enalapril to Improve Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF). [NCT02768298]	Phase 4	201 participants (Actual)	Interventional	2016-07-12	Completed
A Double-blind, Parallel-group Comparison Study of BIBR 277 Capsule in Patients With Essential Hypertension [NCT02177448]	Phase 3	225 participants (Actual)	Interventional	1998-09-30	Completed
A Randomized, Double-Blind, Controlled Trial on the Homocysteine-Lowering Effects of Different Doses of Folic Acid Among Patients With Hypertension According to Methylenetetrahydrofolate Reductase C677T Genotypes [NCT03472508]	Phase 4	3,600 participants (Anticipated)	Interventional	2018-03-20	Recruiting
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: Randomized Trial ANSWER-HF [NCT04853758]	Phase 3	200 participants (Anticipated)	Interventional	2021-05-06	Recruiting
Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars [NCT05259137]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements [NCT01211314]	Phase 4	10 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to sponsor decision)
Interest of Angiotensin-converting Enzyme Inhibitors on Early Sickle Cell Renal Disease in Children. A Randomized, Double-blind Trial Enalapril vs Placebo. [NCT01096121]		5 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Not enough inclusions)
Impact of Angiotensin Converting Enzyme Activity on Exercise Training Sensitivity [NCT03949075]		52 participants (Actual)	Interventional	2019-05-15	Completed
Angiotensin-II Receptor Antibody Blockade With Losartan in Patients With Lupus Nephritis [NCT03526042]		40 participants (Anticipated)	Interventional	2017-09-10	Recruiting
Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy [NCT04183101]	Phase 2	30 participants (Anticipated)	Interventional	2020-10-01	Recruiting
A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active-controlled, Forced-titration, 12-week Comparison of Combined Angiotensin-neprilysin Inhibition With Sacubitril and Valsartan Versus Enalapril on Changes in Central Aortic Stiffn [NCT02874794]	Phase 4	465 participants (Actual)	Interventional	2016-08-17	Completed
A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Sacubitril/Valsartan Compared With Enalapril to Improve Erectile Function in Patients With Heart Failure With Reduced Ejection Fraction and Erectile Dysfunction [NCT03917459]	Phase 3	27 participants (Actual)	Interventional	2019-04-16	Completed
The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients [NCT05232370]	Phase 2	39 participants (Actual)	Interventional	2022-01-01	Completed
Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease [NCT02652741]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomy [NCT04023227]	Phase 4	919 participants (Actual)	Interventional	2019-12-10	Active, not recruiting
Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype [NCT02135263]	Phase 4	44 participants (Actual)	Interventional	2012-04-30	Completed
Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: a Phase 3 Randomised, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced CardioToxicity [NCT03265574]	Phase 3	128 participants (Anticipated)	Interventional	2017-10-04	Recruiting
A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertensio [NCT02177461]	Phase 4	374 participants (Actual)	Interventional	2000-04-30	Completed
A Multicenter, Double-blind, Randomized, 52-week, Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age [NCT01151410]	Phase 3	208 participants (Actual)	Interventional	2010-08-31	Completed
A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension [NCT00568178]	Phase 3	306 participants (Actual)	Interventional	2007-06-01	Completed
Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. [NCT00734123]	Phase 4	2,948 participants (Anticipated)	Interventional	2008-04-30	Recruiting
"Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on Vaccinated Immune Attacks" [NCT05711810]	Phase 4	1 participants (Actual)	Interventional	2023-01-02	Completed
A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Sy [NCT00391846]	Phase 4	252 participants (Actual)	Interventional	2006-10-31	Completed
Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial. [NCT00794885]	Phase 4	20,702 participants (Actual)	Interventional	2008-05-31	Completed
Randomized, Parallel Group, Double-blind Trial to Evaluate Different Dose Combinations of Lercanidipine and Enalapril in Comparison With Each Component Administered Alone and With Placebo in Patients With Essential Hypertension [NCT01093807]	Phase 2	1,039 participants (Actual)	Interventional	2010-03-31	Completed
An Extension to Study Protocol CVAL489K2302 to Evaluate the Long Term Safety, Tolerability and Efficacy of Valsartan in Children 6 to 17 Years of Age With Hypertension, Versus Enalapril Treatment for 14 Weeks, or Combined With Enalapril Versus Enalapril f [NCT00446511]	Phase 3	250 participants (Actual)	Interventional	2007-06-30	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia [NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia [NCT00899587]	Phase 1	0 participants	Interventional		Recruiting
Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study [NCT02817503]	Phase 4	100 participants (Anticipated)	Interventional	2015-12-31	Enrolling by invitation
Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril [NCT02654678]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2016-03-31	Not yet recruiting
Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy [NCT02652728]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients [NCT01041963]	Phase 4	90 participants (Anticipated)	Interventional	2009-06-30	Recruiting
A Clinical Study on Anti-Hypertensive Agent (ACEi) and Heart Function Improvement [NCT01069042]	Phase 4	60 participants (Anticipated)	Interventional	2010-02-28	Recruiting
Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network) [NCT00113087]	Phase 3	230 participants (Actual)	Interventional	2003-08-31	Completed
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in [NCT00853658]	Phase 3	7,064 participants (Actual)	Interventional	2009-03-31	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction - PRESENT HF Study [NCT05487261]	Phase 4	260 participants (Anticipated)	Interventional	2022-12-13	Recruiting
The Effect of Enalapril on Doxorubicin Exposure in Adjuvant Breast Cancer Treatment [NCT00895414]		19 participants (Actual)	Interventional	2009-04-30	Completed
NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial [NCT02817360]	Phase 4	2,400 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial [NCT00963976]	Phase 2	74 participants (Actual)	Interventional	2007-01-31	Completed
[NCT00000516]	Phase 3	0 participants	Interventional	1985-07-31	Completed
[NCT00000522]	Phase 2	0 participants	Interventional	1985-08-31	Completed
Bariatric Surgery and Pharmacokinetics Enalapril: BAR-MEDS Enalapril [NCT03460366]		12 participants (Anticipated)	Observational	2016-11-02	Recruiting
A Multicenter, Randomized, Double-blind, Parallel-group, Evaluation of 12 Weeks of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children 6 to 17 Years of Age With Hypertension [NCT00433836]	Phase 3	300 participants (Actual)	Interventional	2007-01-31	Completed
[NCT01015937]		50 participants (Actual)	Interventional	2008-03-31	Completed
A Phase 2 Study of the Efficacy of Antioxidant Therapy Compared With Enalapril in Slowing the Progression of Sickle Nephropathy in Children [NCT01891292]		30 participants (Anticipated)	Interventional	2013-07-31	Not yet recruiting
Treatment of HYpertension: Morning Versus Evening [NCT02214498]	Phase 4	120 participants (Anticipated)	Interventional	2015-05-31	Not yet recruiting
Department of Geriatrics [NCT02575092]	Phase 2/Phase 3	4,000 participants (Actual)	Interventional	2015-11-01	Completed
A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology [NCT02571842]	Phase 4	30 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Comparison Between the Efficacy of Sodium-Glucose Co-transporter 2 Inhibitor Therapy Versus Angiotensin-converting Enzyme Inhibitor in the Treatment of Diabetic Kidney Disease [NCT05373004]	Phase 2/Phase 3	212 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction [NCT01035255]	Phase 3	8,442 participants (Actual)	Interventional	2009-12-31	Terminated(stopped due to Early termination was approved due to compelling efficacy of LCZ696 in patients with HF & reduced EF after final pre-specified interim analysis 28-Mar-2014.)
The Renin-angiotensin System (RAS) in Barrett's Esophagus as Future Biomarkers for Dysplasia and Cancer? A Randomized Controlled Trial [NCT02879721]	Early Phase 1	33 participants (Actual)	Interventional	2009-10-31	Completed
A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Assess the Efficacy and Tolerability of MK8141 in Hypertensive Patients [NCT00543413]	Phase 2	160 participants (Actual)	Interventional	2007-10-31	Completed
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure [NCT01411735]	Phase 3	71 participants (Actual)	Interventional	2003-07-31	Completed
An International Randomised Controlled Trial to Establish the Effects of Low-dose rtPA and the Effects of Early Intensive Blood Pressure Lowering in Patients With Acute Ischaemic Stroke [NCT01422616]	Phase 3	4,587 participants (Actual)	Interventional	2012-03-31	Completed
[NCT00006137]		43 participants	Interventional	2000-05-31	Completed
The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors in Resistant Hypertension [NCT02623036]	Phase 1	20 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2 [NCT03005184]	Phase 2	0 participants (Actual)	Interventional	2017-09-30	Withdrawn(stopped due to Study is being redesigned and submitted as a new study.)
Enalapril Maleate and Folic Acid Tablets for Prevention of Chronic Kidney Diseases in Patients With Hypertension: a Double-blind Randomized Controlled Trial [NCT01871740]	Phase 4	0 participants (Actual)	Interventional	2008-05-31	Withdrawn(stopped due to The sponsor and the PIs both agreed that the CSPPT-CKD should be a sub-study of the CSPPT insted of an independent randomized trial.)
Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study [NCT00446862]		36 participants (Actual)	Observational	2007-03-31	Completed
Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure. [NCT00456963]	Phase 4	3,000 participants (Anticipated)	Interventional	2007-09-30	Terminated(stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.)
Effect of Chicken-Based Diet Versus Enalapril on Albuminuria in Patients With Type 2 Diabetes and Microalbuminuria: a One-Year Randomized Controlled Study [NCT00484068]		28 participants (Actual)	Interventional	2003-01-31	Completed
Efficacy of Antihypertensive and Plasma Total Homocysteine Lowering Combined Therapy With Enalapril and Folic Acid in Hypertensive Patients:A Multicenter Double Blind Randomized Clinical Trial [NCT00520247]	Phase 2	443 participants (Actual)	Interventional	2005-09-30	Completed
Renin Angiotensin System Blockage-DN (RASS) [NCT00143949]	Phase 2	285 participants (Actual)	Interventional	1997-03-31	Completed
The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution After the Bidirectional Cavopulmonary Connection [NCT00741156]	Phase 3	12 participants (Actual)	Interventional	2008-07-31	Completed
Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients [NCT01007994]	Phase 2/Phase 3	33 participants (Actual)	Interventional	2009-11-30	Completed
Trial of ACE Inhibition in Children With Mitral Regurgitation After Repair of AVSD [NCT00113698]	Phase 3	5 participants (Actual)	Interventional	2004-12-31	Terminated(stopped due to lower than expected enrollment)
The Renin-Angiotensin System in Essential Hypertension [NCT00141583]		11 participants (Anticipated)	Interventional	2004-04-30	Terminated(stopped due to Insufficient accrual rate)
Hydrochlorothiazide and Amiloride vs Hydrochlorothiazide and Enalapril: a Randomized Clinical Trial of Antihypertensive Effectiveness. [NCT00394394]	Phase 2	0 participants	Interventional	2005-02-28	Completed
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study [NCT01669434]	Phase 4	291 participants (Actual)	Interventional	2015-06-01	Completed
Genetic Determinants of ACEI Prodrug Activation [NCT03051282]	Phase 4	21 participants (Actual)	Interventional	2017-04-01	Active, not recruiting
A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of [NCT02554890]	Phase 4	887 participants (Actual)	Interventional	2016-04-29	Completed
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study [NCT00235287]	Phase 4	60 participants (Anticipated)	Interventional	2005-09-30	Recruiting
The Use of ACE Inhibitors in the Early Renal Post-transplant Period [NCT00270153]	Phase 1	110 participants (Actual)	Interventional	2004-09-30	Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study). [NCT00295542]	Phase 4	3,344 participants (Actual)	Interventional	2000-03-31	Completed
DETAIL = Diabetics Exposed to Telmisartan And enalapIL: A Randomised, Double-blind, Parallel-group Comparison of the Renal and Antihypertensive Effects of Telmisartan and Enalapril in Subjects With Mild to Moderate Hypertension and Concurrent Type II Diab [NCT00274118]	Phase 3	250 participants	Interventional	1997-07-31	Completed
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients [NCT00292526]	Phase 4	114 participants (Actual)	Interventional	2000-11-30	Completed
Prospective, Randomized, Open-Label Study in Patients With Mild-to-Moderate Essential Hypertension to Compare the Antihypertensive Efficacy Determined by Ambulatory Blood Pressure Monitoring of Valsartan and Enalapril After Missing One Dose [NCT00302705]	Phase 4	150 participants (Actual)	Interventional	2005-01-31	Completed
Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus [NCT00419835]	Phase 4	80 participants (Actual)	Interventional	2005-05-31	Completed
A Double Blind Clinical Trial to Examine the Renal Effects of an Angiotensin Converting Enzyme Inhibitor (Enalapril) in Adults With Chronic Kidney Disease of Uncertain Aetiology (CKDu) [NCT01624064]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2012-08-31	Not yet recruiting
Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital [NCT01631409]		0 participants (Actual)	Observational	2013-09-30	Withdrawn(stopped due to The study has been withdrawn due to organizational problems)
Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome [NCT00666848]	Phase 4	24 participants (Actual)	Interventional	2008-03-31	Completed
Randomized Trial of ACEIs in Treatment of COVID-19 [NCT04345406]	Phase 3	60 participants (Anticipated)	Interventional	2020-04-15	Not yet recruiting
Prospective Comparison of an ARNI With an ACE Inhibitor on enDOthelial Function by Brachial Artery Reactivity (PARADOR) [NCT03119623]	Phase 4	0 participants (Actual)	Interventional	2017-06-01	Withdrawn(stopped due to Lost funding prior to study commencing)
A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension. [NCT01705392]	Phase 2	2 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to Lack of financing of the study drug. Not sufficient financial support.)
An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enal [NCT01822639]	Phase 1	15 participants (Actual)	Interventional	2013-04-03	Completed
Mitigation of Radiation Pneumonitis and Fibrosis [NCT01754909]	Phase 2	50 participants (Actual)	Interventional	2013-11-01	Completed
Contribution of Neuropeptide Y (NPY) to Vasoconstriction and Sympathetic Activation in the Setting of Dipeptidyl Peptidase IV (DPP4) Inhibition [NCT02639637]	Phase 4	18 participants (Actual)	Interventional	2015-12-31	Completed
Is There a Benefit to Optimize HF (Heart Failure) Treatment in Aged Over 80 Year's Old Patients? [NCT01437371]	Phase 3	35 participants (Actual)	Interventional	2011-08-31	Completed
Feasibility Study on the Effects of Postnatal Enalapril on Maternal Cardiovascular Function Following Preterm Pre-eclampsia. [NCT03466333]	Phase 2	118 participants (Actual)	Interventional	2018-09-05	Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Afterload Reduction Therapy for Late Anthracycline Cardiotoxicity: A Pediatric Oncology Group Cancer Control Study [NCT00003070]	Phase 3	13 participants (Actual)	Interventional	2000-09-30	Completed
Systemic Hemodynamics and Cerebral Blood Flow in Persons With Tetraplegia [NCT00248807]		30 participants (Actual)	Interventional	2005-10-31	Completed
[NCT00000547]	Phase 3	0 participants	Interventional	1994-04-30	Completed
[NCT00004328]	Phase 2	1 participants	Interventional	1992-12-31	Completed
ICOS-ONE - Prevention of Anthracycline-induced Cardiotoxicity: a Multicentre Randomized Trial Comparing Two Therapeutic Strategies. [NCT01968200]	Phase 3	268 participants (Anticipated)	Interventional	2012-12-31	Active, not recruiting
Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCZ696 Followed by a 52-week Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared [NCT02678312]	Phase 2/Phase 3	393 participants (Actual)	Interventional	2016-11-03	Completed
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy [NCT00367562]	Phase 4	20 participants	Interventional	1996-01-31	Completed
A Multi-center, Prospective Randomized Controlled Trial on the Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction [NCT04912167]	Phase 3	376 participants (Anticipated)	Interventional	2021-11-30	Not yet recruiting
Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - Angiotensin-Converting-Enzyme (ACE) Inhibitor Therapy [NCT02432885]	Phase 3	76 participants (Actual)	Interventional	2009-06-30	Completed
Blood Pressure Management in Stroke Following Endovascular Treatment [NCT04484350]	Phase 2	30 participants (Actual)	Interventional	2020-10-23	Completed
Radiofrequency Ablation for Atrial Fibrillation in Advanced Chronic Heart Failure [NCT00292162]		41 participants (Actual)	Interventional	2007-01-31	Completed
Randomized Controlled Blind End Point Study of Enalapril Folic Acid Tablets Combined With Calcium Antagonist or Diuretic to Prevent Stroke in Patients With Type H Hypertension [NCT04952051]	Phase 3	1,000 participants (Actual)	Interventional	2014-07-01	Completed
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction. [NCT02468232]	Phase 3	225 participants (Actual)	Interventional	2015-06-15	Completed
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvascular Function and Vessel Remodeling in Hypertensive Humans [NCT03179163]	Phase 1/Phase 2	46 participants (Actual)	Interventional	2016-07-20	Terminated(stopped due to COVID shut down human subjects research and then the grant funding expired)
Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition [NCT04640571]	Phase 4	18 participants (Actual)	Interventional	2021-04-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00113087 (29) [back to overview]	MacArthur-Bates Inventory -Total Gestures
NCT00113087 (29) [back to overview]	MacArthur-Bates Inventory -Words Produced
NCT00113087 (29) [back to overview]	MacArthur-Bates Inventory -Words Understood
NCT00113087 (29) [back to overview]	Neurodevelopmental Status (FSII)
NCT00113087 (29) [back to overview]	Neurodevelopmental Status (PDI): the Bayley Scales of Infant Development,Psychomotor Development Index Z-score
NCT00113087 (29) [back to overview]	Neurodevelopmental Status(MDI): Bayley Scales of Infant Development, Mental Developmental Index Z-score
NCT00113087 (29) [back to overview]	Number of Participants With Moderate to Severe AV Valve Regurgitation
NCT00113087 (29) [back to overview]	Number of Participants With Moderate to Severe AV Valve Regurgitation
NCT00113087 (29) [back to overview]	Number of Participants With Ross Heart Failure Class I
NCT00113087 (29) [back to overview]	Number of Participants With Ross Heart Failure Class I
NCT00113087 (29) [back to overview]	Ventricular Filling Pressure
NCT00113087 (29) [back to overview]	Ventricular Mass
NCT00113087 (29) [back to overview]	Ventricular Mass
NCT00113087 (29) [back to overview]	Ventricular Mass to Volume Ratio
NCT00113087 (29) [back to overview]	Ventricular Mass to Volume Ratio
NCT00113087 (29) [back to overview]	Ventricular Mass Z-score
NCT00113087 (29) [back to overview]	Ventricular Mass Z-score
NCT00113087 (29) [back to overview]	Weight-for-age Z-score at 14 Months of Age
NCT00113087 (29) [back to overview]	End-diastolic Volume
NCT00113087 (29) [back to overview]	End-diastolic Volume
NCT00113087 (29) [back to overview]	End Diastolic Volume Z-score
NCT00113087 (29) [back to overview]	Ejection Fraction (%)
NCT00113087 (29) [back to overview]	Ejection Fraction (%)
NCT00113087 (29) [back to overview]	B-type Natriuretic Peptide Level
NCT00113087 (29) [back to overview]	B-Type Natriuretic Peptide
NCT00113087 (29) [back to overview]	MacArthur-Bates Inventory -Phrases Understood
NCT00113087 (29) [back to overview]	Height-for-age Z-score
NCT00113087 (29) [back to overview]	Head Circumference-for-age Z-score
NCT00113087 (29) [back to overview]	End-diastolic Volume Z-score
NCT00248807 (2) [back to overview]	Systolic Blood Pressure
NCT00248807 (2) [back to overview]	Cerebral Blood Flow
NCT00292162 (6) [back to overview]	Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months
NCT00292162 (6) [back to overview]	Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%
NCT00292162 (6) [back to overview]	Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)
NCT00292162 (6) [back to overview]	Plasma B-type Natriuretic Peptide (BNP) at Baseline
NCT00292162 (6) [back to overview]	Plasma B-type Natriuretic Peptide (BNP) at 6 Months
NCT00292162 (6) [back to overview]	Plasma B-type Natriuretic Peptide (BNP)
NCT00391846 (8) [back to overview]	Changes in Heart Failure Symptoms
NCT00391846 (8) [back to overview]	Changes in Health-related Quality of Life
NCT00391846 (8) [back to overview]	Changes in NT-proBNP Values Over Time in All Patients
NCT00391846 (8) [back to overview]	Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)
NCT00391846 (8) [back to overview]	Discontinuations
NCT00391846 (8) [back to overview]	Number of CV Deaths
NCT00391846 (8) [back to overview]	Number of Days in Hospital for CV Reason
NCT00391846 (8) [back to overview]	Total Number of Titration Steps in Prescribed Heart Failure Treatment
NCT00433836 (4) [back to overview]	Change From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients
NCT00433836 (4) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)
NCT00433836 (4) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)
NCT00433836 (4) [back to overview]	Decrease in MSSBP to < 95th Percentile for Age, Gender and Height
NCT00446511 (5) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26
NCT00446511 (5) [back to overview]	Percentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26
NCT00446511 (5) [back to overview]	Change From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20
NCT00446511 (5) [back to overview]	Number of Patients With Adverse Events
NCT00446511 (5) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Change From Baseline in Diastolic Blood Pressure in Hypertensive Participants at Week 12
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12
NCT00568178 (5) [back to overview]	Double-Blind Treatment Phase: Change From Baseline in Systolic Blood Pressure in Hypertensive Participants at Week 12
NCT00568178 (5) [back to overview]	Open Label Extension: Change From Baseline in Glomerular Filtration Rate (GFR) at Month 36
NCT00568178 (5) [back to overview]	Open Label Extension: Percent Change From Baseline of Urinary Pr/Cr Ratio (gm/gm) at Month 36
NCT00666848 (2) [back to overview]	Change in MAP During Sitagliptin
NCT00666848 (2) [back to overview]	Change in MAP During Placebo
NCT00741156 (2) [back to overview]	Systemic, Pulmonary and Cerebral Blood Flow at Baseline and After Enalaprilat
NCT00741156 (2) [back to overview]	Systemic, Pulmonary and Cerebral Resistance at Baseline and After Enalaprilat
NCT00853658 (3) [back to overview]	Change From Baseline to Month 12 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score
NCT00853658 (3) [back to overview]	Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
NCT00853658 (3) [back to overview]	All Cause Death
NCT00882440 (3) [back to overview]	Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8
NCT00882440 (3) [back to overview]	Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8
NCT00882440 (3) [back to overview]	Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8
NCT00895414 (3) [back to overview]	The Number of Participants With a Significant Increase or Decrease in the Baseline Levels of Btype Natriuretic Peptide, Cardiac Troponins, and Urine Microalbumin With or Without Enalapril
NCT00895414 (3) [back to overview]	The Number of Participants With a Significant Increase or Decrease in Doxorubicin Hydrochloride Metabolite Levels With or Without Enalapril
NCT00895414 (3) [back to overview]	Number of Patients With Doxorubicin Plasma Concentrations Demonstrating a Significant Increase or Decrease When Doxorubicin Was Given With Enalapril as Compared to When Doxorubicin Was Given Without Enalapril.
NCT01007994 (1) [back to overview]	Number of Participants Who Are Non Dippers
NCT01035255 (6) [back to overview]	Number of Patients Reported With Adjudicated Primary Causes of Death
NCT01035255 (6) [back to overview]	Number of Patients With First Confirmed Renal Dysfunction
NCT01035255 (6) [back to overview]	Number of Patients - All-cause Mortality
NCT01035255 (6) [back to overview]	Change From Baseline to Month 8 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score
NCT01035255 (6) [back to overview]	Percentage of Participants With New Onset of Atrial Fibrillation (AF)
NCT01035255 (6) [back to overview]	Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
NCT01151410 (3) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study
NCT01151410 (3) [back to overview]	Change in Mean Arterial Pressure (MAP) (mmHg) From Baseline to End of Study
NCT01151410 (3) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at to End of Study
NCT01669434 (6) [back to overview]	Acute Renal Failure
NCT01669434 (6) [back to overview]	Low Blood Pressure Subgroup
NCT01669434 (6) [back to overview]	Number of Participants With Interoperative Hypotension
NCT01669434 (6) [back to overview]	Postoperative Hypertension
NCT01669434 (6) [back to overview]	Postoperative Hypotension
NCT01669434 (6) [back to overview]	Older Age Subgroup
NCT01754909 (3) [back to overview]	Number of Participants With Radiation Pneumonitis by CT Scan
NCT01754909 (3) [back to overview]	Number of Participants With Radiation Pneumonitis
NCT01754909 (3) [back to overview]	Number of Participants With Radiation Fibrosis
NCT02468232 (27) [back to overview]	Percentage of Participants Hospitalized
NCT02468232 (27) [back to overview]	Percentage of Participants Reaching Target Dose Level 3 at Week 8 and Maintained at Month 4 (Open Label Extension (OLE))
NCT02468232 (27) [back to overview]	Total Number of CEC Confirmed Composite of CV Death and Total (First and Recurrent) HF Hospitalizations for Heart Failure
NCT02468232 (27) [back to overview]	Association Between Change in NT-proBNP Concentration and Change in Echocardiographic Parameters From OLE Baseline at Month 12 (OLE)
NCT02468232 (27) [back to overview]	Change in B-type Natriuretic Peptide (BNP) From OLE Baseline to Predefined Timepoints (OLE)
NCT02468232 (27) [back to overview]	Change in Blood NT-proBNP From Baseline
NCT02468232 (27) [back to overview]	Change in Key Echocardiographic Parameters From OLE Baseline at Month 12 (OLE)
NCT02468232 (27) [back to overview]	Change in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) From OLE Baseline to Predefined Timepoints (OLE)
NCT02468232 (27) [back to overview]	Change in NYHA Classification From OLE Baseline (OLE)
NCT02468232 (27) [back to overview]	Change in Urine cGMP From OLE Baseline to Predefined Timepoints (OLE)
NCT02468232 (27) [back to overview]	Changes in Urine Cyclic Guanosine 3',5'-Monophosphate (cGMP) From Baseline
NCT02468232 (27) [back to overview]	Exposure-adjusted Incident Rate (EAIR) of CEC Confirmed Composite Endpoints
NCT02468232 (27) [back to overview]	Key Secondary: Change From Baseline in Clinical Summary Score for Heart Failure Symptoms and Physical Limitations Assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ).
NCT02468232 (27) [back to overview]	Key Secondary: Change From Baseline to the Pre-defined Time-points in Log-transformed Concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
NCT02468232 (27) [back to overview]	Key Secondary: EAIR of CEC-confirmed First Triple Composite Endpoint (Cardiovascular (CV) Death, Heart Failure (HF) Hospitalization, or Worsening of HF in Outpatients)
NCT02468232 (27) [back to overview]	Key Secondary: Number of Participants by Changes in New York Heart Association (NYHA) Classification From Baseline at Predefined Timepoints
NCT02468232 (27) [back to overview]	Key Secondary: Number of Participants With CEC-confirmed First Triple Composite Endpoint (Cardiovascular (CV) Death, Heart Failure (HF) Hospitalization, or Worsening of HF in Outpatients)
NCT02468232 (27) [back to overview]	Number of Participants by Changes in Clinical Composite Score (as Assessed by NYHA Classification and Patient Global Assessment) at Predefined Timepoints
NCT02468232 (27) [back to overview]	Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints
NCT02468232 (27) [back to overview]	Percentage of Re-hospitalizations
NCT02468232 (27) [back to overview]	Change in Cardiac Measurements by Key Echocardiographic Parameter LVEF, From OLE Baseline at Month 12 (OLE)
NCT02468232 (27) [back to overview]	Change in Procollagen Type III N-Terminal Propeptide From Baseline
NCT02468232 (27) [back to overview]	Days in Intensive Care Unit (ICU) Per Participant Per Year
NCT02468232 (27) [back to overview]	EAIR of All-cause Mortality
NCT02468232 (27) [back to overview]	Emergency Department/Urgent Care Facility Visits for HF Per Patient Per Year
NCT02468232 (27) [back to overview]	Hospitalization Admissions Events Per-participant Per Year
NCT02468232 (27) [back to overview]	Number of Participants With All-cause Mortality
NCT02554890 (9) [back to overview]	Number of Patients With Incidences of Symptomatic Hypotension
NCT02554890 (9) [back to overview]	N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Change From Baseline at Week 8
NCT02554890 (9) [back to overview]	N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Values and Time-averaged Change From Baseline
NCT02554890 (9) [back to overview]	Number of Patients With Incidences of Angioedema
NCT02554890 (9) [back to overview]	Number of Patients With Incidences of Hyperkalemia
NCT02554890 (9) [back to overview]	Change From Baseline in Urinary cGMP
NCT02554890 (9) [back to overview]	Change From Baseline in High Sensitivity Troponin (Hs-Troponin)
NCT02554890 (9) [back to overview]	Change From Baseline in BNP to NTproBNP Ratio
NCT02554890 (9) [back to overview]	Change From Baseline in Urinary cGMP to Urinary Creatinine Ratio
NCT02639637 (13) [back to overview]	NPY Metabolites
NCT02639637 (13) [back to overview]	ACE Activity
NCT02639637 (13) [back to overview]	Arterial Norepinephrine
NCT02639637 (13) [back to overview]	Arterial tPA
NCT02639637 (13) [back to overview]	DPP4 Activity
NCT02639637 (13) [back to overview]	Forearm Blood Flow
NCT02639637 (13) [back to overview]	Glucose
NCT02639637 (13) [back to overview]	Heart Rate
NCT02639637 (13) [back to overview]	Insulin
NCT02639637 (13) [back to overview]	Low Frequency Variability of Blood Pressure Activity
NCT02639637 (13) [back to overview]	Mean Arterial Pressure
NCT02639637 (13) [back to overview]	Venous Norepinephrine
NCT02639637 (13) [back to overview]	Venous tPA
NCT02678312 (24) [back to overview]	Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, and Valsartan): Clearance From Plasma (CL/F)
NCT02678312 (24) [back to overview]	Part 1 and Part 2: Population PK of LCZ696 Analytes: Absorption Rate Constant (Ka)
NCT02678312 (24) [back to overview]	Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma N-terminal Pro-brain Natriuretic Peptide (NTproBNP)
NCT02678312 (24) [back to overview]	Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma N-terminal Pro-brain Natriuretic Peptide (NTproBNP)
NCT02678312 (24) [back to overview]	Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma Cyclic Guanosine Monophosphate (cGMP)
NCT02678312 (24) [back to overview]	Part 1: Pharmacodynamics (PD) of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma B-type Natriuretic Peptide (BNP)
NCT02678312 (24) [back to overview]	Part 1 and Part 2: Population PK of LCZ696 Analytes: Volume of Distribution in Steady State
NCT02678312 (24) [back to overview]	Part 1 and Part 2: Population PK of LCZ696 Analytes: Time Required to Drug Concentration to Decrease by Half (T 1/2)
NCT02678312 (24) [back to overview]	Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Number of Participants With Area Under the Plasma Concentration-time Curve From Time Zero to Last (AUClast)
NCT02678312 (24) [back to overview]	Part 1 and Part 2: Population PK of LCZ696 Analytes: Clearance From Plasma (CL)
NCT02678312 (24) [back to overview]	Part 2: Exposure-adjusted Incidence Rate of Category 1 or Category 2 Event
NCT02678312 (24) [back to overview]	Part 2: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02678312 (24) [back to overview]	Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril): Time Required to Drug Concentration to Decrease by Half (T 1/2)
NCT02678312 (24) [back to overview]	Part 2: Percentage of Participants With Worst Event in Each Category Based on Global Ranking
NCT02678312 (24) [back to overview]	Part 2: Percentage of Participants With Change From Baseline in Patient Global Impression of Severity (PGIS) Score
NCT02678312 (24) [back to overview]	Part 1 and Part 2: Population PK of LCZ696 Analytes: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau at Steady State (AUCtau,ss)
NCT02678312 (24) [back to overview]	Part 2: Percentage of Participants With Change From Baseline in New York Heart Association (NYHA)/Ross Functional Class
NCT02678312 (24) [back to overview]	Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Time to Maximum Plasma Concentration (Tmax)
NCT02678312 (24) [back to overview]	Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Urine cGMP
NCT02678312 (24) [back to overview]	Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Maximum Drug Concentration in Plasma (Cmax)
NCT02678312 (24) [back to overview]	Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)
NCT02678312 (24) [back to overview]	Part 1 and Part 2: Population PK of LCZ696 Analytes: Maximum Drug Concentration in Plasma at Steady State (Cmax,ss)
NCT02678312 (24) [back to overview]	Part 1 and Part 2: Population PK of LCZ696 Analytes: Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin,ss)
NCT02678312 (24) [back to overview]	Part 1: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02768298 (5) [back to overview]	Change From Baseline in Exercise Capacity (Watt) at Ventilatory Anaerobic Threshold (VAT)
NCT02768298 (5) [back to overview]	Change From Baseline in the Minute Ventilation (VE) to Carbon Dioxide Output Slope (VE/VCO2 Slope)
NCT02768298 (5) [back to overview]	Change From Baseline in Rate of Perceived Exertion (Perceived Dyspnea and Perceived Fatigue) During Exercise Assessed by Borg Scale
NCT02768298 (5) [back to overview]	Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 6 Weeks of Treatment
NCT02768298 (5) [back to overview]	Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 3 Months of Treatment
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Mitral Annular E' Velocity (Doppler Tissue Imaging)
NCT02874794 (12) [back to overview]	Pearson Correlation Coefficient Between Change From Baseline in Aortic Characteristic Impedance and Biomarker Levels: cGMP/U-creatinine During Both Trough and 4 Hours Post-dose at Week 4
NCT02874794 (12) [back to overview]	Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Ventricular-vascular Coupling (Ea/Ees)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Left Ventricular End Systolic Volume Index (LVESVi)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Left Ventricular End Diastolic Volume Index (LVEDVi)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Left Ventricular Ejection Fraction (LVEF)
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Left Atrial Volume Index (LAVi)
NCT02874794 (12) [back to overview]	Pearson Correlation Coefficient Between Change From Baseline in Aortic Characteristic Impedance and Biomarker Levels: B-type Natriuretic Peptide (BNP) During Both Trough and 4 Hours Post-dose at Week 4
NCT02874794 (12) [back to overview]	Change From Baseline in Echocardiographic Measure: Global Longitudinal Strain
NCT02874794 (12) [back to overview]	Change From Baseline in Aortic Characteristic Impedance at Week 12
NCT02874794 (12) [back to overview]	Change From Basekine in Echocardiographic Measure: Mitral E/E'
NCT02900378 (13) [back to overview]	Total Weekly Time Spent in Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Change From Baseline in Mean Daily Moderate-to-Vigorous Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Change From Baseline in Mean Daily Non-sedentary Daytime Activity in Two-weekly Intervals
NCT02900378 (13) [back to overview]	Change From Baseline in Mean Daily Non-sedentary Daytime Activity in Weekly Intervals
NCT02900378 (13) [back to overview]	Total Weekly Time Spent in Light Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Total Weekly Time Spent in Moderate-to-Vigorous Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Number and Percentage of Participants Achieving PGA Score at Weeks 4, 8 and 12
NCT02900378 (13) [back to overview]	Number and Percentage of Participants With Improved Symptoms of Heart Failure as Assessed by Patient Global Assessment (PGA)
NCT02900378 (13) [back to overview]	Change From Baseline in Mean Daily Light Non-sedentary Daytime Physical Activity
NCT02900378 (13) [back to overview]	Change From Baseline (Week 0) in the Six Minute Walk Test (6MWT) at End of Study (Week 12)
NCT02900378 (13) [back to overview]	Change From Baseline (Week 0) in Mean Daily Non-sedentary Daytime Activity at End of Study (Week 12)
NCT02900378 (13) [back to overview]	Change From Baseline in Peak Six Minutes of Daytime Physical Activity
NCT02900378 (13) [back to overview]	Change From Baseline (Week 0) in the Six Minute Walk Test (6MWT) at Weeks 4 and 8
NCT02970669 (6) [back to overview]	Change in Mean Activity Counts During Most Active 30 Minutes of Day From Baseline to Week 9 and 16
NCT02970669 (6) [back to overview]	Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 9 and 16
NCT02970669 (6) [back to overview]	Ratio of Mean Activity Counts Collected During the Most Active 30 Minutes of the Subject's Day Between Week 8 and Baseline
NCT02970669 (6) [back to overview]	Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 8
NCT02970669 (6) [back to overview]	Change in Mean Activity (Counts Per Minute) During Sleep From Baseline to Week 1
NCT02970669 (6) [back to overview]	Change in Mean Activity Counts During Most Active 30 Minutes of Day From Baseline to Week 1
NCT03066804 (7) [back to overview]	Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24
NCT03066804 (7) [back to overview]	Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24
NCT03066804 (7) [back to overview]	Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
NCT03066804 (7) [back to overview]	Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12
NCT03066804 (7) [back to overview]	Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24
NCT03066804 (7) [back to overview]	Change From Baseline in NYHA Functional Class at Week 24
NCT03066804 (7) [back to overview]	Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24
NCT04236258 (13) [back to overview]	Creatinine Level Around 6 Weeks After Delivery
NCT04236258 (13) [back to overview]	Creatinine Values at 1-2 Weeks After Discharge
NCT04236258 (13) [back to overview]	Number of Participants Who Needed for Additional Antihypertensives
NCT04236258 (13) [back to overview]	Number of Participants With Self-reported Side Effects Attributed to the Antihypertensive They Received
NCT04236258 (13) [back to overview]	Visit to Labor and Delivery Triage for Evaluation
NCT04236258 (13) [back to overview]	Continued Need for Antihypertensive
NCT04236258 (13) [back to overview]	Unscheduled Clinic Appointment
NCT04236258 (13) [back to overview]	Time to Discharge
NCT04236258 (13) [back to overview]	Clinically Significant Hypotension or Hypertension
NCT04236258 (13) [back to overview]	Time to Blood Pressure Control
NCT04236258 (13) [back to overview]	Prolonged Hospitalization
NCT04236258 (13) [back to overview]	Postpartum Readmission
NCT04236258 (13) [back to overview]	Patient Self-reported Compliance With Their Antihypertensive Regimen

MacArthur-Bates Inventory -Total Gestures

MacArthur-Bates Communicative Development inventory( Words and Gestures)-Total Gestures z-score. (NCT00113087)
Timeframe: at 14 months of age

Intervention	standard deviation (Mean)
Enalapril	-0.86
Placebo	-1.31

Intervention	mmHg (Mean)
CKD Patients: Valsartan+Enalapril	-20.4
CKD Patients: Enalapril	-11.7
Non-CKD Patients: Valsartan	-7.5
Non-CKD Patients: Enalapril	-7.2

Intervention	Percentage of patients (Number)
	Systolic BP control	Diastolic BP control
Non-CKD Patients: Enalapril	63.0	91.7
Non-CKD Patients: Valsartan	66.0	95.1

Intervention	mmHg (Mean)
	Systolic BP	Diastolic BP
CKD Patients: Enalapril	-0.3	2.9
CKD Patients: Valsartan+Enalapril	-23.3	-17.8
Non-CKD Patients: Enalapril	-4.1	-4.5
Non-CKD Patients: Valsartan	-11.5	-12.2

Intervention	mmHg (Mean)
CKD Patients: Valsartan+Enalapril	-23.6
CKD Patients: Enalapril	-18.2
Non-CKD Patients: Valsartan	-11.6
Non-CKD Patients: Enalapril	-10.2

Intervention	mm Hg (Least Squares Mean)
Losartan-Hypertensive Participants	-3.8
Amlodipine-Hypertensive Participants	0.8

Intervention	mm Hg (Least Squares Mean)
Losartan-Hypertensive Participants	-5.5
Amlodipine-Hypertensive Participants	-0.1

Intervention	Change in GFR mL/min1.73m^2 (Least Squares Mean)
Losartan Open Label Extension	3.3
Enalapril Open Label Extension	7.0

Intervention	Percent Change in Pr/Cr (Geometric Mean)
Losartan Open Label Extension	-30.01
Enalapril Open Label Extension	-40.45

Intervention	l/min/m2 (Median)
Systemic Blood Flow Baseline	1.4
Systemic Blood Flow After Enalaprilat	1.8
Pulmonary Blood Flow Baseline	1.9
Pulmonary Blood Flow After Enaliprilat	1.9
Cerebral Blood Flow Baseline	1.9
Cerebral Blood Flow After Enalaprilat	1.8

Intervention	Wood units per metre squared (Median)
Systemic Resistance at Baseline	40.94
Systemic Resistance After Enalaprilat	20.26
Pulmonary Resistance at Baseline	2.87
Pulmonary Resistance After Enalaprilat	2.54
Cerebral Resistance at Baseline	24.07
Cerebral Resistance After Enalaprilat	17.32

Intervention	KCCQ Score (Least Squares Mean)
Combination Aliskiren / Enalapril	-5.04
Aliskiren	-6.03
Enalapril	-5.01

Intervention	participants (Number)
	Primary Composite	CV death	1st HF Hospitalization
Aliskiren	791	562	442
Combination Aliskiren / Enalapril	770	512	430
Enalapril	808	547	452

Intervention	mm Hg (Mean)
Placebo	-4.7
Losartan 10 mg	-7.3
Losartan 25 mg	-9.9
Losartan 50 mg	-11.9
Losartan 100 mg	-10.4
Losartan 150 mg	-13.1
Enalapril 20	-16.2

Intervention	Participants (Number)
	Category I	Category II	Category III
Enalapril 20	35	16	31
Losartan 10 mg	19	17	44
Losartan 100 mg	29	19	41
Losartan 150 mg	28	12	44
Losartan 25 mg	21	7	54
Losartan 50 mg	24	15	39
Placebo	10	14	54

Intervention	mm Hg (Mean)
Placebo	-5.6
Losartan 10 mg	-7.9
Losartan 25 mg	-6.8
Losartan 50 mg	-10.1
Losartan 100 mg	-9.9
Losartan 150 mg	-9.7
Enalapril 20	-11.2

Intervention	Participants (Count of Participants)
Doxorubicin Hydrochloride Alone	0
Doxorubicin Hydrochloride With Enalapril	0

Intervention	participants (Number)
	Number of patients who died	CV Death - Fatal MI	CV Death - Pump Failure	CV Death - Sudden Death	CV Death - Presumed Sudden Death	CV Death - Presumed CV Death	CV Death - Fatal Stroke	CV Death - Pulmonary Embolism	CV Death - CV procedural	Other CV Death	Non-CV death - Infection	Non-CV death - Malignancy	Non-CV death - Renal	Non-CV death - Accidental	Non-CV death - Pulmonary	Non-CV death - Suicide	Non-CV death - GI	Other Non-CV death	Unknown Death
Enalapril	837	33	185	311	23	95	34	3	4	6	34	41	1	6	13	1	10	4	33
LCZ696	714	25	147	251	26	67	30	4	3	7	36	41	1	13	7	4	16	2	34

Intervention	Peason's correlation (Number)
	NT-proBNP / LAVi( =0,0, 67, 55)	NT-proBNP/ LVEDVi (n = 0, 0, 62, 53)	NT-proBNP / LVESVi (n = 0, 0, 62, 53)	NT-proBNP / LVEF (n = 0, 0, 62, 53)
Enalapril (Core) OLE Epoch	0.0640	-0.0059	0.0047	0.0233
LCZ696 (Core) OLE Epoch	0.0178	-0.1869	-0.0775	-0.2582

Intervention	pg/mL (Mean)
	Weeks 2-4 (n = 0, 0, 78, 70)	Week 8 (n = 0, 0, 78, 68)	Month 4 (n = 0,0, 76, 69)	Month 12 (n = 0,0, 71, 66)
Enalapril (Core) OLE Epoch	89.77	170.87	200.87	153.06
LCZ696 (Core) OLE Epoch	-81.78	-34.86	12.86	115.11

Intervention	pg/mL (Mean)
	Week 2 (n = 111, 108, 0, 0)	Week 4 ( n = 111, 110, 0, 0)	Week 8 (n = 111, 108, 0, 0)	Month 6 (110, 106, 0, 0)
Enalapril	-86.2222	-224.8545	-234.2963	-240.7264
LCZ696	-366.5766	-233.9279	-252.0090	-327.5000

enalapril

Description

Cross-References

Synonyms (112)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (4)

Drug Classes (2)

Protein Targets (19)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (95)

Molecular Functions (33)

Ceullar Components (19)

Bioassays (294)

Research

Studies (5,888)

Market Indicators

Research Demand Index: 115.45

Study Types

Clinical Trials (124)

Trial Overview

Trial Outcomes

MacArthur-Bates Inventory -Total Gestures

MacArthur-Bates Inventory -Words Produced

MacArthur-Bates Inventory -Words Understood

Neurodevelopmental Status (FSII)

Neurodevelopmental Status (PDI): the Bayley Scales of Infant Development,Psychomotor Development Index Z-score

Neurodevelopmental Status(MDI): Bayley Scales of Infant Development, Mental Developmental Index Z-score

Number of Participants With Moderate to Severe AV Valve Regurgitation

Number of Participants With Moderate to Severe AV Valve Regurgitation

Number of Participants With Ross Heart Failure Class I

Number of Participants With Ross Heart Failure Class I

Ventricular Filling Pressure

Ventricular Mass

Ventricular Mass

Ventricular Mass to Volume Ratio

Ventricular Mass to Volume Ratio

Ventricular Mass Z-score

Ventricular Mass Z-score

Weight-for-age Z-score at 14 Months of Age

End-diastolic Volume

End-diastolic Volume

End Diastolic Volume Z-score

Ejection Fraction (%)

Ejection Fraction (%)

B-type Natriuretic Peptide Level

B-Type Natriuretic Peptide

MacArthur-Bates Inventory -Phrases Understood

Height-for-age Z-score

Head Circumference-for-age Z-score

End-diastolic Volume Z-score

Systolic Blood Pressure

Cerebral Blood Flow

Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)at 6 Months

Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)%

Baseline Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)

Plasma B-type Natriuretic Peptide (BNP) at Baseline

Plasma B-type Natriuretic Peptide (BNP) at 6 Months

Plasma B-type Natriuretic Peptide (BNP)

Changes in Heart Failure Symptoms

Changes in Health-related Quality of Life

Changes in NT-proBNP Values Over Time in All Patients

Composite Value of 3 Variables After 9 Months: Cardiovascular Death (Days Alive), Cardiovascular Hospitalization (Days Out of Hospital), Heart Failure Symptoms (Symptom Score Subset of the Kansas City Cardiomyopathy Questionnaire - Questions 3,5,7,9)

Discontinuations

Number of CV Deaths

Number of Days in Hospital for CV Reason

Total Number of Titration Steps in Prescribed Heart Failure Treatment

Change From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients

Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)

Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)

Intervention	mL/m^2 (Mean)
	LAVi (n = 0, 0, 67, 55)	LVEDVi (n = 0, 0, 62, 53)	LVESVi (n = 0, 0, 62, 53)
Enalapril (Core) OLE Epoch	-1.47	0.99	-2.65
LCZ696 (Core) OLE Epoch	-3.31	2.54	-2.32

Intervention	pg/mL (Mean)
	Weeks 2-4 (n = 0, 0, 78, 70)	Week 8 (n = 0, 0, 78, 68	Month 4 (n = 0,0, 76, 69)	Month 12 (n = 0,0, 71, 66)
Enalapril (Core) OLE Epoch	-333.12	-279.53	-280.35	-358.98
LCZ696 (Core) OLE Epoch	-235.73	-219.47	-83.49	266.43

Intervention	Participants (Count of Participants)
	Improved	Unchanged	Worsened
Enalapril (Core) OLE Epoch	4	60	2
LCZ696 (Core) OLE Epoch	3	64	4

Intervention	nmol/L (Mean)
	Weeks 2-4 (n = 0, 0, 78, 69)	Week 8 (n = 0, 0, 78, 68)	Month 4 (n = 0, 0, 76, 68)	Month 12 (n = 0, 0, 71, 66)
Enalapril (Core) OLE Epoch	411.16	356.41	580.40	493.21
LCZ696 (Core) OLE Epoch	106.78	142.59	176.50	-131.86

Intervention	nmol/L (Mean)
	Week 4 (n = 110, 109, 0, 0)	Week 8 (n = 111, 107, 0, 0)	Month 6 (n = 110, 102, 0, 0)
Enalapril	-25.9725	-52.7944	-41.9706
LCZ696	556.3182	587.4414	507.9182

Intervention	Events per 100 patient-years (Number)
	Primary composite	Cardiovascular (CV) Death	1st heart failure (HF) Hospitalization
Enalapril	10.497	3.734	7.498
LCZ696	11.376	4.410	9.480

Intervention	scores on a scale (Least Squares Mean)
	Week 8 (n = 111, 111, 0, 0)	Month 6 (n = 111, 110, 0, 0)
Enalapril	-2.5946	-3.4910
LCZ696	-0.0491	-2.2216

Intervention	ratio (Geometric Mean)
	Week 4 (n = 111, 110, 0, 0)	Week 8 (n = 111, 108, 0, 0)	Month 6 (n= 110, 106, 0, 0)
Enalapril	0.8862	0.9134	0.8564
LCZ696	0.7672	0.7798	0.6947

Intervention	Events per 100 patient-years (Number)
	First triple composite endpoint	CV death	First HF Hospitalization	First worsening of HF in outpatient
Enalapril	14.479	3.734	7.498	5.095
LCZ696	14.725	4.410	9.480	4.372

Intervention	Participants (Count of Participants)
	Week 4 Improved (n = 111, 111, 0, 0)	Week 4 Unchanged (n = 111, 111, 0, 0)	Week 4 Worsened (n = 111, 111, 0, 0)	Week 8 Improved (n = 111, 111, 0, 0)	Week 8 Unchanged (n = 111, 111, 0, 0)	Week 8 Worsened (n = 111, 111, 0, 0)	Month 6 Improved (n = 111, 110, 0, 0)	Month 6 Unchanged (n = 111, 110, 0, 0)	Month 6 Worsened (n = 111, 110, 0, 0)
Enalapril	10	96	5	12	93	6	18	84	8
LCZ696	8	102	1	15	95	1	19	91	1